Use of pan-BET inhibitors

Pan-BET inhibitors with a pyrrolopyridine core provide effective, localized treatment for inflammatory diseases like pyoderma gangrenosum and pulmonary fibrosis, reducing cytokines and promoting healing while minimizing systemic side effects.

JP2024542045AInactive Publication Date: 2024-11-13VYNE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525851
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-26
Filing Date
2022-11-02
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for diseases such as pyoderma gangrenosum, generalized pustular psoriasis, palmoplantar pustulosis, vitiligo, arthritis, and pulmonary fibrosis are inadequate, often causing systemic side effects and delayed healing, and there is a need for treatments that can effectively reduce inflammatory cytokines without significant adverse reactions.

Method used

The use of pan-BET inhibitors, specifically soft BET inhibitors with a pyrrolopyridine core, administered topically or intra-articularly, to target BET BRDs and reduce inflammatory cytokines, providing localized treatment with minimal systemic side effects.

Benefits of technology

The pan-BET inhibitors effectively reduce inflammation and promote healing in various diseases, avoiding systemic adverse effects and improving patient compliance by maintaining localized therapeutic concentrations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542045000001_ABST
    Figure 2024542045000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods for the treatment, amelioration, or prevention of inflammatory and / or autoimmune diseases or disorders or diseases or disorders related thereto (e.g., wounds, pigmentation or pigmentation-related diseases and disorders, joint or joint-related diseases and disorders, respiratory or respiratory-related diseases or disorders; and fibrosis or fibrosis-related diseases and disorders) using soft BET inhibitors.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 263,511, filed November 3, 2021, U.S. Provisional Application No. 63 / 268,839, filed March 3, 2022, U.S. Provisional Application No. 63 / 362,122, filed March 29, 2022, U.S. Provisional Application No. 63 / 362,780, filed April 11, 2022, U.S. Provisional Application No. 63 / 364,770, filed May 16, 2022, and U.S. Provisional Application No. 63 / 369,455, filed July 26, 2022, the contents of each of which are incorporated by reference in their entirety into this specification.

[0002] The present disclosure relates to methods for treating or preventing inflammation and inflammation-related diseases or disorders, autoimmune and autoimmune-related diseases or disorders, wounds and wound-related diseases or disorders, pigmentation or pigmentation-related diseases or disorders, joint-related diseases and disorders, respiratory or respiratory-related diseases or disorders, fibrosis or fibrosis-related diseases or disorders using BET inhibitors for diseases and disorders and formulations such as topical and intra-articular formulations.The BET inhibitors are pan-BET inhibitors that can bind to BDI and BDII.The BET inhibitors are soft BET inhibitors. [Background technology]

[0003] Diseases and disorders can be multifactorial. Diseases and disorders can involve inflammation or result in inflammation-associated disorders. Autoimmune diseases and disorders can result in inflammation or result in inflammation-associated disorders. Inflammatory or autoimmune diseases or disorders can cause or result in changes, damage and / or wounds. An important aspect of the treatment of many diseases or disorders is facilitating proper healing. A broken or about to break healing process can leave, for example, lesions, wounds and / or fibrosis. Pyoderma gangrenosum (PG) is a severe, life-threatening autoimmune neutrophilic dermatosis that causes significant skin ulcers and has a prevalence in the United States of 5.8 / 100,000. 2 The disease occurs primarily in adults, although rare pediatric cases have been reported. Gender incidence varies from equal to predominantly females affected in up to 76% of cases. Classic PG most often presents as an extremely painful erythematous lesion that rapidly progresses to a bullous or necrotizing ulcer. An irregular exhumed border with a violet / erythematous border is often present. PG can appear anywhere, but the lower legs are most frequently affected. Lesions can be precipitated by minor trauma. Most cases of PG are of the classic ulcerative type (approximately 85%), but other subtypes include bullous, vegetative, pustular, peristomal, and superficial granulomatous variants, and PG subtypes sometimes transition from one form to another. Because there are no clear laboratory or histopathologic criteria for PG, the differential diagnosis includes all other causes of skin ulceration. Although the pathogenesis of PG remains unclear, it is recognized that neutrophils play an important role in the disease process. Elevated expression of several important proinflammatory and neutrophil chemotactic factors within the lesions has been identified, including IL-1β, IL-17, TNFα, IL-8, IL-6, IL-18, INFγ, IL-36γ, and IL-23. IL-8 has been demonstrated to cause PG in animal models. IL-8 is also induced in fibroblasts in PG ulcers, and its associated ligand is overexpressed in PG.

[0004] An important aspect of the treatment of PG is wound healing. Often, wound healing is incomplete, resulting in scar formation. Attempts to accelerate the healing process may result in increased incidence of scar formation. If wound is infected with bacteria, the healing process may become more difficult and take longer. Scars occur relatively often after improper treatment.

[0005] Despite being a well-recognized disease, PG often fails to be diagnosed early. Potent topical corticosteroids and tacrolimus ointment applied to the ulcer surface are helpful, and intralesional injections of corticosteroids into the active borders of the erythema may be considered. In more severe disease, systemic therapy is required. Oral corticosteroids are the mainstay of treatment and are used to achieve rapid control. When prolonged treatment is required, cyclosporine is used alone or in combination with corticosteroids as a steroid-sparing agent. Other systemic treatments that have been utilized include colchicine, sulfasalazine, dapsone, minocycline, apremilast, and thalidomide, with variable success.

[0006] Some limitations of current therapies include inadequate efficacy of nonsteroidal topical treatments, restrictions on application to certain body areas, "steroid and CNI phobia," and application site reactions. Potential long-term safety concerns include systemic side effects and skin atrophy (related to striae and other atrophic changes) with topical corticosteroids and increased risk of infection with CNIs.

[0007] Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, development of pustules, and systemic inflammation, and may manifest in the presence or absence of chronic plaque psoriasis. IL-1β, IL-17, IL-8, and IL-36γ are the major cytokines increased in GPP. Current treatments are inadequate, and further understanding of the pathogenesis of GPP is needed.

[0008] Palmoplantar pustulosis (PPP) is a chronic dermatitis characterized by intraepidermal vesicles / pustules containing neutrophils (PMNs) found on the palms and soles. Although several pathogenic mechanisms of PPP have been proposed, such as concomitant tonsillitis, periodontitis, or metal allergy, the etiology of PPP remains unclear. IL-1, IL-8, IL-17, and IL-36γ are the main cytokines increased in PPP. Current treatments are inadequate, and further understanding of the pathogenesis of PPP is needed.

[0009] Many other local disorders involve inflammation and share similar biomarker patterns. Anything that can reduce the inflammatory cytokines involved in inflammation and treat or ameliorate the disorder while avoiding or minimizing systemic and skin-related side effects would be advantageous and improve patient compliance with treatment.

[0010] Autoimmune skin diseases characterized by various pigmented spots, such as vitiligo, are difficult to treat. For example, vitiligo is a disease in which the immune system attacks pigment cells in the body. It can be found anywhere in the body and can range from mild to severe. Vitiligo is an acquired chronic depigmentation disorder of the skin, characterized by patchy loss of skin color, usually with sharp edges, where the skin turns white with loss of pigment. Sometimes the disease occurs on the skin and inside the mouth and nasal cavity. Typically, the disease occurs on both sides of the body. Often the spots start on areas of the skin that are exposed to the sun. This is more noticeable in people of color. Vitiligo is not life-threatening, but it can cause psychological stress and sufferers are sometimes stigmatized.

[0011] The exact cause of vitiligo is unknown. Without wishing to be bound by theory, vitiligo is typically considered a multifactorial disorder, ultimately resulting in autoimmune-mediated loss of functional melanocytes (see, e.g., Boniface K, et al. Clin Rev Allergy Immunol. 2018;54:52-67; Seneschal J, et al. Pigment Cell Melanoma Res. 2021;34:236-243; Chen J, et al. Med Res Rev. 2021;41:1138-1166; Frisoli M, et al. Annu Rev Immunol. 2020;38:621-648). Loss of melanocytes is a pathological hallmark of vitiligo, which may be induced by an excessive immune response involving autoreactive CD8 T cells producing high levels of type 1 cytokines. However, the relationship between this inflammatory response and melanocyte loss has yet to be fully characterized. It is hypothesized that the loss of melanocytes in vitiligo is due to melanocytorhagy, a defect in melanocyte adhesion to the basement membrane. It has also been speculated that both genetic susceptibility and environmental factors may be involved. Several studies suggest that changes in the immune system are responsible for the disease. Both mutations in genes that are part of the immune system or part of the melanocytes have been associated with vitiligo. The inflammatory interleukin-1β and interleukin-18 are expressed at higher levels in people with vitiligo. It is also believed that vitiligo is caused by the immune system attacking and destroying melanocytes in the skin. Vitiligo is sometimes associated with autoimmune and inflammatory diseases such as Hashimoto's thyroiditis, scleroderma, rheumatoid arthritis, type 1 diabetes, psoriasis, Addison's disease, pernicious anemia, alopecia areata, systemic lupus erythematosus, and celiac disease.

[0012] Most cases are non-segmental, meaning they occur on both sides, and in these cases, the affected skin area typically does not expand over time. Approximately 10% of cases are segmental, meaning they occur primarily on one side of the body, and in these cases, the affected skin area typically does not expand over time.

[0013] Vitiligo is the most common depigmented skin disease, with an estimated prevalence of 1% of the world's population, with some populations affecting as many as 2-3%. Men and women are affected equally. About half of people show symptoms before age 20, and most develop symptoms before age 40.

[0014] There is no known cure for vitiligo. Current treatments for vitiligo are inadequate. First-line treatments for vitiligo include topical preparations of immunosuppressive drugs such as glucocorticoids (e.g., 0.05% clobetasol or 0.10% betamethasone) and calcineurin inhibitors (e.g., tacrolimus or pimecrolimus). For people with lighter skin, sunscreen and cosmetics are typically recommended. For people with darker skin, treatment options may include phototherapy to darken light spots or hydroquinone to lighten unaffected skin, although the latter is less recommended due to increased risk of skin cancer. If phototherapy and drugs fail, some people with stable disease may be candidates for surgery (skin grafts, blister grafts, and cell suspension transplants). There is currently no FDA-approved repigmentation treatment for vitiligo.

[0015] Joint or joint-related disorders or diseases are diseases that affect the joints of humans. Arthritis is one well-known example of a joint disease. Osteoarthritis is the most common form of arthritis and involves the wear and tear of the cartilage that covers the bones of an individual's joints. Rheumatoid arthritis (RA) is a disease in which the immune system attacks the joints, beginning with the lining of the joint. RA is the most frequent autoimmune chronic inflammatory rheumatism, and mainly affects the synovial membrane of multiple joints. Although its pathogenesis remains unclear, it is now recognized that there are three major mediators during the inflammatory process of arthritis: the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 (see Mori T. et al., IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis, International Immunology, Volume 23, Issue 11, 2011, pp. 701-712).

[0016] Regardless of the cause, inflammation of the joints can cause pain, stiffness, swelling, and some redness of the skin around the joint. Steroids (i.e., corticosteroids) are synthetic drugs used to treat various inflammatory diseases and conditions. However, administration of corticosteroids, especially over a long period of time, can have several unwanted side effects or adverse reactions. The effectiveness of corticosteroids generally decreases over time, their use has disadvantages including increased susceptibility to infection and peptic ulcers, and direct corticosteroid injection into joint tissues can worsen joint damage in some subjects. For example, unwanted adverse reactions of injection of triamcinolone (a type of corticosteroid) include hypersensitivity reactions such as anaphylaxis, joint infection and damage, increased risk of infection, changes in endocrine function, cardiovascular and renal effects, increased intraocular pressure, gastrointestinal perforation, changes in bone density, and abnormalities in behavior and mood. As yet another example, unwanted adverse reactions of dexamethasone (another corticosteroid) include fluid and electrolyte abnormalities, musculoskeletal, gastrointestinal, neurological, dermatological, endocrine, ophthalmological, metabolic cardiovascular, anaphylactic or hypersensitivity reactions, thromboembolic events, weight gain, increased appetite, and nausea (see, e.g., Brinks, A. et al. "Adverse effects of extra-articular corticosteroid injections: a systematic review." BMC musculoskeletal disorders, 11:206, 2010).

[0017] Furthermore, other autoimmune diseases and other diseases characterized by fibrosis or scarring, such as pulmonary fibrosis (PF), are difficult to treat. As an example, PF is a chronic disease that affects at least 5 million people worldwide and shows abnormal remodeling of lung tissue. PF is part of a larger group of more than 200 interstitial lung diseases (also known as ILD or diffuse parenchymal lung disease (DPLD)) that are characterized by lung inflammation and / or scarring. In ILD, injury / damage occurs in the walls of the lung's air sacs (alveoli) and in the tissues and spaces around these air sacs (interstitium). When ILD involves scar tissue in the lung, it is known as PF.

[0018] Fibrosis, defined by the pathological accumulation of extracellular matrix (ECM) proteins, leads to scarring that may be accompanied by thickening of affected tissues. In essence, this is an excessive wound-healing response that interferes with normal organ function. Pulmonary fibrosis is generally characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and deposition of extracellular matrix proteins. The result is the progressive loss of normal lung architecture and impaired gas exchange. Thus, symptoms may include shortness of breath, dry cough, fatigue, weight loss, and clubbed nails (e.g., due to hypoxia in the blood).

[0019] There are many different types of PF, divided into six main categories. Five are based on the type of induction or exposure: environmental, occupational, drug-induced, radiation-induced, and autoimmune lung disease. The other main category, idiopathic PF (IPF), is when no cause can be identified.

[0020] Lung damage (scar tissue) caused by PF cannot be repaired, and currently approved drugs have limited efficacy and suffer from multiple side effects. Drugs and therapies can sometimes improve quality of life, help relieve symptoms, or slow the progression of scarring. Lung transplantation is the only treatment option available in severe cases. Supplemental oxygen, pulmonary rehabilitation, and symptom management are important treatment options for many types of pulmonary fibrosis, depending on severity.

[0021] In addition to fibrosis in lung diseases and disorders, fibrosis can be a significant problem throughout the body, including organs such as the kidney, liver, heart, lymph nodes (e.g., mediastinal fibrosis), bone marrow, skin, tendons, joints, connective tissues, soft tissues, and body cavities (e.g., retroperitoneal space). Fibrosis can be localized or systemic.

[0022] Many disorders, such as local disorders, involve inflammation and share similar biomarker patterns.It would be advantageous to reduce the inflammatory cytokines involved in inflammation and treat or ameliorate disorders while avoiding or minimizing side effects or adverse reactions, such as systemic or skin-related side effects, and improve patient compliance with treatment.

[0023] Bromodomain and Extra-Terminal (BET) proteins are a family of four bromodomain-containing (BRD) proteins (BRD2, BRD3, BRD4, and BRDT), with each family member containing two BRDs (located next to each other toward the N-terminus of the protein) and an extra-terminal domain. The two BRDs are named binding domain I (BDI) and binding domain II (BDII). BET proteins are transcriptional regulators that bind acetylated lysines in the tails of histones H3 and H4 through hydrophobic pockets and regulate chromatin structure and function. BET proteins "read" the acetylated lysines, allowing chromatin remodeling and recruiting transcription factors. In other words, BRDs are responsible for the signals carried by acetylated lysine residues being transmitted to various phenotypes and play a key role in regulating gene transcription through epigenetic interactions ("reading") between bromodomains and acetylated histones during cell proliferation and differentiation. For example, BRD4 recruits the transcription factor P-TEFb to promoters to alter the expression of genes involved in the cell cycle.

[0024] BET proteins are ubiquitously expressed in humans, except for BRDT, which is normally expressed in the testis, but also by some cancers. BET proteins are known to be involved in the regulation of biochemical pathways such as MYC, BCL2, FOSL1, P-TEFb, NFkB, and glucocorticoid signaling. Thus, there is growing interest in BET inhibitors as therapeutic targets for a wide range of diseases, including inflammatory diseases, cancer, infectious diseases, metabolic diseases, CNS disorders, fibrotic diseases, and cardiac diseases. They may be able to treat diseases caused at least in part by aberrant regulation of BET protein activity by modulating gene expression.

[0025] Several small molecules have been reported to be effective in inhibiting BET, including diazepines, 3,5-dimethylisoxazoles, thiazol-2-ones, diazobenzenes, and 4-acylpyrroles. Compounds containing 6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one moieties substituted at the 4- and / or 2-positions have also been described as useful in inhibiting BET proteins. To date, the majority of research on BET inhibitors has focused on oncology and cardiovascular disease.

[0026] Some autoimmune skin diseases are characterized by chronic ulcers and blisters that are difficult to treat and can lead to life-threatening infections and life-altering surgical interventions. In addition to effectively reducing the intralesional inflammatory burden, it is important that treatments do not adversely affect natural skin repair mechanisms that could delay lesion closure. Glucocorticosteroids are frequently used to treat neutrophilic dermatoses, but it is known that prolonged use of topical products is associated with tachyphylaxis, and systemic use can significantly delay the time to ulcer closure and result in significant hormone-related systemic adverse events (Guo S and Dipietro LA, J Dent Res 2010 89(3):219-229; Tan SY, Chandran NS and Ci-En Choi E, Clin Drug Invest. 2021 41:835-842; Wang AS, Armstrong EJ and Armstrong AW, Amer J Surg. 2013 203(3):410-417; Paragliola RM, Papi G, Pontrcorvi A and Corsello SM, Int. J Mol Sci 2017 18(10):2201). Because of these limitations, long-term use of glucocorticosteroids may prolong patient exposure to the risks and complications associated with these serious chronic diseases.

[0027] There remains an unmet need for locally applied BET inhibitors that favorably affect diseases such as inflammation that involve multiple diverse inflammatory cell signaling pathways, as well as rare diseases and other diseases where many patients do not have adequate treatment options.

[0028] For example, IPF is a progressive inflammatory disorder driven by a cascade of fibrotic events including epithelial-mesenchymal transition, extracellular matrix production, and collagen formation in the lung. The first-line treatments are FDA-approved pirfenidone and nintedanib (tyrosine kinase inhibitors), but neither quality of life nor survival rates have been improved due to patient noncompliance caused by multiple side effects (see, for example, Andugulapati SB et al. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Phytomedicine, 2020).

[0029] A drug that requires a short treatment period, is safe, well tolerated, prevents the occurrence and / or reduces the severity grade or incidence of disorders such as PG, PPP, GPP, and scarring, pigmentation disorders such as vitiligo, joint or joint-related disorders or diseases, or pulmonary diseases and disorders, such as fibrotic conditions such as PF, and other pulmonary diseases and disorders involving scarring, while avoiding unwanted side effects and adverse reactions, would be advantageous and improve patient treatment compliance.Therefore, there is a medical need to replace corticosteroids with safer and better drugs to reduce the systemic side effects associated with the administration of corticosteroids.In addition, there is a medical need to slow, stop, reverse, or otherwise inhibit the structural damage to tissues caused by inflammatory diseases, such as damage to joint tissues resulting from osteoarthritis or rheumatoid arthritis.Involvement of bursa, tendons, and tendon sheaths can be part of arthritic diseases.

[0030] The present disclosure provides a particular genus of BET inhibitors (hereinafter BETi) that have been found to be surprisingly effective against diseases involving multiple diverse inflammatory cell signaling pathways in inflammation and rare and other diseases, as well as joint or joint-related disorders or diseases. More specifically, the present disclosure provides exemplary BETi that can provide novel and effective treatment and relief of pigmentation (related) diseases or disorders (such as vitiligo) or joint disorders or diseases, such as arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus or other autoimmune joint disorders.

[0031] The present disclosure provides a BETi that can provide novel and effective treatment and relief of joint-related diseases and disorders. Joints can be infected by many types of microorganisms (bacteria, fungi, viruses) and sometimes animal parasites. Infection-related joint diseases and disorders include infection by direct contamination, infection by bloodstream, e.g., via synovial vessels, and even from adjacent bone infection (osteomyelitis). Infectious arthritis may affect one joint (monoarthritis) or a few joints (oligoarthritis) rather than many joints (polyarthritis). Joints or parts thereof may be damaged, for example, by infection of the cartilage, for example, by Staphylococcus aureus, Streptococcus haemolyticus, and Streptococcus pneumoniae, by tuberculosis, for example, by tuberculous spondylitis (Pott's disease), by bone, or by sexually transmitted diseases, including brucellosis, for example, coccidioides immitis, brucella suis, leprosy, rubella, and serum hepatitis, viral synovitis, dracunculiasis, gonorrhea, reactive arthritis (Reiter's disease), congenital syphilis, for example, Clutton's joint lesion, and yaws, which leads to skeletal lesions. Inflammation can destroy the articular cartilage and underlying bone, causing irreversible deformity. In such cases, adhesions between the components of the joint frequently occur, and the resulting adhesions with loss of mobility are called ankylosis, for example, ankylosing spondylitis (Marie-Strumpell's disease or Bechterew's disease). Other types of arthritis are associated with chronic bowel disease-ulcerative colitis, regional enteritis, inflammatory bowel disease, cirrhosis, and Whipple's disease.

[0032] In addition to joint disorders and diseases resulting from any of the above, the present disclosure provides BETi that may also provide novel and effective treatment or relief of non-inflammatory joint diseases, injuries and degenerative disorders. Trauma to joints includes blunt injury, minor sprains, fractures and dislocations, tears of ligaments, tendons and capsules, tears of meniscus, and hemarthrosis. Degenerative joint diseases include osteoarthritis, osteoarthritis, precocious osteoarthritis congenital dysplasia malum coxae senilis, spondylosis, chondromalacia patellar, metabolic diseases such as gouty arthritis, gouty foot, ochronotic arthropathy, chondrocalcinosis or pseudogout, mucopolysaccharidosis, Hurler syndrome, Morquio disease, and multiple epiphyseal dysplasia.

[0033] The present disclosure provides BETi that may also provide novel and effective treatment or palliation of secondary joint diseases and disorders, including hemorrhagic joints, hemarthrosis, villonodular synovitis, joint diseases occurring in association with avascular necrosis (e.g., as may occur with fractures), osteochondritis dissecans, slipped capital femoral epiphysis, Osgood-Schlatter, Legg-Calve-Perthes, joint disorders resulting from endocrine insufficiency, acromegaly, neurogenic arthropathy, Charcot joints, hypertrophic osteoarthropathy, reflex sympathetic dystrophy, joint tumors, synovial osteochondromatosis, chondrocyte nodules, synovial osteochondromatosis, synovium, synovial sarcoma, and polymyalgia rheumatica.

[0034] The present disclosure further provides exemplary BET inhibitors that can provide novel and effective treatments of fibrotic or scarring (related) diseases or disorders, such as lung or pulmonary fibrosis, by targeting the TGF-β mediated cascade of fibrotic events, thereby improving survival of PF patients. Summary of the Invention

[0035] The present disclosure relates to the treatment or prevention of diseases and disorders that can be effectively treated by pan-BET inhibitors. In one or more embodiments, the pan-BET inhibitor is a soft pan-BET inhibitor. In some embodiments, the compounds disclosed herein are effective drugs in the local treatment of diseases and disorders when the compound or pharmaceutical composition comprising the compound(s) is administered locally or topically.

[0036] In some embodiments, the disclosed derivatives are based on a pyrrolopyridine core. Such derivatives may have a specific group at the 4-position of the pyridone ring, as defined herein. Advantageously, the use of the compounds disclosed herein has the potential to avoid, for example, significant undesired side effects, significant hormone-related systemic adverse events, and adverse events that may be associated with other treatments, such as corticosteroids.

[0037] In some embodiments, the present disclosure provides compounds that are surprisingly active in inhibiting all four BET BRDs, e.g., with effective potency at nanomolar concentrations. In some embodiments, the active compounds bind to BET BDI and BET BDII but do not show high selectivity for BDII. Moreover, it has been surprisingly observed that some of such compounds may show some selectivity or slight bias for BETII, but can effectively function as pan-BET inhibitors that bind to and inhibit both the BDI and BDII domains.

[0038] In one or more embodiments, the active compounds are administered in a composition or vehicle. In some embodiments, they are dissolved, in some embodiments, they are suspended, and in some embodiments, they are partially dissolved and partially suspended in the composition or vehicle. In some embodiments, they are mostly suspended, which may provide a localized reservoir of active compound that dissolves over time. In one or more embodiments, the compounds or compositions containing them are administered topically or locally. In some embodiments, they are applied topically to the skin or mucosa on and / or surrounding the area where the disease or disorder is present. In some embodiments, they are delivered intradermally, e.g., into the epidermis and dermis. In some embodiments, they are delivered transdermally. In some embodiments, they are applied into a body cavity. In some embodiments, they may be applied topically, e.g., into a joint. In some embodiments, they may be applied into a larger cavity such as the lung. In some embodiments, they may be applied onto or into a lesion or wound.

[0039] In some embodiments, for example, the compounds disclosed herein may have significant advantages as potential therapies for neutrophilic skin diseases by not exhibiting a delay in skin healing, a key component for treating diseases such as autoimmune skin diseases that are characterized by chronic ulcers and blisters that are difficult to treat and can lead to life-threatening infections and life-altering surgical interventions.

[0040] For example, in some embodiments, the compounds disclosed herein may have significant advantages as potential therapies for pigmentation diseases or disorders, such as autoimmune skin diseases that are difficult to treat, characterized by various pigmentation patches, such as vitiligo. Vitiligo and other pigmentation disorders can cause psychological distress and affect an individual's way of thinking and social interactions. Common treatments include camouflage therapy, re-pigmentation therapy, phototherapy, and surgery.

[0041] For medical diseases and disorders, topical application may include topical application to a surface of a body cavity, for example, in the lungs (e.g., by inhalation). In some embodiments, inhalation may use a nebulizer to deliver the drug in the form of a mist. In some embodiments, inhalation is by an inhaler, which may be a dry powder inhaler or a metered dose inhaler. In some embodiments, delivery may be by a puff. In some embodiments, delivery to the lungs is by an aerosol. In some embodiments, delivery may be by a liquid bolus. In some embodiments, delivery may be by a spray. In some embodiments, delivery may be a mist.

[0042] In addition, the compounds disclosed herein may have important advantages as potential therapies for joint or joint-related disorders or diseases, including those that are difficult to treat. Furthermore, the compounds disclosed herein may also have important advantages as potential therapies for secondary joint diseases or disorders. Furthermore, the compounds disclosed herein may also have important advantages as potential therapies for autoimmune diseases and other diseases, such as PF, that are characterized by fibrosis or scarring and are difficult to treat.

[0043] In some embodiments, an immediate release form of a composition comprising a BETi (e.g., BETi1) is administered to treat an articular or joint-related disorder or disease, for example, by topical application, or to treat a fibrosis or respiratory-related disorder or disease. In one or more embodiments, the immediate release form, when it comprises suspended particles, provides release over time as the suspended drug particles dissolve. In some embodiments, the immediate release form comprises a solution of the BETi. In some embodiments, the immediate release form comprises a suspension of the BETi or a micronized or nanoparticle suspension of the BETi. In one or more embodiments, when a formulation comprising suspended drug particles is provided for immediate release, any solubilized drug will be immediately available and the suspended particles will dissolve, for example, in the synovial fluid. In one or more embodiments, smaller particles dissolve more quickly than larger particles, which may provide a reservoir and extend the period during which the active drug is available in the joint. In some embodiments, the immediate release form comprises a partially dissolved and partially suspended BETi. In some embodiments, a suspended or partially suspended form administered locally in a limited area (e.g., intra-articularly) may form a reservoir from which the active compound dissolves over time, resulting in a longer-lasting therapeutic effect compared to a solution. In some embodiments, a sustained or extended release form of a composition comprising a BETi (e.g., BETi1) is administered to treat, for example, fibrosis or respiratory-related disorders or diseases. In some embodiments, a combination of immediate release and sustained or extended release forms is provided. In one or more embodiments, the release dosage form is delivered using an inhalation device such as a nebulizer, a metered dose inhaler (MDI), and a dry powder inhaler (DPI), or an Aerolizer™ inhaler, where the BETi (e.g., BETi1) may be in the form of a capsule. In some embodiments, the release form comprises a suspension of the BETi. In some embodiments, the release form comprises a solution of the BETi or a micronized or nanoparticle suspension of the BETi. In some embodiments, the release form comprises a partially dissolved and partially suspended BETi.In some embodiments, the majority of the BETi is dissolved (e.g., about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more). In some embodiments, the majority of the BETi is suspended (e.g., about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more). In some embodiments, a sustained release form of a composition comprising a BETi (e.g., BETi1) is administered, for example, by topical application to treat a joint or joint-related disorder or disease or a secondary joint disease or disorder, or administered, for example, by topical application, such as inhalation, to treat a respiratory or respiratory-related disorder. In some embodiments, the sustained release form comprises the BETi loaded into an inhalable liposome, an endogenous lipid-based formulation, or a drug-lipid conjugate. In some embodiments, the suspended particles provide a sustained release after an initial release. In some embodiments, the sustained release form comprises a particulate or encapsulated suspension of the BETi. In some embodiments, the sustained release form comprises the BETi that is partially suspended to provide a delayed release and partially dissolved to provide an initial release. As will be appreciated by those skilled in the art, the rate of suspension to dissolution will depend, at least in part, on the amount of vehicle or carrier and the BETi.

[0044] In some embodiments, a composition comprising a BETi (e.g., BETi1) in sustained release form is administered, for example, by local application or administration, to treat a joint or joint-related disorder or disease. In some embodiments, the local administration of a composition comprising a BETi (e.g., BETi1) is performed, for example, via injection into the intra-articular space, peri-articular space, soft tissue, lesion, epidural space, perineural space, or foraminal space at or near the site of pain in a subject. In some embodiments, the formulation (e.g., composition) further contains an immediate release component. In some embodiments, a composition comprising a BETi, e.g., BETi1, in sustained release form is administered to the intra-articular space (e.g., by a single injection or as sequential injections) for the treatment of joint or joint-related disorders or diseases, e.g., arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty's syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus or other autoimmune joint disorders. In some embodiments, a composition comprising a BETi, e.g., BETi1, in sustained release form is administered to soft tissue or lesions (e.g., by a single injection or as sequential injections) for the treatment of inflammatory disorders, such as rheumatoid arthritis. In some embodiments, a sustained release (or sustained release) form of a composition comprising a BETi, e.g., BETi1, is administered to the respiratory system (e.g., by a single injection or as sequential injections) for the treatment of pulmonary fibrosis or respiratory system-related disorders or diseases.

[0045] In some embodiments, a composition, e.g., an intra-articular composition, is provided that includes a BETi (e.g., BETi1). In some embodiments, the intra-articular composition is encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres. In some embodiments, the PLGA microspheres entrap the BETi (e.g., BETi1) and provide for its slow release upon degradation of the PLGA in the joint. In some embodiments, for the PLGA microspheres, the ratio of lactic acid to glycolic acid is about 80:20 to about 60:40, or about 75:25, lactic acid:glycolic acid. In some embodiments, the drug load (i.e., BETi loading) in the microspheres ranges from about 10% to about 80%. In some embodiments, the drug load in the microspheres is about 25% w / w. In some embodiments, the composition includes hyaluronic acid. In some embodiments, the hyaluronic acid is crosslinked to a polymer to increase viscosity and slow degradation in the joint. In some embodiments, a method is provided for restoring viscoelasticity of synovial fluid. In other embodiments, the BETi (e.g., BETi1) is entrapped or suspended within a crosslinked hyaluronic acid polymer to provide sustained release. In some embodiments, BETi formulations for immediate release and / or sustained release (sustained release) are provided in different delivery forms. In some embodiments, the BETi formulation for sustained release is deposited without immediate penetration, allowing delivery over 1, 2, 3, 4, 5, 6 days, or over 1, 2, 3, or 4 weeks, or over 1, 2, 3, or 4 months. In some embodiments, the BETi formulation is provided in a state where it is partially formulated for immediate release and partially formulated for sustained release (sustained release), so that the formulation provides the dual benefit of an initial effect followed by sustained release for a continuous and long-lasting effect, thereby potentially increasing patient compliance and reducing dosing frequency. In addition, there may be an advantage in reducing or ameliorating the peaks and troughs that may be associated with immediate release formulations, and thus the associated side effects that may occur.

[0046] In some embodiments, the BETi formulation may be provided in one or more of a pMDI (puffer inhaler), a dry powder inhaler (DPI), an SMI (mist inhaler) or a nebulizer. Such devices are designed to be administered daily or at other intervals as prescribed. In some embodiments, the BETi formulation is designed for sustained release, depositing the BETi in the lung (lumen) and slowly releasing therein. In some embodiments, the particle size distribution (PSD) of the BETi in the formulation for sustained release affects the penetration of the BETi deposited in the lung (lumen). In some embodiments, the BETi formulation is provided in a liposome, which is suitable for sustained release. In some embodiments, the BETi formulation provided in a DPI is suitable for sustained release, for example, when the BETi is provided coated with one or more layers or incorporated into small particles (e.g., microspheres or nanospheres), from which the BETi is slowly released. Such coatings or particles include materials that can dissolve in the lung and are generally non-irritating.

[0047] In some embodiments, the BETi is provided in a lyophilized formulation. In some embodiments, the lyophilized formulation comprises or consists of one or more of a sugar (e.g., dextran, sucrose, or trehalose) in water, and optionally a surfactant (e.g., polysorbate 80 or polysorbate 20), or a polar solvent (e.g., propylene glycol or glycerin), or a cyclodextrin or a derivative thereof (e.g., 2HP-βCD or betadex sulfobutylethyl sodium).

[0048] In some embodiments, a suitable formulation for a DPI comprises or consists of spray-dried lactose or lactose monohydrate about 50-200 μm, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, an ultrafine grade with a d50<20 μm is used. In some embodiments, a DPI formulation comprises or consists of about 10:90-90:10% w / w lactose:mannitol mixture, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, a DPI formulation comprises or consists of about 10:90-90:10% w / w lactose:sucrose mixture, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, the dry powder inhaler formulation comprises or consists of silicon dioxide (e.g., about 0.5%), magnesium stearate (e.g., about 5%), lactose monohydrate (e.g., about >90%), loaded with up to about 5% BETi (e.g., BETi1).

[0049] In some embodiments, a formulation suitable for a capsule for a DPI comprises or consists of crystalline lactose, e.g., about 50-200 μm, or about 50-20 μm, or about <20 μm, loaded with up to about 5-10% BETi (e.g., BETi1), HPMC (hydroxypropyl methylcellulose), and optionally magnesium stearate of about <20 μm. In some embodiments, a formulation suitable for a capsule for a DPI comprises or consists of crystalline lactose, e.g., as described above, HPMC, and optionally carrageenan of about <20-200 μm, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, a formulation suitable for a capsule for a DPI comprises or consists of crystalline lactose, e.g., as described above, HPMC, and optionally silicon dioxide of about <20-200 μm, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, a suitable formulation for a capsule for a DPI comprises or consists of crystalline lactose, e.g., as described above, about <20 μm mannitol, and HPMC, loaded with up to about 5-10% BETi (e.g., BETi1). In some embodiments, a suitable formulation for a capsule for a DPI comprises or consists of crystalline lactose, e.g., as described above, about <20 μmol and about <20 μm sucrose, trehalose, or another sugar, loaded with up to about 5-10% BETi (e.g., BETi1), and HPMC. In some embodiments, a suitable formulation for a capsule for a DPI comprises or consists of crystalline lactose, e.g., as described above, about <20 μmol and about <20 μm sucrose, trehalose, or another sugar, loaded with up to about 5-10% BETi (e.g., BETi1), loaded with up to about 5-10% BETi (e.g., BETi1), loaded with up to about 50-200 μm crystalline lactose, about <20 μm mannitol, and HPMC.

[0050] In some embodiments, the liposome formulation comprises or consists of phospholipids (e.g., about 5%) in water. In some embodiments, the liposome formulation comprises or consists of phospholipids (e.g., about 2%) and cholesterol (e.g., about 2%) in water. In some embodiments, the liposome formulation comprises or consists of phosphatidylcholine (e.g., about 0.5%) in water.

[0051] In some embodiments, the liposomal formulation comprises or consists of a phospholipid or derivative thereof, water or saline, soybean oil, and optionally a polar solvent (e.g., propylene glycol or glycerin). In some embodiments, the liposomal formulation comprises or consists of a phospholipid or derivative thereof, water or saline, soybean oil, and cholesterol. In some embodiments, the liposomal formulation comprises or consists of a phospholipid or derivative thereof, water or saline, soybean oil, cholesterol, and a polar solvent (e.g., propylene glycol or glycerin). In some embodiments, the liposomal formulation comprises or consists of a phosphatidylcholine, soybean oil, water or saline, and optionally a polar solvent (e.g., propylene glycol or glycerin).

[0052] In one or more embodiments, exemplary ingredients may be provided in the following amounts or ranges: dextran (about 0.1% to about 10% or about 0.1% to about 1%), sugar (about 0.1% to about 5%), short chain alcohols, such as ethanol (about 0.1% to about 40% or about 0.1% to about 5%), glycerin or glycol (about 0.1% to about 5% or about 0.1% to about 2.5%), polymeric agents such as carbomers or carrageenans (about 0.05% to about 3% or about 0.1% to about 0.5%), surfactants (about 0.1% to about 5% or about 0.1% to about 2%), and poloxamers (about 0.1% to about 2% or about 0.2% to about 1%). When oils or triglycerides are present, they may be about 0.1% to about 10%. In the case of liposomes, the composition includes phospholipids and optionally cholesterol, each of which can be about 0.3% to about 8% or about 0.5% to about 5%.

[0053] In some embodiments, the formulation is provided as a micellar solution or suspension. In some embodiments, the micellar solution comprises or consists of water (e.g., about 90%), natural oil (e.g., canola, sesame, soybean, grape seed) (e.g., about 3%), hexylene glycol (e.g., about 2%), propylene glycol (e.g., about 5%), and poloxamer, e.g., poloxamer 182 / 184 (e.g., about 0.5%).

[0054] In some embodiments, the micellar solution or suspension comprises or consists of water, a natural oil (e.g., canola, sesame, soybean, grape seed), at least one polar solvent (e.g., hexelenium glycol and / or propylene glycol), and optionally a poloxamer (e.g., poloxamer 182 / 184). In some embodiments, the micellar solution or suspension comprises or consists of water, a natural oil (e.g., canola, sesame, soybean, grape seed), a poloxamer (e.g., poloxamer 182 / 184), and optionally a surfactant (e.g., polysorbate 80 or polysorbate 20). In some embodiments, the micellar solution or suspension comprises or consists of water, a natural oil (e.g., canola, sesame, soybean, grape seed), and a surfactant (e.g., polysorbate 80 or polysorbate 20). In some embodiments, the micellar solution or suspension comprises or consists of water, at least one polar solvent (e.g., hexylene glycol and / or propylene glycol), a poloxamer (e.g., poloxamer 182 / 184), a medium chain triglyceride (MCT), an MCT derivative, or coconut oil. In some embodiments, the micellar solution or suspension comprises or consists of water, a poloxamer (e.g., poloxamer 182 / 184), a medium chain triglyceride (MCT), an MCT derivative, or coconut oil, and optionally at least one surfactant (e.g., polysorbate 80 or polysorbate 20). In some embodiments, the micellar solution or suspension comprises or consists of water, at least one surfactant (e.g., polysorbate 80 or polysorbate 20), a medium chain triglyceride (MCT), an MCT derivative, or coconut oil, and optionally at least one poloxamer (e.g., poloxamer 182 / 184). In some embodiments, the micellar solution or suspension comprises or consists of water, a poloxamer (e.g., poloxamer 182 / 184), a medium chain triglyceride (MCT), an MCT derivative or coconut oil, and optionally at least one polar solvent (e.g., hexylene glycol and / or propylene glycol).

[0055] In some embodiments, the active compounds bind to BET BDI and BET BDII but do not exhibit high selectivity for BDII. Moreover, it has been surprisingly observed that some such compounds may exhibit some selectivity or slight bias towards BETII, but can effectively function as pan-BET inhibitors that bind to and inhibit both the BDI and BDII domains.

[0056] In some embodiments, the compounds and compositions of the present disclosure have been found to be surprisingly active in inhibiting BET BRD I and II. In some embodiments, the compounds disclosed herein exhibit effective potency at low concentrations, including nanomolar concentrations. Furthermore, it has been surprisingly found that such compounds with higher liver clearance rates can be effective when applied locally, for example to a body cavity surface (e.g., in the lungs), for example, by inhalation, or locally, for example, intra-articularly. The higher clearance rate helps the active compound maintain its low plasma concentration as it enters the blood, for example, through the lung surface, or out of the joint, or transdermally. It has also been surprisingly found that such compounds are stable when applied locally or topically. It has also been surprisingly found that such compounds with lower plasma or systemic stability can be effective when administered or applied locally (e.g., by inhalation) or as an intra-articular composition. Moreover, it has been surprisingly found that such compounds with higher liver clearance rates and lower plasma or systemic stability may be effective when administered or applied, for example, locally, for example, to the surface of a body cavity, or as an intra-articular injection. In one or more embodiments, when the compound is applied locally to the skin or body cavity, or to a mucosal surface (e.g., in the lungs), it penetrates into the skin, the surface of the body cavity, or into the mucosa, respectively, but there is no or only minimal percutaneous penetration. In that case, the compound may be below the therapeutic range and may not have significant systemic effects or undesired systemic side effects. In one or more embodiments, when the compound is applied locally to the skin, body cavity, or to a mucosal surface (e.g., in the lungs), it penetrates percutaneously, permucosally, or through tissues, and therefore may have significant systemic effects or undesired systemic side effects in addition to the effects in the skin, tissue, or mucosa. In some embodiments, the percutaneous or tissue penetration may be at a level that may induce therapeutic range and / or undesired side effects. In some embodiments, the compositions have no significant systemic effects or undesirable systemic side effects when administered, for example, as an intra-articular injection.In some embodiments, by selecting a compound with a higher liver clearance rate and / or lower plasma stability level, any systemic presence may be eliminated quickly and any systemic effects may be minimized or avoided. In one or more embodiments, by selecting a compound that can penetrate the skin, body cavity surfaces (e.g., in the lungs), or mucosa and that also has a lower liver clearance rate and / or higher plasma stability level, any systemic presence may be eliminated more slowly and in some embodiments, such compounds may have a systemic therapeutic effect that complements the therapeutic effect of the skin, tissue, or mucosa.

[0057] In some embodiments, one or more inactive ingredients are added to the formulation, for example at the following concentrations or levels: antioxidants (about ≦2% w / w), pH buffers (about pH 6-8), preservatives (e.g., for larger doses), such as benzyl alcohol (about ≦1% w / w), chelating agents (about ≦2% w / w). In some embodiments, one or more co-solvents are provided.

[0058] In some embodiments, the particle size distribution of the BETi (e.g., BETi1) in suspension or in a dry powder inhaler ("DPI") is, for example, about 2-3 μm. In some embodiments, the concentration of the BETi (e.g., BETi1) in a DPI formulation is up to about 10% w / w of dry weight. In some embodiments, coarse and fine lactose are combined to modify the flowability of the BETi (e.g., BETi1) in a DPI.

[0059] In some embodiments, the concentration of the BETi (e.g., BETi1) in the formulation can be about 0.001% to about 1% w / v. In some embodiments, the concentration of the BETi (e.g., BETi1) in the formulation can be about 0.001% to about 0.1% w / v.

[0060] In some embodiments, the concentration of a BETi (e.g., BETi1) in a formulation other than a DPI can be up to about 1 mg / mL or about 1% w / v. In some embodiments, depending on the route, formulation, and type of application, this can be higher, for example up to about 1.5%, or up to about 2%, or up to about 3%, or up to about 6%. In some embodiments, excipients for inhaled use have an established history of use via respirators.

[0061] In some embodiments, the sustained release formulation comprises a mucoadhesive, SiO 2 In some embodiments, the BETi may comprise or consist of one or more of: cellulose, sugar, diatomaceous earth (e.g., bentonite), or calcium carbonate. In some embodiments, a sugar is used to generate a suspension (depending on the length of the carbon chain). In some embodiments, a sugar (e.g., lactose monohydrate) is used in a dry powder inhaler. In some embodiments, a tablet coating (e.g., povidone, e.g., about 0.5%) is used to slow the release of the BETi (e.g., BETi1).

[0062] It has been reported that aerosol particles can respond to changes in ambient conditions on a time scale comparable to inhalation / exhalation time. Aerosols formed from hygroscopic components (e.g., saline) can increase in size significantly when inhaled, whereas insoluble drug particles can only absorb a molecular layer of water. It has been suggested that inhaled particles smaller than 1 μm in diameter can respond quickly to the moisture content of the environment, except that if they contain surfactant or are crystalline or amorphous particles, the absorption of moisture can be delayed. Inhaled particles larger than 1 μm in diameter are said to absorb water much more slowly, but the moisture content gained can still affect the particle's properties upon deposition. Thus, the microphysical processes occurring in the aerosol phase can be partially regulated or controlled in one or more embodiments, for example, by selecting the composition and size of the aerosol particles to delay absorption or enhance dissolution.

[0063] In some embodiments, the compounds disclosed herein are therapeutically effective by administration locally, e.g., to a surface of a body cavity (e.g., by inhalation) or by administration using an inhaler. In some embodiments, the body cavity surface can be a mucous membrane. In some embodiments, the body cavity surface can be an epithelium. In some embodiments, the body cavity surface can be a surface of an air sac in the lung. In some embodiments, the body cavity surface can be a surface of the interstitium. In some embodiments, the body cavity surface can be a surface of the respiratory epithelium or parenchyma. In some embodiments, e.g., when applied locally, systemic penetration is low and / or below the therapeutic range. In other embodiments, e.g., when applied locally, systemic penetration can be sufficient to allow the compound to have a systemic therapeutic effect in addition to any local effects. In some embodiments, administration is designed to be intradermal. In some embodiments, administration is designed to be transdermal. In some embodiments, administration is designed to be intramucosal or intratissue within an epithelial layer. In some embodiments, administration is designed to be transmucosal or transepithelial.

[0064] Local delivery can be achieved by applying the compound or a pharmaceutical composition containing the compound to the skin, epithelium, or mucosal surface of a subject, including the inner surface of body cavities such as the rectum, gastrointestinal tract, vagina, airways, and lungs. Potential half-life can be indicated by factors such as liver clearance rate and / or plasma stability. Compounds with both properties of higher liver clearance rate and lower plasma stability can be more effective locally or regionally in one or more embodiments. Compounds with either the properties of higher liver clearance rate or lower plasma stability can be more effective locally in one or more embodiments.

[0065] Potential efficacy against one or more of the disorders or diseases described herein may, in one or more embodiments, be indicated by the ability of the compound to modulate or reduce a biomarker known or implicated in, for example, inflammatory or immune responses. Non-limiting examples include reducing the levels of one or both of IL-17 and IL-22; and / or reducing the levels of one or more of the TH17 cytokine biomarkers, including IL-1β, IL-17, IL-6, IL-36, TNFα, and CXC motif chemokine ligand 10 (LP-10); and / or reducing the levels of one or more of the TH2 cytokine biomarkers IL-4, IL-13, and IL-31.

[0066] In some embodiments, the compounds disclosed herein are therapeutically effective when administered as an intra-articular injection or by administration using an inhaler. In some embodiments, an immediate release, controlled release, or sustained release preparation or formulation containing a BETi is administered as one or more intra-articular injections or as a dry powder. In some embodiments, a combination of an immediate release form and a sustained release form of a BETi (e.g., BETi1) is administered (e.g., by a single injection or as sequential injections) into an intra-articular space or soft tissue to slow, stop, reverse, or otherwise inhibit structural damage to tissues associated with progressive disease, such as damage to cartilage, as associated with the progression of osteoarthritis. In some embodiments, a combination form of a BETi can be administered (e.g., by a single injection or as sequential injections) into the respiratory system or lungs to slow, stop, reverse, or otherwise inhibit structural damage to tissues associated with progressive disease, such as damage to the lungs, as associated with the progression of PF. In some embodiments, the formulations disclosed herein can achieve initial relief of acute symptoms (e.g., inflammation) of a joint or joint-related disease or condition, and further provide a sustained or long-term therapy (e.g., slowing, halting, reversing, or otherwise inhibiting structural damage to tissues associated with progressive disease), while avoiding the long-term systemic side effects associated with corticosteroid (e.g., triamcinolone, dexamethasone) administration. In some embodiments, the formulations disclosed herein can achieve initial relief of acute symptoms (e.g., inflammation) of a lung or respiratory system-related disease or condition, and further provide a sustained or long-term therapy (e.g., slowing, halting, reversing, or otherwise inhibiting structural damage to tissues associated with progressive disease), while avoiding the long-term systemic side effects associated with corticosteroid (e.g., prednisone) administration.

[0067] In some embodiments, the initial relief may be immediate. In some embodiments, the initial relief may begin or be experienced soon after treatment is started, for example, about half a day, about 1 day, about 2 days, about 3 days, about 4 days, or about 5 days. In some embodiments, the relief experienced may increase or improve once it begins, and in some embodiments, may reach a steady state after a period of time. Several factors may affect the presence and therapeutic effectiveness of the active compound, including its rate of local dissolution (e.g., into synovial fluid in a joint) if suspended, its rate of passage into the blood, for example, its clearance by the liver and / or kidney, and its stability / degradation in plasma.

[0068] In one or more embodiments, the compound is more soluble in bodily fluids (e.g., synovial fluid) than in the formulation. Since smaller particles may dissolve and dissipate more quickly, in one or more embodiments, increasing the particle size can provide a depot effect that retains the drug locally, e.g., in a joint, for a longer period.

[0069] In some embodiments, the sustained release formulation is a suspension of a BETi compound (or two or more BETi) in a vehicle or carrier. In some embodiments, the suspension contains two or more average particle sizes of BETi. In some embodiments, smaller particles may release at a higher rate than larger particles. In some embodiments, at least a portion of the particles are coated to facilitate a slower release rate. In some embodiments, the BETi is encapsulated, for example, in microparticles or microspheres.

[0070] In some embodiments, when about 0.05% to about 15%, e.g., about 0.01% to about 10%, about 0.1% to about 10%, about 0.1% to about 5%, about 1% to about 10%, or about 1% to about 5% of BETi is applied intraarterially or intravenously based on the weight of the composition or the weight of the volume of the composition, there is an improvement in at least one symptom of a joint disorder or disease. In some embodiments, when about 0.001% to about 10%, e.g., about 0.001% to about 1%, about 0.01% to about 1%, or about 0.1% to about 1% of BETi is applied intranasally or intrapulmonaryly based on the weight of the composition or the weight of the volume of the composition, there is an improvement in at least one symptom of a respiratory disorder or disease. Unless otherwise specified, amounts expressed in weight units (whether absolute weights or amounts relative to another weight or volume, or as a percentage) of BETi or "at least one compound, tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative" are based on the weight of the free base of the BETi or compound, respectively.

[0071] In some embodiments, there is an improvement in at least one symptom of a joint disorder or disease upon topical application of 0.1% to about 15% BETi, or about 0.2% to about 10%, by weight of the composition or by weight of the volume of the composition. In some embodiments, the BETi is about 0.1%, or about 0.25%, or about 0.5%, or about 0.75%, or about 1%, or about 1.25%, or about 1.5%, or about 1.75%, or about 2%, or about 2.25%, or about 2.5%, or about 2.75%, or about 3%, or about 3.25%, or about 3.5%, by weight of the composition or by weight of the volume of the composition. , or about 3.75%, or about 4%, or about 4.25%, or about 4.5%, or about 4.75%, or about 5%, or about 5.5%, or about 6%, or about 6.5%, or about 7%, or about 7.5%, or about 8%, or about 8.5%, or about 9%, or about 9.5%, or about 10%, or about 11%, or about 12%, or about 13%, or about 15%, or about 15%. In some embodiments, the application of BETi is, for example, inter-articular and for immediate release, and can be administered in a single dose of about 1 mg / vial to about 750 mg / vial, or about 2 mg / vial to about 500 mg / vial, the vial being about 5 ml or about 2.5 ml or about 1 ml or about 0.5 ml depending on the size of the joint and the age and size of the subject.In some embodiments, the BETi is for interarticular and immediate release and is about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg The compound may be administered in a single dose of about 150 mg / vial, or about 200 mg / vial, or about 250 mg / vial, or about 300 mg / vial, or about 350 mg / vial, or about 400 mg / vial, or about 450 mg / vial, or about 500 mg / vial, or about 550 mg / vial, or about 600 mg / vial, or about 650 mg / vial, or about 700 mg / vial, or about 750 mg / vial. In some embodiments, application of the BETi is for inter-articular and sustained release and can be administered in a single dose of about 1 mg / vial to about 350 mg / vial, or about 2 mg / vial to about 250 mg / vial, or about 10 mg / vial to about 150 mg / vial, or about 10 mg / vial to about 100 mg / vial, where the vial is about 5 ml, or about 2.5 ml, or about 1 ml, or about 0.5 ml, depending on the size of the joint and the age and size of the subject. In some embodiments, the BETi is for sustained release and can be administered in a single dose of about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg / vial, or about 150 mg / vial, or about 200 mg / vial, or about 250 mg / vial.In some embodiments, where the composition provides an immediate or initial dose and an extended release dose, the composition can be administered in a single dose of about 1 mg / vial to about 750 mg / vial, or about 2 mg / vial to about 500 mg / vial, or about 2 mg / vial to about 250 mg / vial, or about 10 mg / vial to about 150 mg / vial, or about 10 mg / vial to about 125 mg / vial, where the vial is about 5 ml, or about 2.5 ml, or about 1 ml, or about 0.5 ml, depending on the size of the joint and the age and size of the subject.

[0072] In some embodiments, there is an improvement in at least one symptom of a respiratory disorder or disease upon topical application of 0.001% to about 1%, or about 0.01% to about 1%, or about 0.01% to about 1%, or about 0.01% to about 10% BETi by weight of the composition or by weight of the volume of the composition. In some embodiments, the BETi is about 0.001%, or about 0.002%, or about 0.003%, or about 0.004%, or about 0.005%, or about 0.006%, or about 0.007%, or about 0.008%, or about 0.009%, or about 0.01%, or about 0.02%, or about 0.03%, or about 0.04%, or about 0.05%, or about 0.06%, or about 0.08%, or about 0.08%, or about 0.09%, or about 0.01%, or about 0.02%, or about 0.03%, or about 0.04%, or about 0.05%, or about 0.06 ... is about 0.07%, or about 0.08%, or about 0.09%, or about 0.1%, about 0.2%, or about 0.25%, or about 0.3%, or about 0.4%, or about 0.5%, or about 0.6% or about 0.7%, or about 0.8%, or about 0.9%, or about 1% or about 1.5%, about 2%, or about 2.5%, or about 3%, or about 4%, or about 5%, or about 6% or about 7%, or about 8%, or about 9%, or about 10%. In some embodiments, the application of BETi is, for example, inhaled and for immediate release, and can be administered in a single dose of about 0.001 mg / vial to about 750 mg / vial, or about 0.02 mg / vial to about 50 mg / vial, or about 0.06 mg / vial to about 3 mg / vial, about 0.001 mg / vial to about 100 mg / vial, or about 0.2 mg / vial to about 50 mg / vial, or about 0.6 mg / vial to about 3 mg / vial, where the vial is about 100 ml, or about 50 ml, or about 10 ml, or about 5 ml, or about 2.5 ml, or about 1 ml, depending on the size of the lungs and the age and size of the subject.In some embodiments, the BETi is inhaled and for immediate release and is about 0.005 mg / vial, or about 0.006 mg / vial, or about 0.007 mg / vial, or about 0.008 mg / vial, or about 0.009 mg / vial, or about 0.01 mg / vial, or about 0.02 mg / vial, or about 0.03 mg / vial, or about 0.04 mg / vial, or about 0.05 mg / vial or about 0.06 mg / vial, or about 0.07 mg / vial, or about 0.08 mg / vial, or about 0.09 mg / vial, or about 0.1 mg / vial, or about 0.2 mg / vial, or about 0.25 mg / vial, or about 0.3 mg / vial, or about 0.4 mg / vial, or about 0.5 mg / vial, or about 0.6 mg / vial, or about 0.7 mg / vial, or about 0.8 mg / vial, or about 0.9 mg / vial g / vial, or about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg / vial, or about 150 mg / vial g / vial, or about 200 mg / vial, or about 250 mg / vial, or about 300 mg / vial, or about 350 mg / vial, or about 400 mg / vial, or about 450 mg / vial, or about 500 mg / vial, or about 550 mg / vial, or about 600 mg / vial, or about 650 mg / vial, or about 700 mg / vial, or about 750 mg / vial. In some embodiments, the application of BETi is for sustained release and can be administered in a single dose of about 0.001 mg / vial to about 350 mg / vial, or about 0.002 mg / vial to about 250 mg / vial, the vial being about 100 ml, about 50 ml, or about 10 ml, or about 5 ml, or about 2.5 ml, or about 1 ml, depending on the size of the lungs and the age and size of the subject.In some embodiments, the BETi is for sustained release and is about 0.01 mg / vial, or about 0.02 mg / vial, or about 0.03 mg / vial, or about 0.04 mg / vial, or about 0.05 mg / vial, or about 0.06 mg / vial, or about 0.07 mg / vial, or about 0.08 mg / vial, or about 0.09 mg / vial, about 0.1 mg / vial, or about 0.2 mg / vial, or about 0.3 mg / vial, or about 0.4 mg / vial, or about 0.5 mg / vial, or about 0.6 mg / vial, or about 0.7 mg / vial, or can be administered in a single dose of about 0.8 mg / vial, or about 0.9 mg / vial, or about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg / vial, or about 150 mg / vial, or about 200 mg / vial, or about 250 mg / vial. In some embodiments, where the composition provides an immediate or initial dose and an extended release dose, the composition can be administered in a single dose of about 0.01 mg / vial to about 750 mg / vial, or about 0.02 mg / vial to about 500 mg / vial, or about 0.02 mg / vial to about 250 mg / vial, where the vial is about 50 ml, or about 25 ml, or about 10 ml, or about 5 ml, or about 2.5 ml, or about 1 ml, depending on the size of the lungs and the age and size of the subject.

[0073] In some embodiments, derivatives of the pyrrolo N-methyl-2-pyridone compounds described herein can be surprisingly effective as pan-BET inhibitors, as shown by the examples. In some embodiments, the compounds of the present disclosure act effectively as pan-BET inhibitors and have high liver clearance rates and / or low plasma stability. In some embodiments, the compounds of the present disclosure provide pan-BET inhibition and have lower liver clearance rates and / or some plasma stability.

[0074] In some embodiments, the compounds disclosed herein are effective drugs in the local treatment of diseases or disorders, such as joints and joint-related diseases and disorders, when the compounds or pharmaceutical compositions are administered or applied locally, e.g., into the skin or body cavities, to the surfaces of body cavities such as the alveoli, e.g., by inhalation, or locally as an intra-articular injection.

[0075] In one or more embodiments, the compounds and compositions lack solubility in, and can be homogeneously suspended and dispersed in, a wide variety of solvents, carriers, and formulations suitable for topical application. Such homogeneous suspensions are exemplified herein. In one or more other embodiments, the compounds and compositions are also soluble in a wide variety of other solvents, carriers, and formulations suitable for topical application. In some embodiments, the protic solvent acts to improve the solubility of the active agent. In some embodiments, the delivery of the active agent is improved by the aprotic solvent and / or the protic solvent. In some embodiments, a composition is provided that includes an aprotic polar solvent and / or a protic polar solvent, and the protic polar solvent can be a short-chain alcohol. Advantageously, many of the compounds and compositions described herein are stable, for example, in the respiratory system, mucous membranes, joints, and / or skin of humans and animals. Also, various compounds may exhibit stability under hydrolytic conditions at a range of pH values. Furthermore, the compound and composition formulations can deliver a practical concentration of the compound in the epidermis and / or dermis of the skin or in the mucosa in a therapeutically effective amount, and the compound is not toxic to skin or mucosa cells. The respiratory system refers to the parts of the body involved in breathing, in which oxygen and carbon dioxide are exchanged. It includes the nose, mouth, throat (pharynx), larynx (voice box, larynx), windpipe (trachea), large airways (bronchi), small airways (bronchioles), and lungs. The lungs are air-filled organs that contain airways and the respiratory epithelium or parenchyma that make up the numerous thin-walled alveoli. Also, various compounds may exhibit stability under hydrolytic conditions at a range of pH values. Furthermore, formulations of the compounds and compositions can deliver practical concentrations of the compounds in therapeutically effective amounts within the mucosa or tissues of the respiratory tract, including the lower respiratory tract, and the respiratory epithelium or parenchyma of the lungs, and / or into the epidermis and / or dermis of the skin, and the compounds are not toxic to mucosal cells or tissues of the respiratory tract, including the lower respiratory tract, and the respiratory epithelium or parenchyma of the lungs, or to skin cells. The compounds and compositions of the present disclosure in some embodiments exhibit surprisingly efficient clearance by the liver, offering the potential for pharmaceutical use with a lower risk of side effects.In some embodiments, they degrade more rapidly when entering the blood system, but are stable enough to achieve a therapeutic effect in the respiratory system, including the lower respiratory tract and the respiratory epithelium or parenchyma of the lung, mucosa, and / or skin, offering the potential for use as pharmaceuticals for local administration. Similarly, in some embodiments, they degrade more rapidly when entering the blood system, but are stable enough to achieve a therapeutic effect in the skin, mucosa, or joints. Some of the compounds have some selectivity for BDII over BDI, but offer the potential for improved local or regional therapeutic effects and reduced risk of side effects. In one or more embodiments, the pan-BET inhibitors have low, very low, or insignificant selectivity for BDII over BD1. In some embodiments, the selectivity for BDII over BDI is, for example, about 15-fold to about 1-fold, about 15-fold to about 2-fold, or about 10-fold to about 1-fold, or about 10-fold to about 2-fold, or <50-fold; about <15-fold; about <10-fold; about <8-fold; about <6-fold; about <4-fold; about <2-fold; about <1-fold. In some embodiments, the selectivity for BDII over BDI is less than 2-fold. In some embodiments, the binding to BD1 and BDII is similar. In some embodiments, the selectivity for BD1 and BDII is similar. In some embodiments, the selectivity for BDII over BDI is less than 4-fold. In some embodiments, the selectivity for BDII over BDI is less than 6-fold. In some embodiments, the selectivity for BDII over BDI is less than 8-fold. In some embodiments, the selectivity for BDII over BDI is less than 10-fold. In some embodiments, the selectivity for BDII over BDI is about 1-fold to about 2-fold. In some embodiments, the selectivity for BDII over BDI is about 2-fold to about 4-fold. In some embodiments, the selectivity for BDII over BDI is about 4-fold to about 6-fold. In some embodiments, the selectivity for BDII over BDI is about 6-fold to about 8-fold. In some embodiments, the selectivity for BDII over BDI is about 8-fold to about 10-fold. In some embodiments, the selectivity for BDII over BDI is greater than 10-fold.

[0076] BET inhibitors have been proposed as treatments for numerous disorders and diseases. Nearly all BET inhibitors in development are for oral delivery, e.g., for systemic treatment of cancer. In some embodiments, compounds are provided that can function as "soft" pan-BD BET inhibitors. In one or more embodiments, the BETi is a "soft drug." In one or more embodiments, the BETi is metabolized upon reaching the blood or liver. In one or more embodiments, the clearance of the BETi in the joint is unpredictable. In one or more embodiments, the clearance and pK of the BETi in the joint is multifactorial and can be affected by factors including the solubility of the active compound, the dose, the particle size, the formulation, the size of the joint, the solubility and stability in the joint, and leakage from the joint.

[0077] In one or more embodiments, the compounds and compositions disclosed herein may favorably affect diseases and disorders involving multiple and diverse inflammatory cell signaling pathways. In some embodiments, the compounds and compositions disclosed herein may favorably affect autoimmune or autoimmune-related diseases and disorders. In some embodiments, the compounds disclosed herein may favorably affect skin diseases and disorders, including, for example, diseases or disorders involving lesional wounds where the healing process is about to break down or has broken down. In some embodiments, the compounds disclosed herein may favorably affect joint or joint-related diseases and disorders. In some embodiments, the compounds disclosed herein may favorably affect fibrosis or fibrosis-related diseases and disorders. In some embodiments, the compounds disclosed herein may favorably affect pulmonary or lung-related diseases and disorders.

[0078] As used herein, "BETi" as used in this disclosure refers to compounds of formula (I), their tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and deuterated derivatives: [ka] wherein Ring A is selected from phenyl, N-methyl-2-pyridone, and thiazole; n is 0 or 1, when A is phenyl, n is 1, when A is N-methyl-2-pyridone, n is 0, when A is thiazole, n is 0; R 2 hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 Phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; 2 -C 6 Alkyl; and C 1 -C 6 C optionally substituted with a substituent selected from alkoxy 3 -C 6 It is cycloalkyl.

[0079] In some embodiments, ring A is [ka] is selected from.

[0080] In some embodiments, ring A is [ka] Selected from R 2 hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 and phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino.

[0081] In some embodiments, the compound of formula I has the following structure: [ka] wherein Ring A is selected from phenyl and N-methyl-2-pyridone; n is 0 or 1, and when A is phenyl, n is 1, and when A is N-methyl-2-pyridone, n is 0.

[0082] In some embodiments, in formula II, ring A is [ka] is selected from.

[0083] In some embodiments, the compound of formula I has the following structure: [ka] wherein R 21 are (i) hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1-C 5 phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; and 1 -C 6 C optionally substituted with a substituent selected from alkoxy 3 -C 6 cycloalkyl.

[0084] In some embodiments, in Formula III, R 21 is phenyl, cyclobutyl, or C 1 -C 6 and cyclohexyl optionally substituted with a substituent selected from alkoxy.

[0085] In some embodiments, in Formula III, R 21 is phenyl.

[0086] In some embodiments, the compound of formula I is [ka] It is.

[0087] In some embodiments, the compound of formula I is [ka] It is.

[0088] In some embodiments, the compound of formula I is [ka] It is.

[0089] In some embodiments, the compound of formula I is [ka] It is.

[0090] In some embodiments, the compound of formula I is [ka] Hereinafter, this compound is referred to as BETi1.

[0091] In some embodiments, the compound of formula I is [ka] It is.

[0092] In some embodiments, the compound of formula I is [ka] It is.

[0093] In some embodiments, the compound of formula I is [ka] It is.

[0094] Included herein are tautomers and stereoisomers of the compounds of Formulas (I)-(III), as well as pharma- ceutically acceptable salts, hydrates, and deuterated derivatives of any of the foregoing.

[0095] In one or more embodiments, compounds are provided that may be applicable and have therapeutic activity against a specific set of diseases and disorders involving cytokine pathways as part of the pathogenic factors involved in the development of symptoms, such as multiple neutrophilic skin diseases, such as pyoderma gangrenosum (PG), palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP). Alternatively, compounds are provided that may be applicable and have therapeutic activity against pigmentation disorders, such as vitiligo, and / or pigmentation-related disorders. Pigmentation-related disorders (e.g., skin disorders) that are similar to vitiligo and can be treated by the compounds of the present invention include chemical leukoderma, which is a linear or patchy whitening of parts of the skin, tinea versicolor, albinism, which is a low level of melanin in the skin, and pityriasis alba, which is a patchy lightening of the skin.

[0096] In some embodiments, pigmentation disorders can be divided into two main groups. The first group is related to the appearance of pale or white skin spots, for example where there is a reduction in melanin, resulting in pale spots (hypopigmentation, hypomelanosis) or pale skin or white spots (depigmentation, leukoplakia). These are typically due to the absence of melanocytes or loss of melanin in the epidermis. In one or more embodiments, the utility of the BET inhibitors provided herein for the first group is illustrated by various examples herein with respect to skin morphology, melanocytes, MMP-9, E-cadherin, TRP-1 expression, melanin content, and gene expression. In some embodiments, this first group may benefit from the BET inhibitors provided herein by helping to preserve, maintain, or preserve the localization of melanocytes in the basal layer, which over time may help restore skin color or slow and / or avoid further deterioration of skin color. In one or more embodiments, pigmentation disorders include vitiligo, chemical leukoplakia, tinea versicolor, albinism, and pityriasis alba. Also includes atrophy of the skin, Griscelli syndrome, halo moles, Hermansky-Pudlak syndrome, Ito's hypomelanosis, idiopathic guttate hypomelanosis, leprosy, leukoplakia, lichen sclerosus, lupus erythematosus, morphea, mycosis fungoides, anemic nevus, depigmented nevus, mottling, leukoderma, leukoderma, postinflammatory hypopigmentation, progressive patchy hypopigmentation, tuberous sclerosis (Ashleaf spots), and Waardenburg syndrome.

[0097] In some embodiments, the second group relates to the appearance of darker skin spots with increased melanin (hyperpigmentation, hypermelanosis), which may result from, for example, an increased number of pigment cells (melanocytes) or increased production of melanin. While the examples herein relate to the retention of melanocytes and pigmentation and reduced loss of pigmentation, the second group is in the opposite situation, darkening from increased or concentrated pigmentation, and it is currently unclear how BET inhibitors may affect this group. In one or more embodiments, the disorder is vitiligo.

[0098] In some embodiments, compounds are provided that are applicable and may have therapeutic activity against joint or joint-related disorders or diseases.

[0099] In some embodiments, the joint or joint-related disorder or disease is selected from arthritis, bursitis, Ehlers-Danlos syndrome, Felty syndrome, epicondylitis, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus and other autoimmune joint disorders. In some embodiments, the joint or joint-related disorder or disease is selected from arthritis, bursitis, epicondylitis, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, tenosynovitis, synovitis and autoimmune joint disorders. In some embodiments, the joint or joint-related disorder or disease is rheumatoid arthritis. Other diseases or disorders that can be treated locally by the compounds disclosed herein are listed in the detailed description.

[0100] The present disclosure provides exemplary BETi that may also provide novel and effective treatments or amelioration of secondary joint diseases and disorders.

[0101] In some embodiments, compounds are provided that can be applied to and have therapeutic activity against pulmonary diseases and disorders. Therapeutic activity can include preventing, treating, ameliorating, or delaying the progression of a disease or disorder. In some embodiments, compounds are provided that can be applied to and have therapeutic activity against fibrotic or scarring diseases or disorders, such as PF. In some embodiments, compounds are provided that can be applied to and have therapeutic activity against fibrosis-related disorders. Fibrosis-related disorders similar to PF (e.g., various ILDs) can be characterized by inflammation and / or scarring in lung tissue, air sac walls, or interstitium.

[0102] In some embodiments, a patient may be diagnosed with "unclassifiable interstitial lung disease" if he or she does not meet all the criteria for a confident diagnosis of a certain type of interstitial lung disease or pulmonary fibrosis. This occurs when there are non-specific or contradictory findings in CT scan, lung biopsy, or clinical course of the disease. Another case in which a diagnosis of unclassifiable ILD may occur is when a patient cannot undergo standard diagnostic testing.

[0103] In some embodiments, compounds are provided that are applicable to lung diseases or ILDs that can be classified into two groups: idiopathic or known (secondary). Idiopathic interstitial pneumonia is the term given to ILDs with unknown causes. They represent the majority of cases of interstitial lung disease (up to 2 / 3 of cases). In some embodiments, the fibrosis or respiratory disorder or disease is pulmonary fibrosis (PF). In some embodiments, idiopathic ILDs can include idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP): also known as Hamman-Rich syndrome, nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), idiopathic organizing pneumonia (COP) (also known as bronchiolitis obliterans organizing pneumonia (BOOP)), or lymphocytic interstitial pneumonia (LIP).

[0104] In some embodiments, the secondary ILD is an ILD caused by another disease, such as sarcoidosis or lymphangioleiomyomatosis, or may be a late effect of acute respiratory distress syndrome occurring in critical illness. In some embodiments, the secondary ILD is a disease of known etiology. In some embodiments, the secondary lung disorder includes connective tissue and autoimmune diseases, such as sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, or antisynthetase syndrome. In some embodiments, the secondary ILD includes ILD induced by inhalation of inorganic substances (pneumoconiosis), which may include silicosis, asbestosis, beryllium disease, industrial printing chemicals (e.g., carbon black, ink mist). In some embodiments, secondary ILD includes ILD induced by inhalation of organic substances (pneumoconiosis), which may include hypersensitivity pneumonitis (extrinsic allergic alveolitis), drug-induced diseases such as antibiotics, chemotherapy drugs, and antiarrhythmic drugs, infections (coronavirus disease), atypical pneumonia, Pneumocystis pneumonia (PCP), tuberculosis, chlamydia trachomatis, respiratory syncytial virus), malignant diseases (lymphangitis carcinomatosa). ILD may occur primarily in children due to, for example, pervasive developmental disorders, growth abnormalities, alveolar proliferation failure, infantile disease of undetermined etiology, and alveolar surfactant area-related ILD.

[0105] In some embodiments, the fibrosis or fibrosis-related disorder is interstitial pulmonary fibrosis. In some embodiments, a method is provided for treating fibrosis or fibrosis-related disorder that affects other organs or tissues, such as the liver, epidermis, endothelium, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, ovary, adrenal gland, artery, vein, colon, small intestine, biliary tract, or stomach. In some embodiments, the fibrosis or fibrosis-related disorder is the result of infection by schistosomes. In some embodiments, the fibrosis or fibrosis-related disorder is the result of wound healing. In some embodiments, the wound healing results from a surgical incision.

[0106] In some embodiments, PF can be divided into six main groups. The first group is environmentally induced (also known as hypersensitivity pneumonitis), which includes exposure to pollution, mold, and animals. The second group is occupationally induced (also known as pneumoconiosis), which includes exposure to dust, fibers, fumes, or vapors, such as asbestos, coal, and silica. The third group is drug induced, such as amiodarone, nitrofurantoin, methotrexate, and chemotherapy. The fourth group is radiation induced. The fifth group is autoimmune induced (also known as connective tissue disease-related), which is characterized by joint inflammation, skin changes (especially on the fingers and face), dry mouth or eyes, or abnormal blood tests. The last group is idiopathic, which is the most common form of PF and has a high mortality rate within 3 to 5 years. In some embodiments, fibrotic disorders include PF induced by causes such as long-term exposure to certain toxins (e.g., smoking), secondary effects of other diseases and disorders such as ILDs, viral infections (e.g., COVID-19 and related SARS viruses), and bacterial infections.

[0107] In some embodiments, other forms of PF may have a genetic component, such as familial pulmonary fibrosis and pulmonary fibrosis associated with Hermansky Pudlak syndrome or dyskeratosis congenita.For example, mutations in surfactant protein C (SP-C) have been found to be present in some families with a history of pulmonary fibrosis.Autosomal dominant mutations in the TERC or TERT genes that code for telomerase have been identified in approximately 15 percent of PF patients.

[0108] Some patients have a form of pulmonary fibrosis that does not fit into any of the known categories of interstitial lung disease or have overlapping features of more than one type of ILD, termed "unclassifiable ILD."

[0109] In addition to potential treatment benefits for pigmentation diseases and disorders such as vitiligo and related pigmentation diseases and disorders, lesions and wound diseases (e.g., those with impaired healing) and other similar skin disorders, joint or joint-related diseases or disorders, or lung diseases and disorders, particularly those involving fibrosis or scarring, e.g., PF and other similar disorders involving fibrosis or scarring, the compounds provided herein may, in some embodiments, have a prophylactic or preventative effect, such that by administering them locally or topically after treatment or prior to onset or recurrence of the disease or disorder in subjects prone to developing such a disease or disorder, the disease or disorder is slowed or does not develop further, or the disease or disorder does not develop or appears in a milder or less severe form, or does not appear. [Brief description of the drawings]

[0110] [Figure 1A] Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1B]Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1C] Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1D]Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1E] Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1F]Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1G] Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 1H]Figures 1A-H show efficacy and tolerance results from the mouse imiquimod-induced inflammation model. Figure 1A shows the Psoriasis Index (PASI) of animals treated with different petrolatum-based formulations at different BETi1 strengths for 7 consecutive days compared to three control arms and two dose tolerance arms, and Figure 1C shows photographic images of visual parameters on day 14. Figure 1B shows the average body weight of animals treated with formulations at different BETi1 strengths and controls. Other parameters tested and illustrated are behavioral parameters, namely enrichment use (Figure 1D), inflammatory biomarkers (Figure 1E). Figure 1F shows modified PASI of animals treated with the different formulations, Figure 1G shows the average percent change in modified PASI severity score before induction for three of the doses compared to steroid and vehicle, and Figure 1H shows the change in the average percent change in body weight. [Figure 2A] 1 shows the results of a wound healing animal model study. [Figure 2B] 1 shows the results of a wound healing animal model study. [Figure 2C] 1 shows the results of a wound healing animal model study. [Figure 2D] 1 shows the results of a wound healing animal model study. [Figure 2E] 1 shows the results of a wound healing animal model study. [Figure 2F] 1 shows the results of a wound healing animal model study. [Figure 2G] 1 shows the results of a wound healing animal model study. [Figure 2H] 1 shows the results of a wound healing animal model study. [Figure 2I] 1 shows the results of a wound healing animal model study. [Figure 3A]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3B] Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3C]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3D] Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3E]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3F] Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3G]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3H] Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3I]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3J] Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 3K]Figures 3A-K show the results of qPCR analysis performed on key pro-inflammatory proteins in an ex-vivo human model using Th2 and Th7 stimulation to evaluate two BET inhibitors. Figures 3A-C show the expression of cytokines associated with Th17-mediated autoimmune disease in a Th17-induced phenotype in human skin, and Figures 3D-F show the expression of cytokines associated with Th2-mediated autoimmune disease. Figures 3G-3K show the pharmacodynamic comparison between BETi1 and BETia. Figure 3G shows the percent activity of IL4 and IL13 calculated relative to the Th2 stimulation control. Figure 3H shows the percent activity of IL31 and CCL17 calculated relative to the Th2 stimulation control. Figure 3I shows the percent activity of CCL26 and CCL2 calculated relative to the Th2 stimulation control. Figure 3J shows the percent activity of CXCL10, IL17α, and IL22 calculated relative to the Th17 stimulation control. FIG. 3K shows the percent activity of IL36γ, CCL20, and Serpin B4 calculated relative to the Th17 stimulation control. [Figure 4A] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4B] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4C] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4D] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4E]1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4F] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4G] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 4H] 1 shows H / E staining of histological sections of paraffin-embedded epidermis in a reconstituted human epidermis (RHE) model mimicking vitiligo comparing treatment with 4 doses of BETi1 formulation, BETi vehicle (placebo), and JAK inhibitor versus no treatment. [Figure 5A] Quantification of MMP-9 and E-cadherin secretion by ELISA from harvested culture media is shown. [Figure 5B] Quantification of MMP-9 and E-cadherin secretion by ELISA from harvested culture medium is shown. [Figure 6A] Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are weight percent of the pharmaceutical composition / formulation. Untreated and unstimulated controls are shown. [Figure 6B]Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are percent by weight of the pharmaceutical composition / formulation. Stimulated and untreated controls are shown. [Figure 6C] Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are percent by weight of the pharmaceutical composition / formulation. Stimulated + vehicle are shown. [Figure 6D] Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are weight percent of the pharmaceutical composition / formulation. Stimulated + BETi1 1% is shown. [Figure 6E] Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are weight percent of the pharmaceutical composition / formulation. Stimulated + BETi1 0.1% is shown. [Figure 6F]Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are weight percent of the pharmaceutical composition / formulation. Stimulated + BETi1 0.01% is shown. [Figure 6G] Representative images of Fontana-Masson staining of reconstituted human epidermis treated with test formulations (e.g., BETi1 1%, BETi1 0.1%, BETi1 0.01%, BETi1 0.001%, Ruxolitinib Cream 1.5%; see also Experimental Method K for test formulations) and stimulated with a cytokine cocktail to exhibit characteristics of vitiligo. Note that percentages such as BETi1 1%, BETi1 0.1%, etc. are weight percent of the pharmaceutical composition / formulation. Stimulated + BETi1 0.001% are shown. [Figure 6H] Melanin content in the basal layer of RHE (quantification from FM stained tissue sections) is shown. [Figure 7A] Figure 1 shows TRP-1 expression in the basal layer of the epidermis. Representative images of immunostaining of RHE after TRP-1 staining for all test formulations and controls are shown (top to bottom: untreated and unstimulated control, stimulated and untreated control, stimulated + vehicle, 1% BETi1, 0.1% BETi1, BETi1 0.01%, 0.001% BETi1). Three representative images per epidermis are shown. TRP-1 protein appears in green and nuclei in blue. [Figure 7B] Figure 7 shows TRP-1 expression in the basal layer of the epidermis. Region of interest; image analysis shown in Figure 7A shows in quantified form the abundance of TRP-1 in the basal layer of RHE normalized to the surface of the ROI. [Figure 7C] Figure 7 shows TRP-1 expression in the basal layer of the epidermis. Region of interest; image analysis shown in Figure 7A shows in quantified form the abundance of TRP-1 in the basal layer of RHE without normalization to the surface of the ROI. [Figure 8A] Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increases (red dots) or fold decreases (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of untreated and stimulated controls vs. untreated and unstimulated controls are shown. [Figure 8B] Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increase (red dots) or fold decrease (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of stimulated BETi1 vehicle vs. untreated and stimulated controls are shown. [Figure 8C] Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increase (red dots) or fold decrease (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of stimulated BETi1 1% vs stimulated + BETi1 vehicle are shown. [Figure 8D] Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increase (red dots) or fold decrease (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of stimulated BETi1 0.1% vs stimulated + BETi1 vehicle are shown. [Figure 8E]Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increase (red dots) or fold decrease (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of stimulated BETi1 0.01% vs stimulated + BETi1 vehicle are shown. [Figure 8F] Volcano plots showing significant variation in gene expression in RHE for all test formulations and controls are shown. Data points with significant p-values ​​are shown at the top of the plot above the horizontal threshold line fixed at a p-value of 0.05. Genes with fold increase (red dots) or fold decrease (green dots) are present on either side of the vertical threshold line. Gene symbols are indicated. Volcano plots of stimulated BETi1 0.001% vs stimulated + BETi1 vehicle are shown. [Figure 8G] Volcano plots of ruxolitinib 1.5% vs. untreated and stimulated controls are shown. [Figure 9] Shown is the percent change in mouse body weight on days 3-8, 10, and 12 compared to baseline for four doses of BETi1, vehicle (API positive control), and steroid for intra-articular and IP (systemic) treatment. [Figure 10A] The paw thickness of the treated limb is shown. [Figure 10B] The foot thickness of the untreated limb is shown. [Figure 10C] The delta between paw thickness of the untreated and treated limbs is shown, with a higher delta indicating better local treatment. [Figure 11A] Scoring of arthritis in treated limbs is shown. [Figure 11B] Scoring of arthritis in the untreated paw is shown. [Figure 11C] The arthritis scoring Δ of the untreated limb minus the treated limb is shown, with a higher Δ indicating better local treatment. [Figure 11D]Histograms of the mean histopathological scores (au) of the untreated paw (right paw) versus the treated paw for vehicle steroid and the two highest doses are shown, with greater differences between paws indicating better local treatment. [Figure 11E] Histology results for control and treatment animals, further described in Example 2, are shown. [Figure 11F] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 11G] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 11H] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 11I] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 11J] Histology results for control and treatment animals, further described in Example 2, are shown. [Figure 11K] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 11L] Histology results for control and treatment animals, as further described in Example 2, are shown. [Figure 12] Changes in hot plate escape latency (seconds) are shown. [Figure 13] FIG. 1 shows the homogeneity of the BETi1 suspension using optical microscopy. [Figure 14A] Micrographs of BETi suspensions at 4 mg / g (0.4%), 0.4 mg / g (0.04%) and 0.04 mg / g (0.004%) prepared in NaCMC solution are shown. [Figure 14B] Micrographs of BETi suspensions at 4 mg / g (0.4%), 0.4 mg / g (0.04%) and 0.04 mg / g (0.004%) prepared in NaCMC solution are shown. [Figure 14C]Micrographs of BETi suspensions at 4 mg / g (0.4%), 0.4 mg / g (0.04%) and 0.04 mg / g (0.004%) prepared in NaCMC solution are shown. [Figure 15A] The mean body weights at baseline, week 1, week 2, and week 3, and the percent change in body weight from baseline each week are shown for animals treated with formulations of different BETi1 strengths (0.06 mg / mL, 0.6 mg / mL, 3 mg / mL) and two controls. [Figure 15B] The mean body weights at baseline, week 1, week 2, and week 3, and the percent change in body weight from baseline each week are shown for animals treated with formulations of different BETi1 strengths (0.06 mg / mL, 0.6 mg / mL, 3 mg / mL) and two controls. [Figure 15C] The mean body weights at baseline, week 1, week 2, and week 3, and the percent change in body weight from baseline each week are shown for animals treated with formulations of different BETi1 strengths (0.06 mg / mL, 0.6 mg / mL, 3 mg / mL) and two controls. [Figure 15D] The mean body weights at baseline, week 1, week 2, and week 3, and the percent change in body weight from baseline each week are shown for animals treated with formulations of different BETi1 strengths (0.06 mg / mL, 0.6 mg / mL, 3 mg / mL) and two controls. [Figure 16] Shown are whole lung weights at week 3 for animals treated with different BETi1 strength formulations and two controls. [Figure 17] The survival probability at week 3 for animals treated with different BETi1 strength formulations and two controls is shown. [Figure 18] Hydroxyproline content of lung tissue measured by colorimetric assay at week 3 in animals treated with different BETi1 strength formulations and two controls. [Figure 19A]Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19B] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19C] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19D] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19E] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19F] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19G]Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19H] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19I] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19J] Representative micrographs (3 x 100 for each group, 1 x 40 for each group) of fixed lung tissues stained with H&E and Masson's trichrome stains from uninduced (sham) and induced treated with vehicle or three intensities of BETi1 and two controls at week 3 are shown. [Figure 19K] Histograms of histopathological changes scored by the Ashcroft scale (modified by Hubner) in the lungs of each group are shown. [Figure 20A] Shown are synovial fluid concentrations of BETi1 in dogs treated with BETi1 formulations containing doses of 7.5 mg (diamonds), 75 mg (squares), and 150 mg (triangles). [Figure 20B] Plasma concentrations of BETi1 in dogs treated with BETi1 formulations containing doses of 7.5 mg (diamonds), 75 mg (squares), and 150 mg (triangles) of BETi1 are shown. [Figure 21A] Representative histological sections from vehicle-treated beagle dogs are shown. [Figure 21B] Representative histological sections from a beagle dog treated with 7.5 mg of BETi1 are shown. [Figure 21C]Representative histological sections from beagle dogs treated with 75 mg of BETi1 are shown. [Figure 21D] Representative histological sections from a beagle dog treated with 150 mg of BETi1 are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0111] The present disclosure relates to the treatment and / or prevention of a set of diseases and disorders that can be treated using a specific set (i.e., genus) of inhibitors based on the N-methyl-2-pyridone structure / scaffold. These derivatives have a specific group attached at the 4-position of the pyridone ring. The genus and compounds contained in this genus (i.e., compounds of the present disclosure) disclosed herein have been found to be surprisingly effective when administered topically or locally in compositions. Experimental data demonstrates that they can be effective in the context of lesions and wounds, inflammatory diseases and disorders, autoimmune diseases and disorders, pigmentation diseases and disorders, joint diseases and disorders, fibrotic diseases and disorders, and other diseases and disorders, such as wounds, inflammation, cytokines, biomarkers, genetic pathways, vitiligo, arthritis, fibrosis, and PF, as provided by the various models and studies described herein.

[0112] The potential of the compounds disclosed herein is demonstrated to treat, reduce or alleviate scarring and reduce swelling.In addition, the potential of the compounds disclosed herein is demonstrated to treat, reduce or alleviate vitiligo and similar disorders (e.g., pigmentation-related disorders).In addition, the potential of the compounds disclosed herein is demonstrated to treat joint or joint-related disorders and diseases.The potential of the compounds disclosed herein is demonstrated to treat, reduce or alleviate PF and similar disorders (e.g., fibrosis and scarring-related disorders).

[0113] The pathology of vitiligo results from the selective loss of melanocytes from the basal layer of the epidermis, a phenomenon called melanocytopathy. This loss of functional melanocytes can be attributed to multiple factors, including metabolic abnormalities, oxidative stress, production of inflammatory mediators, autoimmune responses, and cell detachment.

[0114] This detachment of melanocytes from the basal layer is associated with a disruption of the surface distribution of the adhesion molecule E-cadherin and the release of soluble E-cadherin, a key adhesive glycoprotein involved in maintaining the position of melanocytes within the basal layer of the skin epidermis. Disruption of E-cadherin adhesion increases both the soluble form and suprabasal melanocytes, resulting in depigmentation of the skin.

[0115] Cleavage of E-cadherin can be induced by several proteases, including MMP-9, which is secreted by keratinocytes in response to various proinflammatory cytokines, such as IFN-γ and TNF-α. These type 1 cytokines are known to induce melanocyte detachment in both in vitro and in vivo models, and this effect depends on the inhibition of E-cadherin gene expression, the internalization of E-cadherin, and its cleavage via the release of MMP-9 by keratinocytes.

[0116] In healthy skin, stimulation of the WNT pathway by keratinocytes and melanocytes induces differentiation and proliferation of melanocyte stem cells, allowing constant turnover of the pool of epidermal melanocytes (see Regazzetti et al. Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients, Journal of Investigative Dermatology, 135, 3105-3114 (2015)).

[0117] In vitiligo skin, oxidative stress may trigger an immune response in genetically predisposed individuals. Destruction of melanocytes by the immune system releases melanocyte antigens, which stimulate an autoimmune response and ultimately result in the complete loss of melanocytes from the epidermis (and sometimes hair follicles). At the same time, oxidative stress reduces WNT pathway activity in melanocytes and keratinocytes. This effectively induces a decrease in cell adhesion with melanocyte detachment and impaired differentiation of melanocyte stem cells, altering the capacity of melanocyte turnover. One hypothesis, depending on the patient and the disease process, is that these two mechanisms may be differentially involved, resulting in resistance to active skin depigmentation and repigmentation procedures (see, for example, Regazzetti et al. Journal of Investigative Dermatology 2015, 135, 3105-3114).

[0118] Furthermore, compared to normal skin, vitiligo-lesioned (depigmented) skin typically contains genes with reduced or absent expression (mostly melanocyte-specific genes). Unlike vitiligo-lesioned skin, most of the genes that are downregulated in vitiligo-lesioned skin (including melanocyte markers) do not show such changes in non-lesioned (pigmented) skin (see Yu R, et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One. 2012; 7(12): e51040; also see Moretti et al., Focus on vitiligo: a generalized skin disorder, Eur J Inflamm., vol. 4, no. 1, 21-30, 2006).

[0119] The present disclosure includes, for example, the effect of BETi1 compositions and their vehicles at different concentrations (e.g., doses) on vitiligo using a 3D skin model consisting of reconstructed human epidermis (RHE-VIT) stimulated with a cocktail of cytokines (IFN-γ and TNF-α) to induce melanocytosis. The BETi1 compositions can be topically applied to the stratum corneum of RHE-VIT and compared to vehicle compositions and ruxolitinib cream 1.5% (positive control) uninduced untreated (healthy skin) and induced untreated skin models.

[0120] The effect of these compositions on vitiligo models may be assessed, for example, using one or more of the following methods: (i) measurement of melanin content based on Fontana-Masson images of paraffin-embedded epidermal sections; (ii) paraffin-embedded sections of the epidermis to analyze the localization of melanocytes throughout the epidermis by TRP-1 (tyrosinase-related protein-1) immunostaining; (iii) cell culture medium to quantify the release of two biomarkers, MMP-9 and E-cadherin, by specific ELISA assays.

[0121] The effect of the composition on the expression of 92 genes that play important roles in melanogenesis (melanin synthesis, melanosome maturation and transport) can be assessed by RT-qPCR (reverse transcription-quantitative polymerase chain reaction) using TaqMan low density array (TLDA) technology.

[0122] In some embodiments, preliminary morphological analysis may be performed after staining of paraffin-embedded tissue sections, for example after hemalum / eosin staining, to confirm the absence of cytotoxic effects of the compositions and vehicles in the 3D model.

[0123] In some embodiments, immediate release compositions are provided that include larger suspended particles for extended retention and release, including at least one BETi (e.g., BETi1) disclosed herein, used to treat or prevent joint or joint-related disorders or diseases by local administration of the composition. In some embodiments, sustained release compositions are provided.

[0124] In some embodiments, the local administration of the composition comprising at least one BETi (e.g., BETi1) is carried out via injection into at least one space selected from, for example, the intra-articular space, the peri-articular space, the soft tissue, the lesion, the epidural space, the perineural space, or the foramen space at or near the site of joint pain or discomfort in the subject. In some embodiments, the composition further comprises at least one immediate release component. In some embodiments, the composition comprising at least one BETi (e.g., BETi1) is administered into the intra-articular space (e.g., by a single injection or as sequential injections) for the treatment of joint or joint-related disorders or diseases, such as arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus, or other autoimmune joint disorders. In some embodiments, the composition is formulated for immediate release. In some embodiments, the composition is formulated for immediate and extended release. The term "immediate release" is intended to include formulations that provide immediate and extended release, which in one or more embodiments is achieved by suitable particle size distribution. In some embodiments, the formulations disclosed herein in method S may be suitable for monthly injections. In some embodiments, the presence / time in the joint can be improved by changing the particle size and distribution of the suspended API. This can also be further increased by preparing a sustained release formulation.

[0125] In some embodiments, the formulations disclosed herein are formulated for sustained release. In some embodiments, they are formulated for both immediate and sustained release. In some embodiments, an immediate release composition comprising at least one BETi (e.g., BETi1) is administered. In some embodiments, a sustained release composition comprising at least one BETi (e.g., BETi1) is administered. In some embodiments, a combination early release and sustained release composition comprising at least one BETi (e.g., BETi1) is administered. In some embodiments, the sustained release formulation is a suspension of at least one BETi, i.e., one or more BETi, in a vehicle or carrier. In some embodiments, the suspension comprises one or more BETi compounds of two or more average particle sizes (at least one larger and one smaller). In some embodiments, the smaller particles release at a higher rate than the larger particles. In some embodiments, at least some of the particles are coated to facilitate a slower release rate. In some embodiments, the compound or compounds are encapsulated, for example, in microparticles or microspheres.

[0126] In some embodiments, a sustained release composition comprising BETi1 is administered (eg, by a single injection or as sequential injections) into soft tissue or into a lesion for the treatment of inflammatory disorders such as rheumatoid arthritis.

[0127] In some embodiments, compositions for controlled or sustained release are provided that include a microparticle matrix (e.g., PLGA, gel, hydrogel, hyaluronic acid, etc.) and at least one BETi. The composition may or may not rapidly release the BETi over a first period of 0-10 days, e.g., from the beginning of day 1 to the end of day 10, in addition to a sustained steady state release of the BETi over a second period of at least 1 week, at least 2 weeks, or at least 3 weeks, including 1 month, or 2 months, or up to 3 months or more and beyond.

[0128] In some embodiments, for immediate and / or controlled release, the dose of BEti for intra-articular administration in humans is about 1 mg to about 700 mg. In some other embodiments, the dose of BETi for intra-articular administration in humans is about 1 mg to about 10 mg. For immediate and / or controlled release, the volume of BETi1 dispersion injected into the joint is about 5 mL. Thus, a dose of 500 mg BETi corresponds to 5 mL of product having a concentration of 10% / w. The homogeneity of the dispersion (including the absence of agglomerates of solid particles) is analyzed and confirmed by optical microscopy.

[0129] In some embodiments, the dose for immediate release and / or immediate and extended release is about 10 mg to about 500 mg BETi, or about 10 mg to about 150 mg BETi, or about 10 mg to about 80 mg BETi. In some embodiments, the dose for controlled release is about 10 mg to about 250 mg BETi, or about 10 mg to about 120 mg BETi, or about 10 mg to about 70 mg BETi. In some embodiments, the dose for sustained or extended release is about 30%, about 35%, about 40%, or about 50% lower than the dose for controlled release. In some embodiments, the dose for immediate release is about twice the dose for sustained release.

[0130] In some embodiments, compositions for controlled or sustained release are provided that include a microparticle matrix (eg, PLGA, gel, hydrogel, hyaluronic acid, etc.) and at least one BETi.

[0131] In some embodiments, a formulation of the present disclosure comprising a BETi may provide an initial release of the BETi at the site of administration, e.g., in the intra-articular and / or peri-articular space, In some embodiments, after the initial release of the BETi subsides, a controlled or sustained release of the BETi-microparticle formulation is continued for an additional treatment period following administration to provide a therapeutic (e.g., intra-articular and / or peri-articular) concentration of the BETi, suppress inflammation, maintain pain relief, and / or slow, stop, or reverse structural damage to tissue.

[0132] In some embodiments, an intra-articular composition is provided that includes a BETi (e.g., BETi1). In some embodiments, the intra-articular composition is encapsulated in a PLGA microsphere. In some embodiments, the PLGA microsphere entraps the BETi (e.g., BETi1) and provides for its slow release upon degradation of the PLGA in the joint. In some embodiments, for the PLGA microsphere, the ratio of lactic acid to glycolic acid is about 50:50, about 65:35, about 70:30, about 75:25, or about 80:20. In some embodiments, the ratio of lactic acid to glycolic acid is about 80:20 to about 60:40, or about 80:20 to about 70:30. In some embodiments, the drug (i.e., BETi) loading in the microsphere ranges from about 10% to about 80%. In some embodiments, the drug loading in the microsphere is about 25% w / w. In some embodiments, the composition includes hyaluronic acid. In some embodiments, the hyaluronic acid has a high molecular weight and may provide a higher viscosity. In some embodiments, the hyaluronic acid has a medium level molecular weight. In some embodiments, the hyaluronic acid has a low molecular weight. The molecular weight of hyaluronic acid is variable and ranges from thousands to millions of kDa. In normal human synovial fluid, this is equal to about 6000-7000 kDa, while in rheumatoid synovial fluid, the molecular weight is lower, equal to about 3000-5000 kDa. In some embodiments, the hyaluronic acid is crosslinked to a polymer to increase viscosity and slow degradation within the joint. In some embodiments, a method of restoring viscoelasticity of the synovial fluid is provided. In some embodiments, the PLGA microsphere composition comprises hyaluronic acid. In some embodiments, the PLGA microsphere composition comprising hyaluronic acid provides or helps restore viscoelasticity of the joint, e.g., synovial fluid. In some embodiments, the BETi (e.g., BETi1) is entrapped within the hyaluronic acid. In other embodiments, the BETi (e.g., BETi1) is entrapped within a crosslinked hyaluronic acid polymer to provide sustained release. In some embodiments, the PLGA microsphere composition comprises lubricin.In some embodiments, the composition includes lubricin to provide or aid in the restoration of joint lubrication. In some embodiments, the PLGA microsphere composition includes hyaluronic acid and lubricin. In some embodiments, the composition includes hyaluronic acid and lubricin to provide or aid in the restoration of joint, e.g., synovial viscoelasticity and / or lubrication.

[0133] In some embodiments, there is an improvement in at least one symptom of a joint disorder or disease when about 0.1% to about 10% of the BETi is applied intra-arterially or intravenously. In some embodiments, there is an improvement in at least one symptom of a joint disorder or disease when about 0.1% to about 15% of the BETi or about 0.2% to about 10% is applied topically, for example, by weight of the composition or by weight of the volume of the composition. In some embodiments, the BETi is about 0.1%, or about 0.25%, or about 0.5%, or about 0.75%, or about 1%, or about 1.25%, or about 1.5%, or about 1.75%, or about 2%, or about 2.25%, or about 2.5%, or about 2.75%, or about 3%, or about 3.25%, or about 3.5%, by weight of the composition or by weight of the volume of the composition. , or about 3.75%, or about 4%, or about 4.25%, or about 4.5%, or about 4.75%, or about 5%, or about 5.5%, or about 6%, or about 6.5%, or about 7%, or about 7.5%, or about 8%, or about 8.5%, or about 9%, or about 9.5%, or about 10%, or about 11%, or about 12%, or about 13%, or about 14%, or about 15%. In some embodiments, the application of BETi is, for example, inter-articular and for immediate release, and can be administered in a single dose of about 1 mg / vial to about 750 mg / vial, or about 2 mg / vial to about 500 mg / vial, the vial being about 5 ml or about 2.5 ml or about 1 ml, depending on the size of the joint and the age and size of the subject.In some embodiments, the BETi is for immediate release and is about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg / vial. 1, or about 150 mg / vial, or about 200 mg / vial, or about 250 mg / vial, or about 300 mg / vial, or about 350 mg / vial, or about 400 mg / vial, or about 450 mg / vial, or about 500 mg / vial, or about 550 mg / vial, or about 600 mg / vial, or about 650 mg / vial, or about 700 mg / vial, or about 750 mg / vial. In some embodiments, the application of BETi is for inter-articular and sustained release and can be administered in a single dose of about 1 mg / vial to about 350 mg / vial, or about 2 mg / vial to about 250 mg / vial, with the vial being about 5 ml or about 2.5 ml or about 1 ml depending on the size of the joint and the age and size of the subject. In some embodiments, the BETi is for sustained release and can be administered in a single dose of about 1 mg / vial, or about 2 mg / vial, or about 3 mg / vial, or about 4 mg / vial, or about 5 mg / vial, or about 6 mg / vial, or about 7 mg / vial, or about 8 mg / vial, or about 9 mg / vial, or about 10 mg / vial, or about 25 mg / vial, or about 50 mg / vial, or about 75 mg / vial, or about 100 mg / vial, or about 150 mg / vial, or about 200 mg / vial, or about 250 mg / vial.In some embodiments, where the composition provides an immediate or initial dose and an extended release dose, it can be administered in a single dose of about 1 mg / vial to about 750 mg / vial, or about 2 mg / vial to about 500 mg / vial, or about 2 mg / vial to about 250 mg / vial, where the vial is about 5 ml or about 2.5 ml or about 1 ml, depending on the size of the joint and the age and size of the subject.

[0134] As stated above, unless otherwise specified, amounts expressed in weight units (whether absolute weights or amounts relative to another weight or volume, or as a percentage) of BETi or "at least one compound, tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative" are based on the weight of the free base of the BETi or compound, respectively.

[0135] The present disclosure provides an exemplary BETi that can further provide novel and effective treatment and relief of joint-related diseases and disorders. Joints can be infected by many types of microorganisms (bacteria, fungi, viruses), and sometimes animal parasites. Infection-related joint diseases and disorders include infection by direct contamination, infection by bloodstream, for example, via synovial vessels, and even from adjacent bone infection (osteomyelitis). Infectious arthritis may affect one joint (monoarthritis) or a few joints (oligoarthritis) rather than many joints (polyarthritis). Joints or parts thereof may be damaged, for example, by infection of the cartilage, for example, by Staphylococcus aureus, Streptococcus haemolyticus, and Streptococcus pneumoniae, by tuberculosis, for example, by tuberculous spondylitis (Pott's disease), by bone, or by sexually transmitted diseases, including brucellosis, for example, coccidioides immitis, brucella suis, leprosy, rubella, and serum hepatitis, viral synovitis, dracunculiasis, gonorrhea, reactive arthritis (Reiter's disease), congenital syphilis, for example, Clutton's joint lesion, and yaws, which leads to skeletal lesions. Inflammation can destroy the articular cartilage and underlying bone, causing irreversible deformity. In such cases, adhesions between the components of the joint frequently occur, and the resulting adhesions with loss of mobility are called ankylosis, for example, ankylosing spondylitis (Marie-Strumpell's disease or Bechterew's disease). Another type of arthritis is associated with chronic intestinal disease-ulcerative colitis, regional enteritis, inflammatory bowel disease, cirrhosis, and Whipple's disease. In addition to joint disorders and diseases resulting from any of the above, the present disclosure provides exemplary BETi that may also provide novel and effective treatment or mitigation of non-inflammatory joint diseases, injuries, and degenerative disorders. Trauma to joints includes blunt injury, minor sprains, fractures and dislocations, tears of ligaments, tendons, and capsules, tears of the meniscus, and hemarthrosis. Degenerative joint diseases include osteoarthritis, osteoarthritis, early onset osteoarthritis, congenital dysplasia, senile hip joint, spondylosis, chondromalacia patellar, metabolic diseases such as gouty arthritis, gouty foot, osteoglossal degenerative arthropathy, chondrocalcinosis, or pseudogout, mucopolysaccharidosis, Hurler syndrome, Morquio disease, and multiple epiphyseal dysplasia.

[0136] The present disclosure provides exemplary BETi that may also provide novel and effective treatment or palliation of secondary joint diseases and disorders, including hemorrhagic joints, hemarthrosis, villonodular synovitis, joint diseases occurring in association with avascular necrosis (e.g., as may occur with fractures), osteochondritis dissecans, slipped capital femoral epiphysis, Osgood-Schlatter, Legg-Calve-Perthes, joint disorders resulting from endocrine insufficiency, acromegaly, neurogenic arthropathy, Charcot joints, hypertrophic osteoarthropathy, reflex sympathetic dystrophy, joint tumors, synovial osteochondromatosis, chondrocyte nodules, synovial osteochondromatosis, synovium, synovial sarcoma, and polymyalgia rheumatica.

[0137] In some embodiments, an immediate release form of a composition comprising a BETi (e.g., BETi1) is administered, for example, by topical application, to treat a joint or joint-related disorder or disease or secondary joint disease or disorder. In some embodiments, the immediate release form comprises a solution of the BETi. In some embodiments, the immediate release form comprises a suspension of the BETi as a micronized or nanoparticle suspension of the BETi. In some embodiments, the immediate release form comprises a partially dissolved and partially suspended BETi. In some embodiments, the majority of the BETi is dissolved (e.g., about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more). In some embodiments, the majority of the BETi is suspended (e.g., about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more). In some embodiments, a sustained release form of a composition comprising a BETi (e.g., BETi1) is administered, for example, by topical application, to treat a joint or joint-related disorder or disease or secondary joint disease or disorder. In some embodiments, the suspended particles provide an initial release followed by a sustained release. In some embodiments, the sustained release form comprises a particle or encapsulated suspension of a BETi. In some embodiments, the sustained release form comprises a BETi that is partially suspended to provide a delayed release and partially dissolved to provide an initial release. As will be appreciated by one of skill in the art, the rate of suspension to dissolution depends, at least in part, on the amount of vehicle or carrier and BETi.

[0138] In one or more embodiments, a BETi compound or a composition comprising a BETi is provided that is suitable for treating fibrosis or fibrosis-related diseases. The development of fibrotic diseases is at least partially caused by the stimulation of fibroblast activity, whether induced or spontaneous. The influx of inflammatory cells and activated fibroblasts into injured organs depends on the ability of these cell types to interact with interstitial matrices that mainly contain collagen. Exemplary tissues that can be affected by fibrosis include lung, kidney, liver, skin, central nervous system, bone, bone marrow, tissues of the cardiovascular system, endocrine organs, and tissues of the gastrointestinal system.

[0139] In one or more embodiments, fibrosis is in the lung. PF can result from a pathological wound healing process in which connective tissue replaces normal parenchymal tissue, resulting in tissue remodeling and the formation of permanent scar tissue. The processes of fibrosis and scarring are similar in that both involve stimulated fibroblasts that build up connective tissue that includes collagen and glycosaminoglycans.

[0140] The formation of granulation tissue is a tightly regulated process in which the expression of protease inhibitors and extracellular matrix proteins is upregulated and the expression of proteases is reduced, leading to the accumulation of extracellular matrix. However, the abnormal accumulation of fibrous material can ultimately lead to organ failure.

[0141] The fibrotic process is initiated when immune cells such as macrophages release soluble factors that stimulate fibroblasts. The best characterized profibrotic mediator is transforming growth factor-β (TGF-β), which is released by macrophages as well as damaged tissue between surfaces, called the interstitium. Other soluble mediators of fibrosis include connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), and interleukin 10 (IL-10).

[0142] These initiate signaling pathways such as the AKT / mTOR and SMAD pathways that ultimately result in the proliferation and activation of fibroblasts that deposit extracellular matrix into the surrounding connective tissue. This process of tissue repair is complex, with tight regulation of the synthesis and degradation of extracellular matrix (ECM) to ensure the maintenance of normal tissue architecture. However, when tissue injuries are severe or frequent, or when the wound healing response itself becomes dysregulated, the entire process can sometimes result in a progressive, irreversible fibrotic response.

[0143] In the lung, myofibroblasts (a state between fibroblasts and smooth muscle cells) are primarily involved in fibrosis. They are involved in wound consolidation by extracellular collagen fiber deposition, and wound contraction by intracellular contraction and concomitant orientation of collagen fibers by integrin-mediated attraction into collagen bundles. In wounds that fail to resolve and result in keloid or hypertrophic scars, myofibroblasts may persist rather than disappear by apoptosis. Myofibroblast formation is a TGF-β1-dependent differentiation from fibroblasts. Activation of TGF-β receptor 1 and TGF-β receptor 2 leads to induction of the canonical SMAD2 / SMAD3 pathway. Together with the concomitant activation of the non-canonical EGFR pathway, these events lead to upregulation of the ACTA2 gene and subsequent alpha-smooth muscle actin protein production.

[0144] The disclosed methods and compositions may, in some embodiments, be therapeutically useful for fibrosis or fibrosis-related diseases affecting any tissue, including, for example, visceral fibrosis, fibrotic disorders of the skin or dermis, and fibrotic diseases of the eye. In some embodiments, the fibrosis or fibrosis-related disease includes visceral (e.g., liver, lung, kidney, cardiovascular, gastrointestinal tract) fibrosis. In some embodiments, the fibrosis or fibrosis-related disease includes pulmonary fibrosis, idiopathic fibrosis, autoimmune fibrosis, myelofibrosis, liver cirrhosis, veno-occlusive disease, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy, renal interstitial fibrosis, renal fibrosis in subjects receiving cyclosporine, allograft rejection, HIV-associated nephropathy. In some embodiments, the fibrosis-related disorder includes systemic sclerosis, eosinophilic myalgia syndrome, and fibrosis-related CNS disorders, such as intraocular fibrosis. In some embodiments, dermal fibrotic disorders include, for example, scleroderma, morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, and collagenous connective tissue nevi. In some embodiments, ocular fibrotic diseases include diseases such as diabetic retinopathy, post-operative scarring (e.g., after glaucoma filtration surgery and after cross-eye (strabismus) surgery), and proliferative vitreoretinopathy. In some embodiments, fibrotic diseases that can be treated by the methods of the present invention can result from, for example, rheumatoid arthritis, diseases associated with long-term joint pain and joint deterioration, progressive systemic sclerosis, polymyositis, dermatomyositis, eosinophilic fasciitis, morphea, Raynaud's syndrome, and nasal polyposis.

[0145] The present disclosure includes, for example, the effect of BETi1 compositions at different concentrations (e.g., doses) and their vehicles on PF using a bleomycin-induced mouse model of idiopathic PF. The BETi1 compositions can be applied topically (e.g., by inhalation) in bleomycin-induced mice and compared to bleomycin-induced mice treated with a vehicle composition or uninduced mice (healthy mice) treated with a vehicle.

[0146] The effect of these compositions on IPF mouse models can be assessed, for example, using one or more of the following methods: (i) hydroxyproline content of lung tissue measured by colorimetric assay; (ii) fixed lung tissue stained with H&E, MT and / or PSR stains; (iii) clinical observations (body weight, whole lung weight, and survival probability); and (iv) histograms of oxygen saturation measured by pulse oximetry.

[0147] In some embodiments, preliminary morphological analysis may be performed after staining of lung embedded tissue sections, e.g., after hemalum / eosin staining, to confirm that the compositions and vehicles have no cytotoxic effects in mice.

[0148] A non-exhaustive list of methods of administering the compound includes topical administration to a body surface, such as the skin, an epithelial surface, or a mucous membrane. The body surface may be an external surface, such as the skin or the eye, or an internal body cavity surface, such as the mucous membrane in the respiratory tract, respiratory system, lungs, intestinal tract, or vagina. Application may be through the airways (e.g., by inhalation spray, by inhalation nebulizer, by inhaler (dry powder or metered dose), and by insufflation). Application may be intramucosal, transmucosal, intrapulmonary, intradermal, intranasal, buccal, intrarectal, transdermal, sublingual, and vaginal in some embodiments.

[0149] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All ranges disclosed herein are inclusive. Use of the term "or" shall be construed to mean "and / or" unless otherwise stated in the specific context. All patents, applications, published applications, and other published documents are incorporated by reference in their entirety. In the event that there are multiple definitions for a term herein, those in this section prevail unless otherwise specified.

[0150] All percentage values ​​are provided on a weight / weight (w / w) basis unless otherwise stated.

[0151] Various carriers and compositions or formulations are described herein. These are often described for use in a method. Reference to or examples of a carrier, composition or formulation for use in one method in no way limits the carrier, composition or formulation to use in that method, but may also be for use in any other method or embodiment described herein. The carriers, compositions or formulations described herein are provided in some embodiments as carriers, compositions or formulations, and in some embodiments as products, even if they are described only for use in a method.

[0152] As used herein, the term "about" has its ordinary meaning with respect to pharmaceutical and cosmetic formulations and methods of using them, allowing for reasonable variation in amounts that can achieve the same effect, typically within ±30%. For example, when an amount of "about 1" is presented, the amount can be 1.3 or less or 0.70 or more. When "about X" is a number greater than 100%, in one or more embodiments, this term can be interpreted to represent up to 100% by weight, minus the total of the minimum amounts of other components. Similarly, as will be understood by those skilled in the art, when X decreases from its upper limit, the amount of other components increases as appropriate. As will be understood by those skilled in the art, in the formulation of a composition, there is some reasonable flexibility such that when one or more components are changed, a successful formulation can still be made even if an amount is slightly outside the range. Thus, to allow for this possibility, amounts are modified by about. In one or more embodiments, examples such as amounts of formulation components can be interpreted as if the term "about" preceded them. In one or more embodiments, examples can be interpreted without the term "about". In one or more embodiments, numbers can be interpreted with the term "about". In one or more other embodiments, numbers can be interpreted without the term "about". In some, more narrow embodiments, "about" can be within ±15% unless otherwise indicated by context. When "about" is used in relation to ">X" or "<X", or a series of such alternatives, this can, in one or more embodiments, include about X. When "about" is used only at the beginning of a series of alternative amounts of ">about X" or "<about X" or "about>X" or "about<X", this can, in one or more embodiments, be understood to include "about" before all other alternatives of that series.

[0153] As used herein, the terms "composition(s)" and "formulation(s)" can be used interchangeably as will be understood by those skilled in the art, depending on the context in which they are used.

[0154] As used herein, the terms "mean" and "average" may also be used interchangeably depending on the context in which they are used, as would be understood by one of ordinary skill in the art.

[0155] The term "comprising" or variations thereof is understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0156] The term "consisting of" or variations thereof will be understood to mean the inclusion of a specified element, integer or step, or group of elements, integers or steps, and the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0157] As used herein, the term "selected from the group consisting of" may be understood to refer to an exclusive group. When the terms "chosen from" or "selected from" or "includes" or "comprises" are used, they encompass an open-ended group.

[0158] As used herein, the terms "disorder(s)" and "disease(s)" may be used interchangeably depending on the context in which they are used, as will be understood by one of skill in the art.

[0159] The term "room temperature" or "RT" as used herein means 20°C to 25°C. In one embodiment, this is 20°C. In one embodiment, this is 21°C. In one embodiment, this is 22°C. In one embodiment, this is 23°C. In one embodiment, this is 24°C. In one embodiment, this is 25°C. The term "ambient conditions" as used herein means room temperature, room pressure and room humidity. Ambient temperature and room temperature are used interchangeably herein.

[0160] The term "thixotropic" as used herein means that the formulation exhibits a decrease in viscosity upon application of shear force. The structure of the formulation breaks down, resulting in a decrease in viscosity. When the formulation is allowed to stand without shear force, the viscosity is restored.

[0161] As used herein, the term "gel" refers to a carrier or formulation or composition that is not flowable at room temperature and therefore retains its shape when exposed to standard gravity at room temperature. The term "flowable semi-solid" as used herein refers to a base carrier or formulation that can flow slowly at room temperature and can conform to the shape of a container over time and assume that shape when exposed to standard gravity at room temperature. The term "liquid" refers to a base carrier or formulation at room temperature that can flow easily or readily, can be poured into a container, and can conform to the shape of the container virtually immediately and assume that shape.

[0162] As used herein, "foam" has its usual meaning to one of ordinary skill in the art and may refer, for example, to an object or material formed by trapping gas pockets in a solid or liquid. The gas pockets may include a gas, e.g., oxygen, nitrogen, or a mixture of gases, e.g., helium and xenon, or atmospheric air. The gas pockets within a foam may be connected to one another (e.g., closed-cell foams) or separate (e.g., open-cell foams). As used herein, "foamable composition" refers to any composition capable of forming a foam. In some embodiments, the foamable composition includes a carrier with or without a liquefied or compressed gas propellant, and a foam is formed when the carrier contacts the propellant or by mechanical means such as an air pump. In some embodiments, the foamable composition is contained in an aerosol container with a pressurized propellant. In some embodiments, the foamable composition is separate from the propellant, e.g., in a bag-in-can system. In some embodiments, a valve on the aerosol container is actuated to release the foamable composition to form a foam. In some embodiments, the composition is not a foam and does not form a foam upon release or use.

[0163] As used herein, the term "water-based" or "aqueous" or "water-containing" formulation refers to a composition that contains water as the majority component. In some embodiments, the formulations disclosed herein include water. In some embodiments, the formulations disclosed herein are based on water as the majority component. In some embodiments, the formulations include about >50%, about >55%, about >60%, about >65%, about >70%, or about >75%, about >80%, about >85%, about >90%, or about >95% water by weight. In some embodiments, the formulations disclosed herein are water-free. As used herein, the term "water-free" or "water-free" or "anhydrous" or "non-aqueous" refers to a composition that does not contain free or unassociated or absorbed water. In some embodiments, a water-free or water-free or anhydrous or non-aqueous composition includes 0.0% added water by weight. Such compositions may contain trapped, bound, associated, or otherwise non-free water, for example, within their higher-order crystalline structures, and in some embodiments, such water may be about 1% or less. In some embodiments, the formulations are hydrophilic. In some embodiments, the formulations disclosed herein are water-free. The term "essentially water-free" or "essentially water-free" or "essentially anhydrous" or "essentially non-aqueous" refers to a composition that contains less than 0.05% water by weight. In some embodiments, an essentially water-free or anhydrous or non-aqueous composition contains 0.04%, 0.03%, 0.02%, or 0.01% water by weight. The term "substantially water-free" or "substantially water-free" or "substantially anhydrous" or "substantially non-aqueous" refers to a composition that contains less than 0.5% water by weight. In some embodiments, a substantially water-free or anhydrous or non-aqueous composition contains 0.4%, 0.3%, 0.2%, or 0.1% water by weight. As used herein, "low water" refers to a composition containing about 1% water or less by weight. In some embodiments, the low water composition comprises 0.9%, 0.8%, 0.7%, 0.6% or 0.5% water by weight. In some embodiments, the composition is a substantially low water composition comprising about 5%, about 4%, about 3%, about 2%, or about 1% water by weight.

[0164] The term "single-phase" as used herein means that after preparation, the liquid components of the composition or carrier are completely miscible, and the solid components, if any, are dissolved or homogeneously suspended in the composition, so that only one phase is visible. In the context of a foamable composition, "single-phase" means that after the propellant is added to the composition or carrier, the liquid components of the foamable composition or carrier are completely miscible, and the solid components, if any, are dissolved or homogeneously suspended in the composition, so that only one phase is visible. In some embodiments, the composition has a single phase before the addition of the propellant. In some embodiments, the composition has a single phase after the addition of the propellant.

[0165] The term "substantially single-phase" means that the composition or carrier, after preparation, is primarily or essentially single-phase as described above, but materials capable of forming separate phases may be present in small amounts corresponding to less than about 5% by weight of the composition or carrier, e.g., less than about 3% by weight of the composition, or less than about 1% by weight. In the context of foamable compositions, the term "substantially single-phase" means that the composition or carrier, after addition of the propellant, is primarily or essentially single-phase as described above, but materials capable of forming separate phases may be present in small amounts corresponding to less than about 5% by weight of the composition or carrier, e.g., less than about 3% by weight of the composition, or less than about 1% by weight. In some embodiments, the composition may be single-phase before the addition of the propellant and single-phase after the addition of the propellant. In some embodiments, the composition may be substantially single-phase before the addition of the propellant and substantially single-phase after the addition of the propellant. In some embodiments, the composition may be substantially single-phase before the addition of the propellant and single-phase after the addition of the propellant. In some embodiments, the composition may be single-phase before the addition of the propellant and substantially single-phase after the addition of the propellant.In some embodiments, the composition may be single-phase before the addition of the propellant and substantially single-phase after the addition of the propellant.

[0166] Where an embodiment of the invention is described herein in terms of a method of treatment involving administration of a formulation or composition, it will be understood that the invention also provides not only the formulation, composition or active ingredient(s) thereof for use in that method, but also the use of the formulation, composition or active ingredient(s) thereof in the manufacture of a medicament for use in that method.

[0167] As used herein, the term "emollient" refers to a material or agent that, when placed in contact with human skin, can soften, soothe, reduce scaling and itching, reduce inflammation, improve skin barrier function, and / or act as a carrier for active agents. Examples of emollients include avocado oil, isopropyl myristate, mineral oil, capric triglyceride, caprylic triglyceride, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleic acid modified soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, protease, glyceryl oleate, glyceryl linoleate, wheat germ glycerides, glyceryl oleate, glyceryl linoleate ... Arachidyl pionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentyl glycol dicaprylate / dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyldodecanol, unsaturated or polyunsaturated oils, olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium Examples of suitable emollients include, but are not limited to, oleaginous aromaticum oil, hemp seed oil, herring oil, cod liver oil, salmon oil, linseed oil, wheat germ oil, evening primrose oil, essential oils, silicone oils, dimethicone, cyclomethicone, polyalkylsiloxanes, polyarylsiloxanes, polyalkylarylsiloxanes, polyether siloxane copolymers, and poly(dimethylsiloxane)-(diphenyl-siloxane). In some embodiments, the formulations include one or more emollients. In some embodiments, the emollients are hydrophilic or non-hydrophobic. In some embodiments, the emollients are selected to be compatible with use in joints, including being degradable so that accumulation in the joints is not an issue. In some embodiments, the formulations do not include oily or hydrophobic emollients. In some embodiments, the formulations disclosed herein are essentially free of oily or hydrophobic emollients.In some embodiments, the formulations disclosed herein are substantially free of oily or hydrophobic emollients. The term "essentially free" refers to a composition that contains less than 0.05% (e.g., about <0.04%, about <0.03%, about <0.02%, or about <0.01%) of oily or hydrophobic emollients by weight. The term "substantially free" refers to a composition that contains less than 0.5% (e.g., about <0.4%, about <0.3%, about <0.2%, or about <0.1%) of oily or hydrophobic emollients by weight.

[0168] "Standard surfactant", "conventional surfactant" or "independent surfactant" refers to conventional nonionic, anionic, cationic, zwitterionic, amphoteric and amphiphilic surfactants. Many standard surfactants are derivatives of fatty alcohols or fatty acids, for example, ethers or esters formed from such fatty alcohols or fatty acids and hydrophilic moieties such as polyethylene glycol (PEG). However, natural (undivatized) fatty alcohols or fatty acids and waxes are not considered standard surfactants.

[0169] The term "cosurfactant" as used herein means a molecule that cannot form and sufficiently stabilize an oil-in-water emulsion by itself, but has properties that can help the surfactant to form an emulsion and enhance the stabilizing power or effect of the surfactant when used in combination with a surfactant as defined herein. Examples of cosurfactants include fatty alcohols such as cetyl alcohol, or fatty acids such as stearic acid. Cetyl alcohol is a wax-like hydrophobic material that can be emulsified with water using a surfactant. Some materials can have multiple functions, for example, fatty alcohols can act as cosolvents in some formulations. In certain situations, the cosurfactant itself can be converted into a surfactant or soap, for example, by adding a base such as triethanolamine to a fatty acid such as stearic acid. The term "modifier" as used herein is an agent that, when added to a hydrophobic oil, facilitates the production of a hydrophobic, easily disintegrable vehicle in the form of a gel. In some embodiments, this can facilitate the formation of a collapsible gel or foam, a thixotropic gel, or an elastic gel.

[0170] As used herein, a "foam complex," "foam stabilizer," or "foaming aid" in reference to a foamable composition can include, for example, a fatty alcohol, a fatty acid, and / or a wax. In some embodiments, the foaming aid is a fatty alcohol and a wax or a fatty acid and a wax. In some embodiments, it is a wax. In some embodiments, the foaming aid or modifier comprises at least one of a fatty alcohol, a wax, or a fatty acid. In some embodiments, the foaming aid or modifier is selected from the group consisting of a fatty alcohol, a wax, and a fatty acid. In some embodiments, the foaming aid is a fatty alcohol. In some embodiments, the foaming aid is a fatty acid. In some embodiments, the foaming aid is a wax. In some embodiments, the wax has the properties of a foaming aid. In some embodiments, the fatty alcohol, and / or the fatty acid, and / or the wax are the adjuvants. In some embodiments, the composition is free, essentially free, or substantially free of a foaming aid.

[0171] As used herein, the formulations disclosed herein may further include one or a combination of waxes.

[0172] The term "easily disintegratable" refers to the property of a gel that is stable when it is dispensed from a container, but easily disintegrates and spreads upon application of shear or mechanical forces, which may be minor, such as simple mechanical friction.

[0173] The term "water activity" as used herein refers to the hygroscopic nature of a substance, or the tendency of a substance to absorb water from its surroundings. Microorganisms require water to grow and reproduce, and such water requirement is best defined in terms of the water activity of the substrate. The water activity of a solution is expressed as Aw=P / Po, where P is the water vapor pressure of the solution and Po is the vapor pressure of pure water at the same temperature. Every microorganism has a limit Aw below which it will not grow, for example, for Streptococcus, Klebsiella, Escherichia coli, Clostridium perfringens, and Pseudomonas, the Aw value is 0.95. Staphylococcus aureus is the most resistant and can grow with an Aw as low as 0.86, while fungi can survive with an Aw of at least 0.7.

[0174] The identification of a "solvent" as used herein is not intended to characterize the solubilizing ability of the solvent for any particular active agent or any other component of the composition or foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as components of the compositions or foamable compositions described herein.

[0175] As used herein, the term "hydrophilic solvent" refers to a solvent that has a solubility in distilled water at ambient temperature of greater than about 1 gm per 100 mL, or greater than about 0.5 gm per 100 mL, or even greater than about 0.1 gm per 100 mL. A hydrophilic solvent, in one or more embodiments, remains in a liquid state at ambient temperature.

[0176] The term "hydrophilic gel composition" or "hydrophilic flowable semi-solid composition" or "hydrophilic liquid composition" or "hydrophilic composition" or "hydrogel" or "hydrogel composition" as used herein refers to or includes a composition that is composed primarily of components that are soluble or miscible / mixable with water, and may be aqueous or non-aqueous, or in either case may be essentially or substantially so. The components may include inorganic or organic excipients of various molecular weights and may include polymers. The term "gel" as used herein refers to, among other things, a carrier or formulation or composition that is not flowable at room temperature and therefore retains its form when exposed to standard gravity at room temperature. The term "flowable semi-solid" as used herein refers to, among other things, a base carrier or formulation that can flow slowly when exposed to standard gravity at room temperature and can conform to and assume the shape of a container over time. The term "liquid" refers to, among other things, a base carrier or formulation at room temperature that can flow easily or readily, can be poured into a container, and can conform to and assume the shape of the container virtually or almost immediately.

[0177] The terms "hydrophobic gel composition" or "hydrophobic flowable semi-solid composition" or "hydrophobic liquid composition" or "hydrophobic foamable composition" or "hydrophobic foam composition" or "hydrophobic aerosol composition" or "hydrophobic composition" as used herein refer to a composition that is poorly soluble in water. In some embodiments, 100 to 1000 parts of water are required to dissolve or be miscible with one part of the composition. In some embodiments, 1000 to 10,000 parts of water are required to dissolve or be miscible with one part of the composition. In some embodiments, more than 10,000 parts of water are required to dissolve or be miscible with one part of the composition. In some embodiments, the formulation is not a hydrophobic composition, or a hydrophobic liquid composition, or a hydrophobic flowable semi-solid composition, or a hydrophobic gel composition.

[0178] It should be noted that the term "substantially free of" a component, as used herein, unless otherwise specified, is intended to mean that the composition contains less than about 0.5% by weight of that component.

[0179] As used herein, the term "essentially free of" a certain component, as used herein, unless otherwise specified, is intended to mean containing less than about 0.05% by weight of that component.

[0180] By "essentially free of steroids" is meant an amount that is not a therapeutically effective amount of steroid, or an amount that is less than about 0.05%, less than about 0.04%, less than about 0.03%, less than about 0.02%, less than about 0.01%, less than about 0.008%, less than about 0.006%, less than about 0.004%, less than about 0.002%, or less than about 0.001% by weight.

[0181] In some embodiments, the composition is essentially free or free of steroids. In some embodiments, the composition is essentially free or free of betamethasone, e.g., betamethasone valerate. In some embodiments, the composition is essentially free or free of triamcinolone, e.g., triamcinolone acetonide. In some embodiments, the composition is essentially free or free of dexamethasone, e.g., dexamethasone sodium phosphate. In some embodiments, the composition is essentially free or free of clobetasol, e.g., clobetasol propionate.

[0182] As used herein, the term "free of" a component, unless otherwise specified, is intended to mean that the composition does not contain any amount of the component, for example, when the component is entrapped, bound, associated, or otherwise in a non-free state. In some embodiments, a component is considered to contain components that are normally present in an entrapped, bound, associated, or otherwise non-free state (all according to the purity grade of the component).

[0183] The term "surfactant-free" or "emulsifier-free" or "surfactant-free" refers to a composition that does not contain or contains negligible levels of surfactants, emulsifiers, or surface active agents. If a formulation contains only a small or insignificant amount of surfactants, emulsifiers, or surface active agents, it is considered to be essentially surfactant-free. As used herein, "essentially surfactant-free" refers to less than about 0.05% by weight of surfactants, such as surfactants selected from or selected from the group consisting of nonionic, ionic, anionic, cationic, zwitterionic, amphoteric, and ampholytic surfactants. The term "substantially surfactant-free" refers to a composition that contains less than about 0.5% by weight of surfactants in total, such as surfactants selected from or selected from the group consisting of nonionic, ionic, anionic, cationic, zwitterionic, amphoteric, and ampholytic surfactants. In some embodiments, the composition comprises about 0.2% by weight or less, about 0.15% by weight or less, about 0.1% by weight or less, about 0.05% by weight or less, or about 0.01% by weight or less of surfactant.

[0184] As used herein, the term "prevent" refers to avoiding the onset of a disorder or disease in a subject who has not yet been diagnosed with the disorder or disease, but who may be susceptible thereto.

[0185] As used herein, the term "polyol" is an organic substance that contains at least two hydroxy groups in its molecular structure.

[0186] As used herein, the term "treatment" or "treating" refers to inhibiting, ameliorating, or reducing a disorder or disease, e.g., halting its occurrence; reversing or alleviating a disorder or disease, e.g., causing a reduction in the disorder or disease or reversing the progression of the disorder or disease; slowing the progression of one or more symptoms of a disorder or disease (e.g., joint damage or damage associated with a disease) or alleviating, reducing, stopping, or reversing the symptoms. In some embodiments, "treatment" or "treating" means preventing or helping to prevent a disorder or disease or one or more symptoms thereof. In other words, the term "treatment" defines the therapeutic treatment of a human or non-human animal to slow, reduce, or stop the progression of a disease or to ameliorate or cure a disease. In some embodiments, "treatment" or "treating" includes slowing, stopping, or reversing damage associated with a disorder or disease. Prevention of disease as a result of treatment is also included. Reference to prevention is intended herein not to require complete prevention of the disease: instead, its occurrence may be hindered by treatment according to the invention. Typically, the treatment is not prophylactic and the compound or composition is administered to a patient with a diagnosis or suspicion of the disease. An "effective amount" herein defines an amount of the compound or composition that is sufficient to prevent a recognized disease and thus produce the desired therapeutic or inhibitory effect.

[0187] The phrase "method of treating or preventing a disease or disorder" such as a joint or joint-related disorder or disease, or a fibrosis or respiratory-related disorder or disease, provided throughout this specification, is interchangeable with "use of the composition as a medicament for treating or preventing (or preventing) a disease or disorder." The term "method(s)" of, for example, "prevention," "prophylaxis," or "treatment" of a disease or disorder provided throughout this specification is interchangeable with the term "use of" or "for use." It is noted that the term "disease" is used interchangeably with the term "disorder."

[0188] The term "Psorasis Area and Severity Index Score", also known as "PASI", can be used to monitor the improvement of the cutaneous components of psoriasis in a subject. Methods for determining PASI are described in Fredriksson and Pettersson (1978) Dermatologica 157:238 and Marks et al. (1989) Arch Dermatol 125:235. Briefly, the index is based on the assessment of erythema, induration, and peeling using a 5-point scale (0=absent; 1=mild; 2=moderate; 3=marked; 4=very marked) of four anatomical sites including the head, upper extremities, trunk, and lower extremities. Based on the extent of involvement at a given anatomical site, a number is assigned to the affected area (0=0; 1=<10%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%). A PASI score is then calculated, with possible ranges from 0.0 to 72.0, with the highest score representing the most severe, complete erythroderma.

[0189] The term "modified PASI", also known as "MPASI", is a scale that represents the percentage of area involved and the severity of erythema and scaling, ranked from 0 (normal) to 4 (severe), ranging from 0 to 60. The final sum was the combined score for erythema, induration and scaling. The modified PASI (mPASI), also referred to herein as the composite inflammation severity score, is calculated in the same manner as the mean PASI score, but excludes the scoring of induration (thickening of the skin). It is a composite mean score of erythema and scaling severity, scored on a 4-point ordinal scale (0=none, 1=mild, 2=moderate and 3=severe) for each domain, with a maximum score of 6.

[0190] As used herein, the phrase "pigmentation disorder and / or disease" or "pigmentation-related disorder and / or disease" refers to a health condition that affects skin color (e.g., loss or reduction in color, typically due to loss or destabilization of melanocytes, or an increase in color, typically characteristic of hyperpigmentation disorders such as melasma and age spots). In one or more embodiments, BET inhibitors are used for disorders in which there is loss or reduction in color. In some embodiments, this is loss or reduction in skin color. In some embodiments, this is loss or reduction in hair color. In some embodiments, this is loss or reduction in eye color. For example, vitiligo is due to loss or destruction of melanocytes, the cells that produce melanin. Melanin determines the color of skin, hair, and eyes. If melanocytes are unable to form melanin, or if their numbers are reduced, the skin becomes progressively lighter in color.

[0191] The term "cytokine" refers to a type of small protein (typically about 5-20 kDa) involved in cell signaling, including autocrine, paracrine, and endocrine signaling, and / or as an immunomodulator. Cytokines are produced by certain immune and non-immune cells and have effects on the immune system. For example, some cytokines stimulate the immune system while others slow it down. Exemplary cytokines include interleukins, etc.

[0192] As used herein, "biocompatible biodegradable materials" refer to materials that are biocompatible and biodegradable. The term "biocompatible" materials refers to materials that are not toxic or carcinogenic to the human body and induce limited or no inflammation in body tissues. "Biodegradable" materials refer to materials that are broken down by bodily processes (e.g., enzymes) into products that can be easily processed by the body or absorbed into body tissues. Biodegradable products should also be biocompatible with the body. In the context of intra-articular or respiratory drug delivery systems for the compounds disclosed herein, biocompatible biodegradable materials can be used to fabricate, for example, microparticles, microspheres, matrices, microparticle matrices, microsphere matrices, gels, hydrogels, rods, wafers, liposomes, fibers, pellets, or other suitable pharmaceutical delivery compositions (e.g., capsules and pills) that can be administered intra-articularly by medical practitioners or administered systemically to reach the joint. Biocompatible biodegradable materials can be easily removed, degraded, or dissolved by the body and / or can degrade into non-toxic residues that can be eliminated from the body intact.

[0193] "Fibrosis" is defined as any pathological condition resulting from the excessive or abnormal production of fibrous tissue. Fibrosis can occur in any organ, including, for example, the lung, kidney, liver, skin, central nervous system, bone, bone marrow, cardiovascular system, endocrine organs, or gastrointestinal system. "Fibrosis-associated disease" refers to any disease associated with fibrosis. Thus, fibrosis-associated disease may be caused by, accompanied by, or cause fibrosis.

[0194] "Treating or ameliorating fibrosis" means reducing the level of fibrosis relative to an untreated control, as measured by any standard method. Reduction of fibrosis may also be measured by a reduction in any symptom associated with fibrosis or a fibrosis-related disease. The examples disclosed herein provide exemplary methods of determining whether the level of fibrosis is reduced relative to a control.

[0195] "Treating or ameliorating a fibrosis-related disease (or disorder)" means reducing the occurrence of such a disease before or after its occurrence. The extent of such reduction or prevention is at least about 5%, about 10%, about 20%, about 40%, about 50%, about 60%, about 80%, about 90%, about 95%, or about 100% compared to a comparable untreated control or vehicle. A subject treated for a fibrosis-related disease is one diagnosed by a physician as having such a disease. A subject in which the occurrence of a fibrosis-related disease is prevented may or may not have been so diagnosed. As will be understood by those skilled in the art, these subjects (e.g., patients) may have been subjected to standard tests for diagnosing a fibrosis-related disease, or may have been identified as at high risk due to the presence of one or more risk factors without being tested. Disclosed herein is an exemplary method for determining whether the level of a fibrosis-related disorder is reduced compared to a control.

[0196] By "insignificant" it is meant that the effect is negligible, e.g., so slight that it has no functional impact on the formulation or method.

[0197] As used herein, "chemically stable" refers to a compound (active agent or excipient) or composition in which no significant decrease in the assay, no significant increase in impurities, or no significant appearance of degradation products can be observed under the test conditions and test periods. The decrease in the assay or the increase in impurities can occur, for example, when the compound or composition is oxidized, degraded, and / or reacts in response to exposure to air, light, skin, mucous membranes, tissue, water, any pharmaceutical excipients, or any active agents under ambient conditions. By significant decrease in the assay, we mean a decrease of about 2% or more than about 2% of the initial assay value. By substantially significant decrease in the assay, we mean a decrease of about 5% or more than about 5% of the initial assay value. By significant increase in impurities or degradation products, we mean a decrease of about 2% or more than about 2% of the initial assay value. By substantially significant increase in impurities or degradation products, we mean about 5% or more than about 5% of the initial assay value. By no significant decrease in the assay, we mean a decrease of less than 1% of the initial assay value. By no significant increase in related compounds or degradation impurities is intended an increase of less than 1% of the initial assay value. For clarity, if the initial assay value is 100% and the new assay value is 96%, the decrease is 4%. Similarly, if the initial assay value of an impurity or degradation product is 0.1% and the new assay value is 1.1%, the increase is 1%. In some embodiments, a significant or substantially significant decrease in the assay and / or a significant or substantially significant increase in degradation products / impurities may occur within 24 hours of exposure to, for example, air, light, the respiratory system, skin, water, or pharmaceutical excipients or any active agents under ambient conditions at room temperature, as described above, which may be, for example, within 16 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or 1 hour. The term "chemically unstable" refers to a compound or composition that falls outside the above definition of chemically stable.

[0198] As used herein, the term "physically stable" refers to a compound or composition that does not observe a significant change in state over the time and conditions tested. For example, a physically stable formulation will tolerate 5% or less aggregates.

[0199] As used herein, the term "physically unstable" refers to a compound or composition that is observed to undergo a significant change in state over the time period and conditions tested. For example, a physically unstable formulation is one that undergoes significant phase separation over time or under conditions suitable for its use.

[0200] As used herein, "homogeneous" or "homogeneous distribution" refers to a characteristic of a composition in which particles and / or active agents and / or excipients are proportionally distributed throughout. In some embodiments, a composition comprising a BETi compound is homogeneous.

[0201] As used herein, "micronized" refers to a material that is reduced in size to a fine powder, the diameter of its particles or crystals being measured in micrometers. The measurement of the size of particles or crystals in suspension in a composition can be expressed as D90. For example, if 90% of the particles or crystals in suspension are less than 15 microns, then the D90 is 15 microns. In one or more embodiments, the D90 of the particles is less than about 50 μm. In some embodiments, it is less than 45 μm or less than 40 μm, or less than 35 μm, or less than 30 μm, or less than 25 μm, or less than 20 μm or less than 15 μm, or less than 10 μm. In some embodiments, the D90 is between 50 μm and 15 μm, between 30 μm and 20 μm, or between 25 μm and 15 μm, or between 20 μm and 10 μm, or between 15 μm and 5 μm, or between 10 μm and 3 μm. The measurement of the size of particles or crystals suspended in a composition can alternatively be expressed as D50. For example, if 50% of the particles or crystals in the suspension are less than 25 microns, then D50 is 25 microns. In one or more embodiments, it is less than 25 μm, or less than 20 μm, or less than 15 μm, or less than 10 μm, or less than 5 μm, or less than 2 μm, or less than 1.5 μm, or less than 1 μm. In one or more embodiments, D50 is 25 μm to 5 μm, 20 μm to 10 μm, or 15 μm to 10 μm, or 10 μm to 3 μm, or 15 μm to 5 μm, or 5 μm to 1 μm, or 3 μm to 0.1 μm.

[0202] As used herein, "non-occlusive" refers to a topical formulation or substance that, when applied topically or locally as a continuous layer onto healthy skin, initially allows for significant transepidermal water loss (TEWL), in some embodiments contemplated as greater than 30% water loss 20 minutes after application.

[0203] As used herein, "TEWL" refers to the amount of water that passively evaporates through the skin to the external environment due to the water vapor pressure gradient across the skin barrier, and is used to characterize skin barrier function. The average TEWL in humans is about 300-400 mL / day, but can be influenced by environmental and intrinsic factors. At high humidity, water loss is reduced due to a decrease in the water vapor pressure gradient. TEWL varies at different anatomical sites and is inversely proportional to the size of the keratinocytes. Skin sites with smaller keratinocytes have higher TEWL values. There are several instruments commercially available for measuring TEWL, which provide useful data applied in clinical settings, toxicology, and product development. TEWL is a sensitive indicator of skin irritation and is widely used in the objective analysis of the irritation potential or protective properties of topical products. When TEWL is affected by joint inflammation in the area of ​​inflammation, in one or more embodiments, application of BETi to the joint or respiratory system or associated tissues or lesions can restore or help restore normal TEWL values.

[0204] As used herein, "occlusive" refers to a topical preparation or substance that, when applied topically as a continuous layer on healthy skin, initially substantially slows or allows no or negligible transepidermal water loss.

[0205] As used herein, "partially occlusive" refers to a topical preparation or substance that, when applied topically as a continuous layer on healthy skin, initially allows for moderate transepidermal water loss.

[0206] As used herein, "penetration enhancer" refers to a compound or a component of a topical formulation that increases the penetration of an active ingredient through a skin barrier or tissue. In some embodiments, the penetration enhancer dissolves a significant proportion of the active ingredient. In some embodiments, the penetration enhancer does not dissolve a significant proportion of the active ingredient. In some embodiments, the significant proportion is greater than 0.1% by weight of the composition.

[0207] As used herein, "hydrophilic" refers to a compound or composition that is miscible with water. In one or more embodiments, a composition may be "hydrophilic" in nature even though it may contain compounds that have some hydrophobic properties.

[0208] As used herein, "non-hydrophilic" refers to a compound or composition that is not miscible with water and / or that repels water. In one or more embodiments, a composition may be "non-hydrophilic" in nature even though it may contain compounds that have some hydrophilic properties.

[0209] As used herein, "non-hydrophobic" refers to a compound or composition that is not miscible with oil and / or that repels oil. In some embodiments, a composition may be "non-hydrophobic" in nature even though it may contain compounds that have some hydrophobic properties.

[0210] As used herein, "preservative-free" refers to a composition that is free of preservatives or contains negligible amounts of preservatives. As used herein, "essentially preservative-free" refers to a composition that contains less than 0.05% preservatives by weight. In some embodiments, an essentially preservative-free composition contains 0.04%, 0.03%, 0.02%, or 0.01% preservatives by weight. The term "substantially preservative-free" refers to a composition that contains 3% or less than 3% preservatives by weight. In some embodiments, the composition contains less than 2% preservatives by weight, or less than 1%, or less than 0.5%, or less than 0.4%, or less than 0.3%, or less than 0.2%, or less than 0.1%, or less than 0.09%, or less than 0.08%, or less than 0.07%, or less than 0.06% preservatives by weight.

[0211] As used herein, "antioxidant-free" refers to a composition that is free of antioxidants or contains negligible amounts of antioxidants. As used herein, "essentially free of antioxidants" refers to a composition that contains less than 0.05% antioxidants. In some embodiments, an essentially antioxidant-free composition contains 0.04%, 0.03%, 0.02%, or 0.01% antioxidants by weight. In some embodiments, the composition contains less than 0.04%, or less than 0.03%, or less than 0.02%, or less than 0.01%, or less than 0.005%, or less than 0.001% antioxidants by weight. As used herein, "substantially free of antioxidants" refers to a composition that contains 2% or less than 2% antioxidants by weight. In some embodiments, the composition comprises less than 1.5%, or less than 1%, or less than 0.5%, or less than 0.4%, or less than 0.3%, or less than 0.2%, or less than 0.1% antioxidants by weight.

[0212] As used herein, free of "additional stabilizers" refers to a composition that does not contain additional stabilizers or contains negligible amounts of additional stabilizers. As used herein, essentially free of "additional stabilizers" refers to a composition that contains less than 0.05% additional stabilizers. In some embodiments, a composition that is essentially free of additional stabilizers contains 0.04%, 0.03%, 0.02%, or 0.01% additional stabilizers by weight. In some embodiments, a composition contains less than 0.04%, or less than 0.03%, or less than 0.02%, or less than 0.01%, or less than 0.005%, or less than 0.001% additional stabilizers by weight. As used herein, substantially free of "additional stabilizers" refers to a composition that contains 2% or less than 2% additional stabilizers by weight. In some embodiments, the composition contains less than 1.5%, or less than 1%, or less than 0.5%, or less than 0.4%, or less than 0.3%, or less than 0.2%, or less than 0.1% by weight of additional stabilizers.

[0213] As used herein, the term "suspended" refers to active agent particles dispersed in a composition such that less than 0.1% by weight is dissolved in the composition. As used herein, "substantially suspended" refers to active agent particles dispersed in a composition such that less than 5% by weight is dissolved in the composition. As used herein, "partially suspended" refers to a composition in which a percentage of the active ingredient is dissolved. In some embodiments, the dissolved percentage is at least about 0.1% by weight. In some embodiments, the dissolved percentage is at least about 0.2% by weight. In some embodiments, the dissolved percentage is at least about 0.3% by weight. In some embodiments, the dissolved percentage is at least about 0.4% by weight. In some embodiments, the dissolved percentage is at least about 0.5% by weight. In some embodiments, the dissolved percentage is at least about 0.6% by weight. In some embodiments, the dissolved percentage is at least about 0.7% by weight. In some embodiments, the dissolved percentage is at least about 1% by weight. In some embodiments, the dissolved percentage is at least about 5% by weight. In some embodiments, the dissolved fraction is at least about 10% by weight. In some embodiments, the dissolved fraction is at least about 15% by weight. For clarity, for example, a corollary of at least 0.6% dissolution is less than about 99.4% suspension. In some embodiments, the presence of a dissolved fraction can affect the rate and / or amount and / or depth / area of ​​penetration.

[0214] As used herein, "a compound that dissolves an active agent" or "a compound that dissolves a percentage of an active agent" refers to a compound that promotes dissolution of more than about 1 mg / g, i.e., more than about 0.1% by weight, of an active agent.

[0215] As used herein, "a compound that substantially dissolves an active agent" or "a compound that substantially dissolves a percentage of an active agent" refers to a compound that promotes dissolution of about 0.1 mg / g to about 1 mg / g, i.e., about 0.01% to about 0.1% by weight, of the active agent.

[0216] As used herein, "a compound that essentially dissolves an active agent" or "a compound that essentially dissolves a percentage of an active agent" refers to a compound that promotes dissolution of from about 0.01 mg / g to about 0.1 mg / g, i.e., from about 0.001% to about 0.01% by weight of the active agent.

[0217] As used herein, a "compound that does not dissolve the active agent" or a "compound that does not dissolve a certain percentage of the active agent" refers to a compound that allows dissolution of less than about 0.01 mg / g, i.e., less than about 0.001% by weight, of the active agent.

[0218] As used herein with respect to particle or crystal size, "average uniform size" refers to the average size of the active agent. The average can be expressed as a percentage of the total particles. If 90% of the particles or crystals in the suspension are less than Y microns, then D90 is Y microns. In other words, the majority of the particles are smaller than Y microns.

[0219] As used herein, "agglomerate-free" refers to a composition in which at least about 95% of the active agent is not present as agglomerates and / or does not form clusters, and "substantially agglomerate-free" refers to a composition in which at least about 90% of the active agent is not present as agglomerates and / or does not form clusters.

[0220] As used herein, "adhesion" refers to the property of physical attraction and interaction between different surfaces. It can refer to the attraction and interaction between a composition and the surface of an object (e.g., a body cavity or joint), or it can refer to the attraction and interaction between a compound and the surface of an object (e.g., a body cavity or joint), which can be compared to the competing attraction and interaction between the compound and the composition in which it is suspended.

[0221] As used herein, "scavenger" refers to a compound that can scavenge molecules that promote the decomposition of a product. A scavenger can be, for example, but is not limited to, a free radical scavenger, or an aldehyde scavenger.

[0222] As used herein, "maintenance application" refers to the topical application of a composition in an amount that may help to maintain a steady state level of a disease or disorder, or to reduce the likelihood of a disease or disorder worsening, or to prevent the recurrence or relapse of a disease or disorder.

[0223] As used herein, "syringe" or "injection device" includes needles, such as 14-28 gauge, other conventional methods, catheters, infusion pumps, pumps, pens, and guns.

[0224] As used herein, a joint is where two bones can come into contact or relate to each other.

[0225] As used herein, names of compounds, including organic compounds, may be indicated using common names, IUPAC, IUBMB, or CAS nomenclature recommendations. Given a name, a person skilled in the art can easily ascertain the structure of the compound by systematic abbreviation of the compound structure using the naming rules, or by commercially available software such as CHEMDRAW™ (Cambridgesoft Corporation, USA).

[0226] The term "therapeutic index", also known as the "therapeutic window" or "safety window", defines the relative safety of a drug. Therapeutic index can be calculated as the ratio of the area under the curve (AUC) of the concentration of drug that produces the desired efficacy in the blood, typically the effective dose 50 or ED50, which is the dose that has 50% efficacy, to the concentration of drug that produces no toxicity (No Observed Adverse Effect Level-NOAEL). TI=AUC(NOAEL) / AUC(ED50).

[0227] The term "cyclic" or synonyms thereof define a compound or a substituent on a compound in which a series of one or more atoms in the compound or substituent are joined to form a ring. The term "acyclic" defines a compound or substituent that does not contain a ring of atoms.

[0228] The term "alkyl" is well known in the art and defines a univalent group derived from an alkane by removal of a hydrogen atom from any carbon atom, where the term "alkane" is intended to define a cyclic or acyclic, branched or unbranched hydrocarbon having the general formula CH, where n is an integer equal to or greater than 1.

[0229] The term "cycloalkyl" defines any univalent group derived from a cycloalkane by removal of a hydrogen atom from a ring carbon atom. The term "cycloalkane" defines saturated monocyclic and polycyclic hydrocarbons.

[0230] The term "alkylol" defines the hydroxy derivative of an alkyl radical, i.e., a hydroxy-alkyl.

[0231] The term "halo" is well known in the art and defines a halogen radical that, when attached to a carbon radical, produces a fluorinated, chlorinated, brominated, or iodinated compound.

[0232] The term "alkyloxy" is synonymous with "alkoxy" and, as used herein, defines a monovalent group containing an alkyl single-bonded to an oxygen atom, derived from the corresponding alcohol by removal of the hydrogen atom bonded to the oxygen atom.

[0233] The term "alkylamino" is synonymous with "alkamino" and, as used herein, defines a monovalent group containing an alkyl single-bonded to an amino group, derived from the corresponding amine by removal of the hydrogen atom bonded to the nitrogen atom.

[0234] The term "oxacycloalkyl" defines a monovalent group containing a cycloalkyl in which one of the CH2 moieties has been replaced with an oxide. Similarly, the term "azacycloalkyl" defines a monovalent group containing a cycloalkyl in which one of the CH2 moieties has been replaced with an NH moiety.

[0235] The term "stereoisomers" is used herein to refer to isomers that have identical molecular formulas and sequences of bonded atoms, but that differ in the arrangement of their atoms in space.

[0236] The term "enantiomer" defines one of a pair of molecular entities that are mirror images of each other and are non-superimposable, i.e., cannot be matched by translation and rigid rotation transformations. Enantiomers are chiral molecules, i.e., they can be distinguished from their mirror images.

[0237] The term "racemic" is used herein with reference to a racemate. A racemate defines a substantially equimolar mixture of a pair of enantiomers.

[0238] The term "diastereoisomers" (also known as diastereomers) defines stereoisomers that are not related as mirror images.

[0239] The term "solvate" is used herein to refer to a complex comprising a solute, such as a compound or a salt of a compound, and a solvent. If the solvent is water, the solvate may be referred to as a hydrate, e.g., a monohydrate, a dihydrate, a trihydrate, etc., depending on the number of water molecules present per molecule of substrate.

[0240] The term "isotope" is used herein to define varieties of a particular chemical element whose nuclei necessarily have the same atomic number but have different numbers of neutrons and therefore different mass numbers.

[0241] The term "prodrug" is used herein to refer to a compound that acts as a drug precursor and, upon administration to a subject, is converted by metabolic or other chemical processes to yield a compound of formula (I).

[0242] The term "pharmaceutical acceptable excipient" defines a substance, other than a pharmacologically active drug or prodrug, that is included in a pharmaceutical product.

[0243] The term "topical," when used in reference to a compound or composition, is used to refer to the ability to apply the compound or composition to a body surface, such as the skin, tissue, body cavity, mucous membrane, parenchyma, interstitium, alveoli, mucous membrane, and the respiratory system (by inhaler or nebulizer). Topical compounds or compositions, in some embodiments, can be applied in the form of a mist, spray, aerosol, liquid bolus, or powder, for example, when administration can be internal and local, such as by inhalation. In some embodiments, they can be applied as a foam, cream, gel, lotion, or ointment, for example, when application is external and local.

[0244] The term "oral," when used in reference to a compound or composition, is used to refer to the ability to administer the compound or composition through the mouth. Typically, oral compounds exhibit a systemic effect rather than a local effect, i.e., affect multiple organ systems rather than a local area.

[0245] The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular (IA), intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, intraperitoneal (IP), and intracranial injection or infusion techniques.

[0246] As used herein, the term "prevent" or "prophylaxis" refers to avoiding the onset of a disorder or disease in a subject who has not yet been diagnosed with the disorder or disease, but who may be susceptible thereto.

[0247] The terms "transduce" or "transducing", when used in reference to a signal, are synonymous with "transfer" or "transferring", i.e., "signal transduction" is the process of transmitting a signal throughout an organism, for example through cells.

[0248] The term "pan" is used herein to refer to "all." For example, pan-inhibition of the BET family means that all of the BET family members (BRD2, BRD3, BRD4, and BRDT) are inhibited. For example, a pan-BD inhibitor or pan-BET inhibitor means that it binds to both BDI and BDII.

[0249] The term "T cell" (also known as T lymphocyte) is known in the art to refer to a lymphocyte that has a T cell receptor (a molecule involved in recognizing fragments of antigenic peptides) on the cell surface.

[0250] The term "cytokine" is used herein to refer to small proteins (approximately 5-20 kDa) that are important in cell signaling, including autocrine, paracrine, and endocrine signaling, as immunomodulatory agents.

[0251] The term "chemokine" is used herein to refer to a family of cytokines that can induce directional chemotaxis in responsive cells, i.e., they act as chemotactic factors that direct cell migration.

[0252] The term "intrinsic clearance" is well known in the art and refers to the ability of the liver to remove drugs in the absence of flow restriction and binding to cells or proteins in the blood. As used herein, intrinsic clearance is expressed as a percentage of hepatic blood flow, i.e., the following formula:

number

[0253] The term "pharmaceutically acceptable salt" is intended to define organic and / or inorganic salts that are pharmaceutically useful. All compounds described hereinabove and herein may be in the form of a pharmaceutically acceptable salt. The compounds may be isolated from the reaction mixture as a pharmaceutically acceptable salt. Alternatively, pharmaceutically acceptable salts may be prepared in situ during the final isolation and purification of the compounds by reacting a carboxylic acid-containing moiety with a suitable base, such as a hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, or with ammonia or a primary, secondary, or tertiary amine. Pharmaceutically acceptable salts include cations based on alkali or alkaline earth metals, such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, as well as non-toxic quaternary ammonia and amine cations, including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, and ethylamine. Other examples of organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

[0254] Pharmaceutically acceptable salts can also be prepared by treatment of the compound with a suitable acid, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulfonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.

[0255] All compounds may exist in different stereoisomeric and atropisomeric forms. All stereoisomeric forms and their mixtures, including enantiomers and racemic mixtures, are included within the scope of the present invention. Such stereoisomeric forms include enantiomers and diastereoisomers. Included are individual stereoisomers of the compound, i.e. those associated with less than 5%, preferably less than 2%, especially less than 1% of other stereoisomers. Also included are mixtures of stereoisomers in any proportion, for example racemic mixtures containing substantially equal amounts of two enantiomers.

[0256] Also included are the solvates and isotopically labeled compounds of the present invention.Isotopically labeled compounds are the same as those listed herein, except that one or more atoms are replaced by atoms with different atomic mass or mass number from the atomic mass or mass number that is mainly found in nature.The examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 35S, 18F and 36Cl, respectively.

[0257] Further aspects include intermediates suitable for producing compounds for use in the methods of treatment or prevention described herein.

[0258] Also within the scope of the invention are prodrugs of the compounds and compositions for use in the methods of treatment or prevention described herein, which, when administered to a subject, are converted by metabolic or other chemical processes to yield the compounds of the invention.

[0259] All amorphous and crystalline forms of the compounds are included for use in the methods of treatment or prevention described herein.

[0260] The term "dry powder inhaler (DPI)" is intended to define either passive or active devices depending on the airflow source for powder aerosolization. These devices are further subdivided as single dose reusable, multi-dose, and single use devices.

[0261] The term "passive or active device" is intended to define a DPI in which the patient's inhaled air is the primary energy source for aerosolizing the drug powder. Most passive inhalers consist of an air inlet, a dispersion chamber, and a mouthpiece, but the dispersion mechanisms vary widely. In the case of a traditional passive inhaler, the powder is entrained in the dispersion chamber, and the airflow disperses the powder layer into an inhalable aerosol, which can be inhaled by the patient. This process may depend on the balance between the cohesive / adhesive forces between particles and the deagglomeration forces generated by the airflow. The basic mechanism of airflow-induced dispersion is generally believed to be the combined effect of turbulence and powder collisions. Thus, deagglomeration promoters (e.g., 3D arrays of rods, vibrating beads, or collision grids) are added. Other inhalers may not rely solely on the inhaled airflow to disperse the powder, and a mesh sieving mechanism is applied. During aerosolization, the mesh strip with the powder loaded inside the mesh vibrates and beats to push the powder through the small mesh holes, thereby deagglomerating the powder. Similarly, in other devices, airflow-driven flutter provides the primary dispersion force. A major problem with passive devices is deagglomeration, which relies on inhalation-driven flow. More recent designs have minimized flow dependence, but this remains a potential problem at low flow rates. For patients with compromised lung function, active devices are better suited to deliver pharmaceutical aerosols to the lungs.

[0262] The term "active device" is intended to define a DPI in which an external energy source disperses the drug powder, so that the aerosolization efficiency is independent of inhalation. Dispersion can be achieved by compressed air, electrical vibration, or a mechanical impeller. This DPI can be particularly important for inhalation procedures in patients with limited lung function or greatly reduced lung capacity, such as those with PF.

[0263] The term "multi-dose inhaler" is intended to define the multi-unit and reservoir types. In multi-unit DPIs, the powder is filled into individual blisters or foils, while reservoir type doses are dispensed by a metering valve. Multi-unit devices may use an additional separate package for each dose unit to provide better protection from moisture and light. A mechanical or electronic dose counter is mandatory to indicate the remaining dose.

[0264] The term "single-dose reusable device" is intended to define a device in which each dose is prepared in a separate single unit, such as a capsule or blister. Upon administration, the single-dose unit is loaded into an inhaler, aerosolized for inhalation by the patient, and then discarded. Designing the device to contain the formulation as a separate entity minimizes its dimensions. Furthermore, the powder mass within each unit is flexible, allowing the same device to be used for both low- and high-dose therapy.

[0265] The term "nebulizer" is intended to define a device that delivers liquid medication in the form of a mist to the lungs. Nebulizers are particularly useful for diseases that require higher intrapulmonary doses (e.g., PF) and for patients (e.g., children) whose required flow rates cannot be regulated or achieved using other inhalation devices. Three main types of nebulizers are available, which are classified according to the mechanism used to convert the drug solution or suspension into an inhalable aerosol. Jet nebulizers remain the most common (because they are the cheapest and can be provided by medical care) and use compressed gas to disperse liquid medication into aerosol droplets. However, treatment times are long, the air compressor is heavy and noisy, and mechanical shear forces can affect certain drugs. Alternatively, ultrasonic nebulizers operate quietly and are much more portable. The main drawback is their tendency to heat the liquid in the reservoir, making them unsuitable for thermolabile drugs such as proteins. Vibrating mesh nebulizers are the latest technology and overcome the disadvantages of both jet and ultrasonic nebulizers with fast treatment times, minimal residual volume, and better aerosol delivery. However, their high cost remains a barrier to increased patient use. Also, the formulation and particle size distribution must be designed to avoid potential retention on / in the mesh. The main defect or drawback of these devices is that the aerosol is generated continuously throughout the patient's respiratory cycle. Thus, a significant proportion of the drug is lost during exhalation, resulting in inefficient aerosol drug delivery and variability in dosing. This may be partially controlled by mechanical means, as seen in breath-enhanced or breath-actuated jet nebulizers, which restrict the majority of aerosolization to the patient's inspiratory phase, or by interfacing software control with the nebulizer. In some embodiments, a jet nebulizer is used. In some embodiments, a mesh nebulizer is used.

[0266] As will be understood by those skilled in the art, numerous changes and / or modifications can be made to the invention described herein without departing from the scope of the invention described. Thus, the present embodiment should be considered for descriptive purposes, and not restrictive, and is not limited to the scope described in the embodiment. It will be understood by those skilled in the art that the present embodiment may be taken alone or in combination, and may be combined with any one or combination of features described herein. It should be noted that the abbreviations "ml" and "mL" are used interchangeably herein, and both represent milliliters.

[0267] The subject matter of each patent and non-patent reference cited herein, including its compositions, excipients, methods, and uses, is hereby incorporated by reference in its entirety.

[0268] The compounds and their uses and surprising results are now described in detail. Exemplary compounds useful according to certain embodiments include, for example, those described herein, and further include, for example, those disclosed in patent application No. PCT / EP2020 / 061173, filed on April 22, 2020. The disclosure of said patent application is expressly incorporated herein by reference in its entirety and in particular with respect to the disclosed compounds, their preparation methods, and compositions containing them, including excipients.

[0269] As described in PCT / EP2020 / 061173, many of the compounds and compositions were stable in human skin and under hydrolysis conditions over a range of pH values. Furthermore, formulations of the compounds were deemed capable of delivering practical concentrations of the compounds into the epidermis of the skin, and the compounds were not toxic to skin cells. Some of the compounds and compositions were "soft drugs", i.e., they showed surprisingly effective clearance by the liver, offering the potential for pharmaceutical use with a lower risk of side effects. Some of the compounds were selective for BDII over BDI, offering the potential for improved therapeutic index and reduced risk of side effects, while others were pan-BET inhibitors capable of binding to both BDI and BDII.

[0270] The present disclosure relates to pan-BET inhibitors, including the topical pan-BET inhibitors described above, and more particularly to a particular set of compounds and their use in the treatment and / or prevention of selected diseases and disorders that can be treated locally as described herein, or of the joints or joint-related diseases and disorders that can be treated as described herein.

[0271] In one or more embodiments, one or more compounds are provided, and compounds that may function as "soft" pan-BD BET inhibitors. In one or more embodiments, one or more compounds may have a beneficial effect on diseases and disorders involving multiple diverse inflammatory cell signaling pathways. In one or more embodiments, one or more compounds are provided that may be applicable and have therapeutic activity against certain diseases and disorders involving cytokine pathways as part of the pathogenic factors involved in the manifestation of symptoms, for example, multiple neutrophilic skin diseases such as pyoderma gangrenosum (PG), palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP).

[0272] In one or more embodiments, one or more compounds are provided that may be applicable to and have therapeutic activity against certain pigmentation diseases and disorders in which there is lightening of pigmentation (e.g., the appearance of pale or white spots), such as vitiligo, chemical leukoplakia in which areas of the skin are whitened in linear or patchy areas, tinea versicolor, albinism in which the skin has low levels of melanin, or pityriasis alba in which the skin is lightened in patches. Also, examples of the appearance of pale or white spots include atrophy alba, Griscelli syndrome, lentigines, Hermansky-Pudlak syndrome, Ito's hypomelanosis, idiopathic guttate hypomelanosis, leprosy, leukoplakia, lichen sclerosus, lupus erythematosus, morphea, mycosis fungoides, anemic nevus, depigmented nevus, mottling, leukoderma, leukoderma, postinflammatory hypopigmentation, progressive patchy hypopigmentation, tuberous sclerosis (Ashleaf spots), and Waardenburg syndrome.People with vitiligo may be more likely to develop other autoimmune diseases (where the body's immune system attacks itself), such as hypothyroidism, diabetes, pernicious anemia, Addison's disease, and alopecia areata.People with autoimmune diseases are also at a higher risk of developing vitiligo.

[0273] A joint is where two bones can touch or relate to each other. Joints can be classified histologically based on the predominant type of connective tissue, or functionally based on the amount of movement permitted. Histologically, the three types of joints in the body are fibrous, cartilaginous, and synovial. Functionally, the three types of joints are immobile (cannot be moved), hemijoints (can be moved slightly), and diarthroditism (can be moved freely). The two classification schemes are correlated: immobile joints are fibrous, hemijoints are cartilaginous, and diarthroditism is synovial (see Cope PJ et al. Models of osteoarthritis: the good, the bad and the promising. Osteoarthritis Cartilage. 2019 Feb;27(2):230-239). Fibrous joints are fixed joints where fibrous tissue, composed primarily of collagen, connects the bones. Fibrous joints are usually immobile (immobile) and do not have a joint cavity. These are further subdivided into sutures, ligaments, and syndesmoses. In cartilaginous joints, bones are joined by hyaline cartilage or fibrocartilage. Depending on the type of cartilage involved, joints are further classified into primary and secondary cartilaginous joints. Synovial joints allow free movement (diarthrosis) and are considered the main functional joints of the body. Synovial joints are often further classified by the type of movement they allow. There are six such classifications: hinge joints (elbow), saddle joints (carpometacarpal joint), planar joints (acromio-clavicular joint), pivot joints (atlantoaxial joint), condylar joints (metacarpophalangeal joint), and ball-and-socket joints (hip joint) (see Juneja P. et al., Anatomy, Joints, StatPearls Publishing; 2022, available at https: / / www.ncbi.nlm.nih.gov / books / NBK507893 / ). In some embodiments, the joint is a finger joint, a wrist joint, an elbow joint, an armpit joint, a hip joint, a knee joint, a toe joint, an ankle joint, a shoulder joint, a spinal joint, and / or a temporomandibular joint.

[0274] In some embodiments, one or more compounds may favorably affect joint or joint-related diseases and disorders involving multiple and diverse inflammatory cell signaling pathways. In some embodiments, one or more compounds are provided that may be applicable and have therapeutic activity against specific joint or joint-related diseases and disorders. In some embodiments, at least one compound is provided that may be applicable and have therapeutic activity against specific joint or joint-related secondary diseases and disorders. In some embodiments, the compounds and compositions of the present disclosure reduce inflammation in the joint and / or surrounding tissues. In some embodiments, the joint or joint-related diseases and disorders are selected from arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus, and other autoimmune joint disorders. In some embodiments, the disease is rheumatoid arthritis.

[0275] In some embodiments, one or more compounds are provided that can be applied to diseases with scar tissue formation or increase or fibrosis and have therapeutic activity against them. In some embodiments, the compounds can be applied to cases where scar tissue appears or increases or fibrosis appears in the lung and have therapeutic activity. In some embodiments, the compounds can be applied to cases where scar tissue or fibrosis is between alveoli and have therapeutic activity. In some embodiments, the compounds can be applied to cases where scar tissue or fibrosis damages alveoli and have therapeutic activity. In some embodiments, the compounds can be applied to cases where scar tissue or fibrosis causes reduction in lung surface area and have therapeutic activity. In some embodiments, the compounds can be applied to cases where scar tissue or fibrosis causes reduction in lung tissue elasticity or causes alveolar hardening and have therapeutic activity. In some embodiments, the scar tissue or fibrosis occurs in PF. In some embodiments, the PF is idiopathic PF or IPF.

[0276] In some embodiments, one or more compounds are provided that may be applicable to and have therapeutic activity against, for example, fibrotic diseases and disorders, such as PF, in which there is abnormal or dysregulated wound healing, resulting in significant tissue remodeling and the formation of permanent scar tissue.

[0277] In one or more embodiments, the present application provides certain soft pan-BD BET inhibitors (hereinafter BETi) that have been found to be useful in the treatment or prevention of the diseases described herein.

[0278] In some embodiments, the soft pan BD BET inhibitor is [ka] is selected from.

[0279] In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is delivered in a particulate or powder form, which may include a crystalline form. In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is delivered in a liquid or mist form. In one or more embodiments, the present application provides a composition, such as a topical composition, where the BETi is suspended or substantially suspended. In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is dissolved or substantially dissolved. In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is provided in the form of a micelles. In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is provided in the form of a liposomal composition. In some embodiments, the present application provides a composition comprising a BETi and a carrier, where the BETi is lyophilized. In one or more embodiments, the family of BETi disclosed herein has been found to be surprisingly effective in inhibiting all four BET BRDs at the binding domain II (BDII). In one or more embodiments, the BETi described herein may also have the effect of inhibiting the BET BRD at binding domain I (BDI). In some embodiments, the BETi can effectively bind to both BDII and BDI. In one or more embodiments, the BETi exhibits binding affinity for BDI and BDII, as well as slightly higher selectivity for BDII over BDI. In some embodiments, the BETi compound has similar binding affinity for BDI and BDII.

[0280] In one or more embodiments, the BETi may have a therapeutic effect systemically. In some embodiments, the BETi may be therapeutically effective by local administration. In some embodiments, for example, when applied locally, the systemic penetration is low and below the therapeutic window. In other embodiments, for example, when applied locally, the systemic penetration may be sufficient for the BETi to have a systemic therapeutic effect in addition to any local effects. In some embodiments, administration is designed to be intradermal. In some embodiments, administration is designed to be transdermal. Local delivery may be achieved by applying a pharmaceutical composition comprising the compound or BETi to the skin or mucosal surface of a subject, including the inner surfaces of body cavities such as the gastrointestinal tract, vagina, respiratory tract, and lungs. Local delivery to the respiratory tract and lungs may be achieved by various inhalation methods, including inhalation of powders, solutions, and suspensions. Solutions and suspensions (of active ingredients in a liquid carrier) may be delivered as a mist that is inhaled into the lungs in some embodiments. In some embodiments, administration is designed to be intraparenchymal or intraalveolar. In some embodiments, administration is designed to be transparenchymal or transalveolar. Types of inhalers include metered dose inhalers, dry powder inhalers, soft mist inhalers, and nebulizers. Inhalation therapy can be provided. In some embodiments, this can be provided as a short burst of aerosolized compound or composition, usually as a metered dose. In some embodiments, it can be delivered as a spray. In some embodiments, it can be provided as a mist by a nebulizer over a longer period of time, e.g., 10-20 minutes.

[0281] A key challenge in formulating a formulation suitable for a nebulizer is understanding the effect of key formulation parameters such as viscosity, surface tension, etc. on droplet aerosol properties and, in the case of non-dissolved formulations, on their interaction with drug particle size. For example, deposition in the lungs, especially in the peripheral airways, is influenced by the hygroscopic properties of the nebulized aerosol. The droplet size of the nebulized aerosol can be greatly reduced by adding larger Pluronic polymers to the formulation at micromolar concentrations. For newer vibrating mesh nebulizers, viscosity and conductivity are particularly important. Specifically, an increase in both of these parameters can reduce the aerodynamic size, while an increase in electrolyte concentration can enhance aerosol output. While some parameters are well understood, other factors, such as how the behavior of non-Newtonian fluids affects nebulizer droplet formation, still need to be better understood.

[0282] In some embodiments, the compound or pharmaceutical composition comprising the compound is administered by injection or infusion, which can be administered as a single injection or sequential injections.

[0283] Compounds with both properties of lower liver clearance rate and higher plasma stability may be more effective systemically in one or more embodiments. Compounds with the opposite properties of higher liver clearance rate and lower plasma stability may be more effective locally or regionally in one or more embodiments. Compounds that fall between the aforementioned properties may be effective when applied locally, locally, and / or systemically in one or more embodiments. Also, compounds with one of the properties of lower liver clearance rate or higher plasma stability, or higher liver clearance rate or lower plasma stability, may be effective when applied locally, locally, and / or systemically in one or more embodiments. Compounds with lower selectivity for BDII may potentially be more toxic than compounds with higher selectivity for BDII, and vice versa. This may be reversed in one or more embodiments where potential toxicity is ameliorated or avoided by higher liver clearance and / or lower plasma or systemic stability. In other words, selecting compounds with a higher metabolic burden may surprisingly be converted into therapeutically effective drugs when applied locally or topically, without corresponding undesired systemic effects and / or adverse reactions, e.g., toxicity.

[0284] The BET BDI and BDII inhibitor compounds disclosed herein, or pharmaceutical compositions comprising said compounds, may in one or more embodiments be selected for use in the treatment, amelioration, or prevention of any of the non-limiting examples of disorders and diseases described herein.

[0285] Treatment or amelioration with a composition comprising selected BET BDI and BDII inhibitors and compounds disclosed herein or salts or stereoisomers thereof (or combinations thereof) may be effective in some embodiments when applied locally, in some other embodiments when applied orally, and in some further embodiments when applied locally and orally. Alternatively, treatment or amelioration with a composition comprising selected BET BDI and BDII inhibitors and compounds disclosed herein or salts or stereoisomers thereof (or combinations thereof) may be effective in some embodiments when applied locally, in some other embodiments when applied systemically, and in some further embodiments when applied locally and / or systemically. In the case of respiratory disorders and diseases, local delivery may be through the airways to the lungs, e.g., by inhalation.

[0286] In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered primarily or substantially within the skin, with low levels of percutaneous penetration. In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered primarily or substantially transdermally. In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered intradermally and transdermally. In some embodiments, the penetration of the compound in the epidermis may be greater than that in the dermis. In some embodiments, the penetration of the compound in the dermis may be greater than that in the epidermis. In some embodiments, the penetration of the compound in the dermis is similar to that in the epidermis. In some embodiments, the concentration of the compound per unit volume in the epidermis may be greater than that in the dermis. In some embodiments, the concentration of the compound per unit volume in the dermis may be greater than that in the epidermis. In some embodiments, the concentration of the compound per unit volume in the dermis is similar to that in the epidermis.

[0287] In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered primarily or substantially into the target cells (e.g., alveoli) with low levels of transcellular penetration into the blood system that avoids or reduces potential systemic effects. In some embodiments, when applied topically to the airways and lungs, the compounds disclosed herein may be effective when compound delivery is primarily or substantially transalveolar or transmucosal. In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered intraalveolarly and transalveolarly.

[0288] In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compounds are delivered primarily or substantially to the lung parenchyma (the lung parenchyma contains numerous thin-walled alveoli, creating a vast surface area and helping to maintain adequate gas exchange) with low levels of blood system penetration that avoids or reduces potential systemic effects. In some embodiments, when applied topically to the airways and lungs, the compounds disclosed herein may be effective when compound delivery is primarily or substantially transparenchymal. In some embodiments, when applied topically, the compounds disclosed herein may be effective when compound delivery is intraparenchymal and transparenchymal.

[0289] In some embodiments, when applied topically to the skin, the compounds disclosed herein may be effective when the compound is delivered primarily or substantially intradermally. In some embodiments, when applied topically to the skin, the compounds disclosed herein may be effective when the compound is delivered primarily or substantially transdermally. In some embodiments, when applied topically, the compounds disclosed herein may be effective when the compound is delivered both intradermally and transdermally. In some embodiments, the penetration of the compound in the epidermis may be greater than that in the dermis. In some embodiments, the penetration of the compound in the dermis may be greater than that in the epidermis. In some embodiments, the penetration of the compound in the dermis is similar to that in the epidermis. In some embodiments, the concentration of the compound per unit volume in the epidermis may be greater than that in the dermis. In some embodiments, the concentration of the compound per unit volume in the dermis may be greater than that in the epidermis. In some embodiments, the concentration of the compound per unit volume in the dermis is similar to that in the epidermis.

[0290] Compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) can, in some embodiments, be provided via intra-articular administration.

[0291] In some embodiments, they may be provided by intrabursal administration. In some embodiments, they may be provided by intrabursal administration. In some embodiments, they may be provided by intraspinal administration. In some embodiments, they may be provided by intratissue or intralesional administration. Compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) may be administered bucally, by inhalation (e.g., spray), epidurally, intradermally, intraperitoneally, intrapulmonary, nasally, orally, parenterally, rectally, sublingually, topically, transdermally, vaginally, or via an implanted reservoir, in one or more embodiments. Compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) may be administered intravenously or intraarterially, in some embodiments. Examples of dosage forms for airway or pulmonary parenchymal administration of the compounds disclosed herein or salts thereof include solid particles, powders, liquids, suspensions, solutions, mists, aerosols, or sprays. Examples of dosage forms for topical or transdermal administration of a compound disclosed herein or its salts include creams, drops, lotions, foams, gels, inhalants, mousses, ointments, pastes, patches, powders, solutions, or sprays.

[0292] In some embodiments, compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) may be administered to young children. In some embodiments, compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) may be administered to adolescents or teenagers. In some embodiments, compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof) may be administered to adults.

[0293] Potential effectiveness against one or more disorders or diseases described herein may, in one or more embodiments, be indicated by the ability of the BETi to modulate or reduce biomarkers known or implicated in inflammatory or immune responses, such as, for example, cytokines. A non-limiting example where locally acting / administered topical BETi may be applicable is the treatment of rare neutrophilic dermatological indications through inhibition of important immune targets such as IL-1, IL-1β, IL-17, IL-8, IFNγ, IL-36γ, and TNFα. Another non-limiting example in which locally acting / administered BETi may be applicable is the inhibition or reduction of levels of key immune targets such as IL-17, IL-17A / F, IL-23, TNFα, IL-1β, IL-6, IL-18, TGFβ, IL-4, IL-5, IL-13, IL-15, IL-22, IL-36γ, IFNγ, or IL31, or CCL17, CCL26, CCL2, CCL20, CCL22, or serpin b4, resulting in the inhibition of pro-inflammatory cell migration, inflammatory cell activation, fibroblast or myofibroblast activation and proliferation, extracellular matrix The BETi may be used in the treatment of one or more disorders or diseases described herein, such as the regulation of extracellular matrix (ECM) synthesis and degradation, apoptosis of fibroblasts or myofibroblasts, regulation of AKT / mTOR and SMAD pathways, regulation of profibrotic mediators (e.g., TGF-β), keratinocyte inflammatory response, differentiation of naive Th0 cells to Th2 cells in adaptive immunity, allergic response in diseases or disorders, allergic diseases or disorders, Th2-mediated inflammatory diseases, pruritus signaling diseases or disorders, scarring disorders and diseases involving the formation or increase of scar tissue, fibrotic diseases and disorders, macrophage, neutrophilic, or dermatological indications. Alternatively, the potential for efficacy against one or more disorders or diseases described herein may be indicated in some embodiments by the ability of the BETi to modulate or reduce one or more matrix metalloproteinases (e.g., MMP3 and MMP-9). For example, MMP-3 can degrade collagen and promote the recruitment and accumulation of inflammatory cells, and MMP-9 is upregulated in patients with diabetic osteoarthritis.

[0294] In some embodiments, the BET inhibitor used in the present disclosure is a compound of formula (I) or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof: [ka] where: Ring A is selected from phenyl, N-methyl-2-pyridone, and thiazole; n is 0 or 1, when A is phenyl, n is 1, when A is N-methyl-2-pyridone, n is 0, when A is thiazole, n is 0; R 2 hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 Phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; 2 -C 6 Alkyl; and C 1 -C 6 C optionally substituted with alkoxy 3 -C 6 It is cycloalkyl.

[0295] having formula I, wherein ring A is [ka] 2. The compound according to clause 1, selected from:

[0296] having formula I, wherein ring A is [ka] Selected from R 2 hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 The compound according to clause 1 or 2, which is phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino.

[0297] Formula II having the following structure: [ka] wherein Ring A is selected from phenyl and N-methyl-2-pyridone; The compound of any preceding clause, wherein n is 0 or 1, and when A is phenyl, n is 1, and when A is N-methyl-2-pyridone, n is 0.

[0298] having formula II, wherein ring A is [ka] The compound according to any preceding clause, selected from:

[0299] Formula III having the following structure: [ka] R 21 are (i) hydroxy, halo, C 1 -C 6 Alkyl, C 3-C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; and 1 -C 6 C optionally substituted with alkoxy 3 -C 6 The compound of any preceding clause, wherein said compound is selected from: cycloalkyl.

[0300] having formula III, wherein R 21 In some embodiments, in formula III, R 21 is phenyl.

[0301] A compound according to any preceding clause, having formula I, [ka] The compound has the structure:

[0302] A compound according to any preceding clause, having formula I, [ka] The compound has the structure:

[0303] A compound according to any preceding clause, having formula I, [ka] The compound has the structure:

[0304] In some embodiments, the compound of formula I is [ka] It is.

[0305] The compound according to any preceding clause, having formula I, hereinafter referred to as BETi1, [ka] It has the structure:

[0306] In some embodiments, the compound of formula I is [ka] It is.

[0307] A compound according to any preceding clause, having formula I, [ka] The compound has the structure:

[0308] A compound according to any preceding clause, having formula I, [ka] The compound has the structure:

[0309] A pharmaceutical composition comprising any one or a combination of two or more of the compounds in any preceding clause, in combination with one or more pharmaceutical excipients, for use in the treatment of a disease or disorder disclosed herein.

[0310] 15. The pharmaceutical composition of clause 14, having activity against one or more BET domains.

[0311] 16. The pharmaceutical composition of clause 15, wherein the BET domains are BDII and BDI.

[0312] 17. The pharmaceutical composition according to clause 15 or 16, wherein the compound has a binding affinity for BDI and BDII and a higher selectivity for BDII, or the compound has a similar binding affinity for BDI and BDII.

[0313] 18. The pharmaceutical composition according to any of clauses 14 to 17, wherein the compound or two or more compounds have a hepatic clearance rate of less than 1 hour, or less than 45 minutes, or less than 30 minutes, or less than 15 minutes until elimination.

[0314] 18. The pharmaceutical composition according to any of clauses 14 to 17, wherein the compound or two or more compounds have a hepatic clearance rate of >50%, or >60%, or >70%, or >80% (as a % of hepatic blood flow).

[0315] 20. The pharmaceutical composition according to any of clauses 14 to 19, wherein the compound or two or more compounds have a plasma stability of less than 50% within 120 minutes, or less than 40% within 120 minutes, or less than 30%, or less than 20%, or less than 10%.

[0316] 21. The pharmaceutical composition according to any of clauses 14 to 20, wherein the compound or two or more compounds have a plasma stability of <50%, or <45%, or <40%, or <35%, or <30% remaining after 120 minutes.

[0317] 22. The pharmaceutical composition according to any of clauses 14 to 21, wherein BDI and BDII are inhibited, and the selectivity of the compound for BDII over BDI is less than 3-fold.

[0318] A method for treating or preventing a disorder or disease in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any of clauses 1 to 13, said disorder or disease being a. Skin disorders such as acne, inflammatory acne, acne fulminans, angiofibroma, nodular papulopustular acne, non-inflammatory acne, acne conglobata, acute erysipelas, autoimmune bullous skin disorders such as pemphigus vulgaris (PV) or bullous pemphigoid (BP), bacterial skin infections, viral skin infections, cellulitis, skin abscesses, carbuncles, chronic hand eczema, cutaneous mastocytosis, Dercum's disease, chronic atypical neutrophilic dermatosis with dermatological pain, lipoatrophy and fever (CANDLE), neutrophilic skin diseases such as pyoderma gangrenosum and Sweets' syndrome, periungual infections, pustulosis palmoplantaris edematous, granuloma annulare, pemphigus, epidermal necrolysis pemphigus pemphigus), paraneoplastic pemphigus, erythrasma, ecthyma, eczema, folliculitis, furuncle, gustatory sweating, hyperhidrosis, Hailey-Hailey disease, urticaria, hidradenitis suppurativa, hypertrophic scar, impetigo, ichthyosis, ischemic necrosis, keloid, necrotizing subcutaneous infection, actinic keratosis, keratosis pilaris, miliaria, molluscum contagiosum, lichen planus, netherlands Ton's syndrome, pityriasis rubra pilaris, prurigo nodularis, pediculosis, pityriasis rosea, scalded skin syndrome, skin rashes, trauma or injury to the skin, post-operative or post-surgical skin conditions, wounds, burns (chemical, electric, flame, friction, radiation, temperature related, including heat and cold), photodermatitis, scarring, scabies, skin ulcers, urticaria pigmentosa, and warts; b. viral, bacterial, yeast diseases, for example, when said diseases are manifested in skin or mucous membrane lesions; c. Disorders caused by viruses, such as coronavirus, Epstein-Barr virus (EBV), HIV, HTLV1, chickenpox, herpes simplex virus infection, varicella zoster virus (VZV), and human papillomavirus (HPV) diseases, for example, when the disease manifests itself in skin or mucosal disorders; d. allergic diseases and food allergies, for example when the disease or allergy manifests itself in skin or mucous membrane disorders; e. allograft rejection, graft-versus-host disease, allograft rejection, and graft-versus-host reaction; f. Pernioform lupus and infantile-onset stimulator of interferon gene associated vasculopathy (SAVI); g. Bullous pemphigoid, burns, lichen planus, hidradenitis suppurativa, PG, GPP, PPP, scarring, scar formation, ulcers, skin ulcers, mucosal ulcers, diabetic foot ulcers, wounds, wounds that are resistant to healing, and wound swelling; h. a disease or disorder in which therapeutic benefit is achieved by reduction of TH17 cytokine biomarkers, including IL-22, IL-1β, IL17, IL6, IL36 and TNFα, or CXCL10 and CCL20, or serpin B4; i. a disease or disorder in which a therapeutic benefit is achieved by reducing TH2 cytokine biomarkers, including IL-4, IL13, and IL-31 or CCL2, CCL26, and CCL17; j. restoring the integrity or accelerating the restoration of the integrity of areas of destroyed or damaged tissue, skin, or mucous membranes, as well as reducing and resolving scarring or scarring; k. Pyoderma gangrenosum (PG), palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP); l. Angiofibroma, chronic hand eczema, cutaneous mastocytosis, pigmented urticaria, neutrophilic dermatoses such as pyoderma gangrenosum and Sweets syndrome, chronic atypical neutrophilic dermatosis with lipoatrophy and fever (CANDLE), ichthyosis, keloids, scars, hypertrophic scars, Netherton syndrome, prurigo nodularis, and pigmented urticaria, m. pigmentation diseases and disorders as described herein, including vitiligo, chemical leukoplakia, tinea versicolor, albinism, pityriasis alba, atrophy of the skin, Griscelli syndrome, lentigo areoforms, Hermansky-Pudlak syndrome, Ito's hypomelanosis, idiopathic guttate hypomelanosis, leprosy, leukoplakia, lichen sclerosus, lupus erythematosus, morphea, mycosis fungoides, anemic nevus, depigmented nevus, mottling, leukoderma, leukoderma, postinflammatory hypopigmentation, progressive patchy hypopigmentation, tuberous sclerosis (Ashleaf spots), and Waardenburg syndrome; and n. Fibrosis-related disorders, including scarring, fibrosis, and PF, as described herein. wherein said use in the treatment of one or more of said diseases or conditions listed above comprises administering to a subject an effective amount of a compound of the first aspect or as defined herein, or a pharmaceutical composition of the second aspect.

[0319] The above diseases and disorders may, in one or more embodiments, be associated with the activity of bromodomain-extraterminal proteins.

[0320] The selected BET BDI and BDII inhibitors disclosed herein and pharmaceutical compositions comprising them may, in one or more embodiments, be useful and may be used in the palliative, diagnosis or prevention in humans of any disease, disorder or condition of one or more of the foregoing non-limiting examples of disorders and diseases.

[0321] A method for treating or preventing a disorder or disease in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any of clauses 1 to 13, said disorder or disease being Bullous pemphigoid, lichen planus, hidradenitis suppurativa, PG, GPP, PPP, scarring, scar formation, ulcer, skin ulcer, mucosal ulcer, diabetic foot ulcer, wound, wound that is resistant to healing, wound swelling, or A disease or disorder in which a therapeutic effect is achieved by reducing TH17 cytokine biomarkers, including IL-22, IL-1β, IL-17, IL-6, IL-36 and TNFα, or CXCL10 and CCL20, or serpin B4; or A disease or disorder in which a therapeutic effect is achieved by reducing TH2 cytokine biomarkers, including IL-4, IL-13, IL-17α, IL22, IL-31, IL-36γ, or A disease or disorder in which a therapeutic effect is achieved by reducing neutrophil biomarkers, including IL-1β, IL-17, TNF-α, IL-8, IL-6, and IL-23; or PG, GPP, PPP and Wounds The method is selected from the group consisting of

[0322] 25. The method of clause 23 or 24, wherein said disorder or disease is selected from PG, GPP or PPP.

[0323] A method of inhibiting Bromodomain-Extra Terminal protein activity in a subject comprising administering to the subject an effective amount of any one or a combination of two or more of the compounds defined in any preceding clause, or a pharmaceutical composition comprising one or more of said compounds in combination with one or more pharma- ceutically acceptable excipients.

[0324] 27. The method of any one of clauses 23 to 26, wherein the subject has a disease or condition associated with the activity of the bromodomain-extra-terminal protein.

[0325] 28. The method of claim 27, wherein the compound or a pharmaceutical composition comprising the compound is administered locally, topically, or systemically.

[0326] 29. A method according to claim 28, said method comprising administering a pharmaceutical composition comprising any one or a combination of two or more of the compounds defined in clause 1 in a therapeutically effective amount in combination with one or more pharma- ceutically acceptable excipients, said disorder or disease being treated by Burns, Lichen planus, Hidradenitis suppurativa, PG, GPP, PPP, scarring, scar formation, ulcers, skin ulcers, mucosal ulcers, diabetic foot ulcers, wounds, wounds that are resistant to healing, wound swelling, or A disease or disorder in which a therapeutic effect is achieved by reducing TH17 cytokine biomarkers, including IL-1β, IL17, IL6, IL36 and TNFα; or A disease or disorder in which a therapeutic effect is achieved by reducing TH2 cytokine biomarkers, including IL-4, IL13, and IL-31; or A disease or disorder in which a therapeutic effect is achieved by reducing neutrophil biomarkers, including IL-1β, IL-17, TNF-α, IL-8, IL-6, and IL-23; or PG, GPP, PPP and Wounds The method is selected from the group consisting of

[0327] The method of any of the preceding embodiments, wherein the anti-inflammatory effects in preclinical data in mice are similar to ultra-potent glucocorticosteroids.

[0328] The method of any of the preceding embodiments, wherein the compound was considered well tolerated in mice as determined by the animals' body weight and skin condition.

[0329] The method of any of the preceding embodiments, wherein inhibition of key Th17 or Th2 cytokines in ex vivo data using human skin tissue was more potent when compared directly to the JAK1 / 2 inhibitor ruxolitinib.

[0330] The method of any of the preceding embodiments, wherein the compound significantly reduced the expression of several key pro-inflammatory cytokines associated with Th17 or Th2 mediated immune or autoimmune diseases in animal models and ex vivo human tissue studies.

[0331] The method of any of the preceding embodiments, wherein upon administration of the compound or a pharmaceutical composition comprising the compound, e.g., by topical application, there is a dose-dependent amelioration of signs and symptoms of inflammation.

[0332] The method according to the preceding clause, wherein upon topical application of said compound at high doses, there is a surprising reduction in said dose-dependent improvement of signs and symptoms of inflammation.

[0333] The method of any of the preceding embodiments, wherein in a mouse study, there is about a 94% reduction in the combined inflammation severity score of erythema and scaling compared to a vehicle control group on day 7 of treatment.

[0334] The method of any of the preceding embodiments, wherein a dose-dependent reduction in Th17-associated cytokine biomarkers of inflammation, including IL-1β, IL-17, IL-6, IL-36, TNFα, and C-X-C motif chemokine ligand 10 (LP-10), was observed for all treatment groups.

[0335] The method of any of the preceding embodiments, wherein animals (mice) treated topically at all concentrations continued to gain weight similar to healthy controls, whereas animals treated with 0.05% clobetasol propionate cream experienced an average weight loss of approximately 17% compared to animals treated with 0.1% BETi1.

[0336] The method of any of the preceding embodiments, wherein animals treated with clobetasol propionate 0.05% cream had significant skin atrophy as evidenced by deep wrinkles and rhytids, significant loss of skin translucency and elasticity, whereas animals (mice) to which the compound was applied topically showed no evidence of skin tolerance issues, consistent with the healthy control group.

[0337] The method of any of the preceding embodiments, wherein there is greater than about 95% inhibition of IL-17, IL-36 and CXCL10 release compared to vehicle controls in an ex-vivo human skin tissue study.

[0338] The method of any of the preceding embodiments, wherein there is a strong correlation between improved clinical severity scores and a reduction in many pro-inflammatory biomarkers associated with Th17-mediated autoimmune disease.

[0339] The method of any of the preceding embodiments, wherein there is greater than about 95% inhibition of IL-4, IL-13 and IL31 release compared to vehicle controls in an ex-vivo human skin tissue study.

[0340] The method of any of the preceding embodiments, wherein there is a strong correlation between improvement in clinical severity scores and reduction in many pro-inflammatory biomarkers associated with Th2-mediated autoimmune disease.

[0341] The method of any of the preceding embodiments, wherein it is demonstrated that there is a dose-dependent reduction in biomarker expression, with BETi1 0.1% having the greatest effect.

[0342] The method of any of the preceding embodiments, wherein upon topical application of the compound, there is a dose-dependent improvement in signs and symptoms of pigmentation.

[0343] The method of any preceding embodiment, wherein there is an increase or a dose-dependent increase in melanin content.

[0344] The method of any preceding embodiment, wherein there is a reduction or dose-dependent reduction in MMP-9 secretion.

[0345] The method of any preceding embodiment, wherein there is a reduction or dose-dependent reduction in secretion of E-cadherin.

[0346] The method of any preceding embodiment, wherein there is an increase or dose-dependent increase in TRP-1.

[0347] The method of any of the preceding embodiments, wherein there is a reduction or dose-dependent reduction in melanocytosis, or wherein upon topical application of the compound, the melanocytosis is at least partially reversed or prevented, which may be dose-dependent.

[0348] The method of any of the preceding embodiments, wherein there is a reversal or dose-dependent reversal of specific gene regulation, where one or more of IL1A, ILIB, SOX9, POMC and EDN1 are decreased, and / or one or more of WNT16 and RAB3A are increased.

[0349] Upon topical application of the compound, there is improvement or dose-dependent improvement in any two or more or all of the following signs and symptoms of pigmentation reduction: a. There is an increase or a dose-dependent increase in melanin content; b. There is a decrease or a dose-dependent decrease in MMP-9 secretion; c. There is a decrease or a dose-dependent decrease in E-cadherin secretion. d. There is an increase or dose-dependent increase in TRP-1. e. there is a reduction or dose-dependent reduction in melanocytosis or, upon topical application of the compound, the melanocytosis is at least partially reversed or prevented, which may be dose-dependent; and / or f. The method of any of the preceding embodiments, wherein there is a reversal or dose-dependent reversal of specific gene regulation, and one or more of IL1A, ILIB, SOX9, POMC and EDN1 are decreased, and / or one or more of WNT16 and RAB3A are increased.

[0350] The method of any of the preceding embodiments, wherein the disorder or disease comprises or is selected from vitiligo, chemical leukoplakia, tinea versicolor spots, albinism, pityriasis alba, atrophy of the whites, Griscelli syndrome, lentigo areoforms, Hermansky-Pudlak syndrome, Ito's hypomelanosis, idiopathic guttate hypomelanosis, leprosy, leukoplakia, lichen sclerosus, lupus erythematosus, morphea, mycosis fungoides, anemic nevus, depigmented nevus, mottling, leukoderma, leukoderma, postinflammatory hypopigmentation, progressive patchy hypopigmentation, tuberous sclerosis (Ashleaf spots), Waardenburg syndrome. The method of any of the preceding embodiments, wherein the disorder or disease is selected from diseases or disorders in which a therapeutic effect is achieved by reduction of cytokine biomarkers, including downregulation of one or more of the cytokines SOX9, POMC, IL6, IL1a and b, TNF and EDN1 (vasoconstriction), and upregulation of genes associated with the WNT / β-catenin pathway and / or RAB3A. The WNT / β-catenin pathway is one of the main pathways known to be altered in vitiligo, leading to activation of MITF, a key transcription factor involved in melanocyte differentiation, growth and survival. The method of any of the preceding embodiments, wherein the upregulation of genes associated with the WNT / β-catenin pathway includes WNT16. The method of any of the preceding embodiments, wherein other genes related to melanocyte biology are also affected, with some regulation favoring the melanogenesis process and others unfavorable. The method of any of the preceding embodiments, wherein the vehicle does not have a significant effect on gene expression. The method of any of the preceding embodiments, wherein treatment with the vehicle results in induction of the GADD45A gene, a marker of DNA damage, and downregulation of WNT16.

[0351] In some embodiments, upon topical application of a BETi solution (e.g., BETi1), there is an improvement in at least one symptom of fibrosis or respiratory disorder or disease. In some embodiments, upon topical application of a BETi suspension or partial suspension (e.g., BETi1), there is an improvement in at least one symptom of fibrosis or respiratory disorder or disease. In some embodiments, the symptom of fibrosis or respiratory disorder or disease is accumulation of collagen in the lungs, which is expressed as high levels of hydroxyproline. In some embodiments, the improvement in symptoms is expressed as a reduction in hydroxyproline levels. In some embodiments, a reduction in hydroxyproline levels is observed in subjects (e.g., mice) treated with a BETi, e.g., BETi1 solution (e.g., 0.06 mg / mL, 0.6 mg / mL, and 3 mg / mL) compared to animals treated with vehicle. In some embodiments, the reduction in hydroxyproline levels in subjects (e.g., mice) treated with a solution comprising BETi1 (e.g., 3 mg / mL) is statistically significant compared to subjects treated with vehicle.

[0352] The method of any of the preceding embodiments, wherein upon topical application of a composition comprising the BETi compound, e.g., BETi1, there is an improvement in one or more of the signs and symptoms of fibrosis. The method of any of the preceding embodiments, wherein upon topical application of the compound, there is a slowing or deceleration in the development of the signs and symptoms of fibrosis. The method of any of the preceding embodiments, wherein upon topical application of the compound, there is a reduction in the appearance of scar tissue. The method of any of the preceding embodiments, wherein upon topical application of the compound, there is a reduction in the appearance of one or more of alveolar epithelial cell injury, area of ​​type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, or deposition of extracellular matrix proteins. The method of any of the preceding embodiments, wherein upon topical application of the compound, there is a reduction in the appearance of scar tissue between the alveoli. The method of any of the preceding embodiments, wherein upon topical application of the compound, there is an increase in the appearance of alveolar surface area. In one or more embodiments, the improvement or slowing is multifactorial and depends in part on the dose, in part on the composition and form of the delivery vehicle, in part on the delivery method, and in part on the length of time the airways and lungs are exposed to the dose. In some embodiments, the effect of the dose may be more beneficial when given in lower amounts and / or for a shorter period of time, hi some embodiments, the effect of the dose may be less beneficial when given in higher amounts and / or for too long a period of time.

[0353] In one or more embodiments, the biopsy is the primary data showing reduction or amelioration of fibrosis, followed or combined with the hydroxyproline data. Other data such as body weight are for information purposes. Survival endpoints are subject to significant variability and bias has the inherent limitation that bleomycin-induced damage may have already been lethal, even if treatment was effective.

[0354] A biopsy is a picture or snapshot of the absence or presence of fibrosis. For example, biopsy slides of bleomycin-induced lungs treated with BETi administered at 0.06 mg / mL (e.g., BETi1) compared to bleomycin-induced lungs treated with vehicle controls showed significant areas of normal lung parenchyma, normal conducting airways, including open airways and open spaces, as well as other areas with relatively low levels of localized fibrosis in both parenchymal and airway regions. Other groups using higher concentrations of BETi also appeared to reduce Bleo-induced fibrosis, but to a lesser extent. Such observations are very encouraging and indicate that BETi compounds may provide a useful method of treating, slowing down, or ameliorating PF in humans. Biopsies were scored according to the Ashcroft scale. The best two groups (0.06 mg / mL and 0.6 mg / mL) showed a reduction in fibrosis in subjects by more than about 50% and nearly about 30% in the 20-day study. Over time, this can potentially translate into a significant delay or slowing of the disease and a significant extension of lifespan for the affected subject, in one or more embodiments, the subject's lifespan can be extended by about 3 months, or 6 months, or 9 months, or 1 year, or 18 months, or 2 years, or more.

[0355] Hydroxyproline is a significant diagnostic biomarker for fibrosis. The method of any of the preceding embodiments, wherein there is a reduction in lung hydroxyproline content levels in bleomycin-induced animals treated with a BETi (e.g., BETi1) compared to bleo / vehicle. The method of any of the preceding embodiments, wherein there is a statistically significant reduction in lung hydroxyproline content levels in bleomycin-induced animals treated with a BETi (e.g., BETi1) compared to bleo / vehicle. The method of any of the preceding embodiments, wherein there is a reduction or dose-dependent reduction in lung hydroxyproline content levels in bleomycin-induced animals treated with a BETi (e.g., BETi1), with lower levels of hydroxyproline being observed at all doses (0.006, 0.6 and 3 mg / mL) of the BETi (e.g., BETi1). The method of any of the preceding embodiments, wherein a higher reduction is observed at higher doses (e.g., 3 mg / mL) of the BETi (e.g., BETi1). The method of any of the preceding embodiments, wherein the reduction in lung hydroxyproline content levels in bleomycin-induced animals treated with a BETi (e.g., BETi1) observed at 0.06 mg / mL is nearly as low as that observed at the higher dose of 3 mg / mL. The method of any of the preceding embodiments, wherein there is a statistically significant reduction in lung hydroxyproline content levels in bleomycin-induced animals treated with BETi1 at 3 mg / mL compared to bleo / vehicle. The method of any of the preceding embodiments, wherein BETi1 at 3 mg / mL is highly statistically different from bleomycin-induced animals treated with a vehicle control in preventing the production of lung hydroxyproline. The method of any of the preceding embodiments, wherein lung hydroxyproline content levels in bleomycin-induced vehicle-treated animals are significantly higher than those in sham / vehicle-administered animals, indicating that pulmonary fibrosis has occurred. The method of any of the preceding embodiments, wherein there is an increase or dose-dependent increase in survival rate in bleomycin-induced animals treated with BETi1, with higher survival probability occurring at higher doses (e.g., 0.6 and 3 mg / mL).The method of any of the preceding embodiments, wherein the hydroxyproline content is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, or at least about 60%. The method of any of the preceding embodiments, wherein the hydroxyproline content is reduced by about 10% to about 50% or about 15% to about 45%.

[0356] The method according to any of the preceding embodiments, wherein the bleomycin induction may be lethal to a significant proportion of animals as the study progresses. For example, lethality occurred after 1 day in bleomycin induction untreated control animals. After about 10 days and thereafter, the two highest BETi groups showed better survival rates, but at lower concentrations, survival probability did not differ from bleomycin induction vehicle-treated controls. The method according to any of the preceding embodiments, wherein animals receiving higher doses of BETi (e.g., 0.6 and 3 mg / mL doses of BETi) have higher survival probability compared to the bleomycin vehicle-treated control group. The method according to any of the preceding embodiments, wherein animals receiving higher doses of BETi (e.g., 0.6 and 3 mg / mL doses of BETi) have higher survival probability compared to the bleomycin vehicle-treated control group from about day 10, or from about day 11, or from about day 12 to the end of the study. Meanwhile, subjects with PF do not have to deal with the effects of bleomycin and therefore can better counter the disorder in the absence of bleomycin.

[0357] The method of any of the preceding embodiments, wherein Bleo / vehicle exhibits a higher pathology severity of interstitial fibrosis and subacute interstitial inflammation than the Sham / vehicle treated group. The method of any of the preceding embodiments, wherein a significant increase in both interstitial fibrosis and inflammation is observed in lung samples of the Bleo / vehicle treated group compared to lung samples from the Sham / vehicle group. The method of any of the preceding embodiments, wherein fibrosis is characterized by an increased number of fibroblasts and collagen fibers in the lung interstitium. The method of any of the preceding embodiments, wherein PSR staining severity generally correlates with the average severity of interstitial fibrosis. The method of any of the preceding embodiments, wherein inflammation is characterized by infiltration of lymphocytes and macrophages with occasional neutrophils in the lung interstitium. The method of any of the preceding embodiments, wherein bleomycin-induced animals treated with BETi (e.g., BETi1) have a lower pathology severity of interstitial fibrosis and subacute interstitial inflammation than observed in animals treated with a bleomycin-induced vehicle-treated control. The method of any of the preceding embodiments, wherein bleomycin-induced animals treated with a BETi (e.g., BETi1) have the lowest pathology severity of interstitial fibrosis and subacute interstitial inflammation observed in animals treated with BETi1 0.06 mg / mL.The method of any of the preceding embodiments, wherein in animals treated with a BETi compound described herein, e.g., BETi1, there is a reduction in the pathology severity of interstitial fibrosis and subacute interstitial inflammation.The method of any of the preceding embodiments, wherein in animals treated with a compound described herein, e.g., BETi1, there is a reduction in the number of fibroblasts and collagen fibers in the pulmonary interstitium. The method of any of the preceding embodiments, wherein upon local application of a BETi compound described herein, e.g., BETi1, there is a reduction in infiltration of lymphocytes, macrophages and neutrophils in the pulmonary interstitium, or, upon local application of a BETi compound described herein, e.g., BETi1, infiltration of lymphocytes, macrophages and neutrophils in the pulmonary interstitium is at least partially reversed, slowed down or prevented, which may be dose-dependent.

[0358] The method of any of the preceding embodiments, wherein treatment with 0.06 mg / mL of BETi1 shows normal lung parenchyma including open airways and air spaces and small conducting airways.The method of any of the preceding embodiments, wherein treatment with 0.06 mg / mL of BETi1 results in relatively low localized fibrosis in the parenchyma and relatively low localized fibrosis in the airways.

[0359] The method of any of the preceding embodiments, wherein the mean scores measured according to the Hubner modified Ashcroft scale of 0 to 8 by group are 1.52 for uninduced\vehicle, 6.36 for bleomycin induced\vehicle, 3.00 for bleomycin induced\0.06 mg / mL, 4.64 for bleomycin induced\0.6 mg / mL, and 5.52 for bleomycin induced\0.3 mg / mL. The method of any of the preceding embodiments, wherein the Ashcroft scoring translates to a reduction of about 53% and about 27% for the 0.06 mg / mL and 0.6 mg / mL groups, respectively, when compared to the bleomycin induced vehicle control. The method of any of the preceding embodiments, wherein significant differences were observed when comparing the following groups: Uninduced\vehicle vs. Bleomycin-induced\vehicle, Bleomycin-induced\vehicle vs. Bleomycin-induced\0.06 mg / mL, and Bleomycin-induced\vehicle vs. Bleomycin-induced\0.6 mg / mL (*P<0.05), and Bleomycin-induced\vehicle vs. Bleomycin-induced\0.3 mg / mL showed a trend toward significance but was not significantly different at P<0.05. The method of any of the preceding embodiments, wherein the Bleomycin-induced\0.06 mg / mL group has the greatest inhibitory effect on fibrotic tissue formation in the lungs.

[0360] The method of any of the preceding embodiments, wherein treatment with BETi1 reverses pulmonary fibrosis in bleomycin-induced animals treated with a BETi compound described herein, e.g., BETi1. The method of any of the preceding embodiments, wherein mice are given bleomycin for one day to establish pulmonary fibrosis and then treated with a BETi compound described herein (e.g., BETi1) and bleomycin simultaneously, e.g., daily until day 21. The method of any of the preceding embodiments, wherein vehicle-treated bleomycin-induced mice have pulmonary fibrosis accompanied by extensive collagen deposition.

[0361] The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) can partially reverse, slow down, or prevent fibrotic remodeling in the lungs and / or partially reverse, slow down, or prevent deterioration or damage of normal lung structure and / or unwanted collagen deposition. The method of any of the preceding embodiments, wherein bleomycin-induced mice receiving BETi1 have near-normal lung structure and / or less new collagen deposition at day 21. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) can partially reverse, slow down, or prevent bleomycin-induced fibrotic remodeling in the lungs. The method of any of the preceding embodiments, wherein BETi1 can partially reverse, slow down, or prevent bleomycin-induced fibrotic remodeling in the lungs. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) is involved in regulating redox balance in activated myofibroblasts. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) is involved in downregulating the secretion of TGFβ. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) is involved in downregulation and suppression of collagen and / or fibronectin gene transcription. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) can inhibit the migration of pro-inflammatory and inflammatory cells, for example, by targeting CD4+Th17 that secrete IL17A / F. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi11) reduces inflammation. The method of any of the preceding embodiments, wherein the BETi compound described herein (e.g., BETi1) reduces, prevents, or reverses TGF-β-mediated myofibroblast differentiation.

[0362] The method of any of the preceding embodiments, wherein a BETi compound described herein (e.g., BETi1) reduces or dose-dependently reduces TGF-β-mediated myofibroblast differentiation, or wherein a BETi compound described herein (e.g., BETi1) at least partially reduces, reverses, slows down, or prevents fibrosis, which reduction may be dose-related.

[0363] The method of any of the preceding embodiments, wherein there is a reversal or dose-related reversal of specific gene regulation, wherein one or more of IL17A / F, TGFβ, collagen and fibronectin genes or other genes involved in TGF-β mediated myofibroblast differentiation are reversed.

[0364] Upon topical application by inhalation of a BETi compound described herein, e.g., BETi1, there is improvement in any two or more or all of the following signs and symptoms of fibrosis: There is an increase in oxygen saturation, There is a decrease in lung hydroxyproline levels, There is a reduction in the severity of pathology of interstitial fibrosis and subacute interstitial inflammation, There is a decrease in the number of fibroblasts and collagen fibers in the pulmonary interstitium. There is a reduction in the infiltration of lymphocytes, macrophages and neutrophils in the pulmonary interstitium or, upon local application of BETi1, the infiltration of lymphocytes, macrophages and neutrophils in the pulmonary interstitium is at least partially reversed or prevented; and / or The method of any of the preceding embodiments, wherein there is downregulation of expression of specific genes selected from one or more of IL17A / F, TGFβ, collagen and fibronectin genes or other genes involved in TGF-β mediated myofibroblast differentiation.

[0365] The method of any of the preceding embodiments, wherein the compound is capable of binding to and inhibiting BDI and BDII in lung tissue and upper mucosa, has some selectivity for BDII (e.g., < about 10), has a high liver clearance rate, and has low or no tolerance issues.

[0366] The method of any of the preceding embodiments, wherein the compound or a pharmaceutical composition comprising the compound is administered by injection or infusion, which may be administered as a single injection or sequential injections.

[0367] The method of any of the preceding embodiments, wherein the injection or infusion is administered into the epidural or other spinal space, foraminal space, intra-articular space, lesion, peri-articular space, perineal space, soft tissue, or at or near the location of pain and / or injury.

[0368] The method of any of the preceding embodiments, wherein the joint or joint-related disorder or disease is selected from arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty's syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus or other autoimmune joint disorders.

[0369] The method of any of the preceding embodiments, wherein the disorder or disease is selected from those in which a therapeutic effect is achieved by modulation and / or reduction of one or more cytokines.

[0370] The method or use of any preceding embodiment, wherein the compound and / or pharmaceutical composition is well tolerated.

[0371] The method of any of the preceding embodiments, wherein the compound is capable of binding to and inhibiting BDI and BDII in the skin, has some selectivity for BDII, has a high liver clearance rate, and has low or no skin tolerance issues.

[0372] The method of any of the preceding embodiments, wherein the compound is capable of effectively reducing swelling compared to vehicle.

[0373] The use of any one of the preceding embodiments, wherein the modulation of key cytokines in ex vivo data using reconstituted skin tissue is more potent when compared directly to ruxolitinib, a JAK1 / 2 inhibitor, which downregulates several inflammatory cytokines in in vitro gene expression probes but has no significant effect on the WNT / β-catenin pathway or EDN1.

[0374] The use of any one of the preceding embodiments, wherein the compound is capable of significantly downregulating one or more (e.g., all) of SOX9, POMC, IL-6, IL1a and b, TNF, and EDN1 (vasoconstriction), and upregulating the WNT pathway (e.g., WNT16) and / or RAB3A in ex vivo reconstituted tissue.

[0375] The use of any one of the preceding embodiments, wherein upon topical application of the compound, there is a dose-dependent improvement of signs and symptoms of the pigmentation disorder or disease.

[0376] The use of any one of the preceding embodiments, wherein the pigmentation disease or disorder is vitiligo.

[0377] The use of any one of the preceding embodiments, wherein there is a dose-dependent reduction in one or more cytokine biomarkers. In some embodiments, the one or more cytokine biomarkers are selected from IL6, IL1a and b, SOX9, POMC TNF, and / or EDN1 (vasoconstriction). The use of any one of the preceding embodiments, wherein there is a dose-dependent increase in one or more cytokine biomarkers. In some embodiments, the one or more cytokine biomarkers are selected from WNT16 and RAB3A.

[0378] [ka] The use of any one of the preceding embodiments, wherein administration of reduces melanocytosis. In some embodiments, [ka] has a concentration of about 0.001% to about 1% or about 0.01% to about 1% by weight of the pharmaceutical composition. [ka] is about 0.1% by weight of the composition. [ka] is about 1% by weight of the composition.

[0379] The use of any one of the preceding embodiments, wherein the BET inhibitor is administered in an amount sufficient to reduce secretion of MMP9 by keratinocytes relative to stimulated and vehicle-treated reconstituted human epithelium (RHE).

[0380] The use of any one of the preceding embodiments, wherein MMP9 secretion is reduced by at least about 50% compared to stimulated vehicle control and / or is numerically superior to 1.5% with ruxolitinib.

[0381] The use according to the preceding embodiment, wherein MMP9 secretion is reduced by at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%.

[0382] The use of the preceding embodiment, wherein MMP9 secretion is reduced by at least about 95%.

[0383] The use of any one of the preceding embodiments, wherein the BET inhibitor is administered in an amount sufficient to reduce soluble E-cadherin relative to stimulated and vehicle-treated RHE.The use of the preceding embodiments, wherein the BET inhibitor results in a reduction in E-cadherin secretion of at least about 25%, or at least about 30%, at least about 35%, or at least about 40%, or at least about 45%, or at least about 50% relative to a stimulated control.The use of the preceding embodiments, wherein the BET inhibitor results in a reduction in E-cadherin secretion of no more than 80% relative to a stimulated control.

[0384] The use of any of the preceding embodiments, wherein the amount of the BET inhibitor ranges from about 0.001% to about 1% by weight of the pharmaceutical composition. In some embodiments, the amount of the BET inhibitor ranges from about 0.1% to about 1% by weight of the pharmaceutical composition. In some embodiments, the amount of the BET inhibitor ranges from about 0.05% to about 5%, or from about 0.075% to about 4%, or from about 0.1% to about 3%, or from about 0.125% to about 2.5%, or from about 0.15% to about 2% by weight of the pharmaceutical composition.

[0385] The use of any one of the preceding embodiments, wherein administration of the BET inhibitor results in upregulation of the WNT pathway. In some embodiments, the WNT pathway is upregulated by about >50%, >60%, >70%, >75%, >80%, >85%, >90%, >95%, >96%, >97%, >98%, or >99% after administration of the BET inhibitor. In some embodiments, WNT16 and / or RAB3A are upregulated by about >50%, >60%, >70%, >75%, >80%, >85%, >90%, >95%, >96%, >97%, >98%, or >99% after administration of the BET inhibitor.

[0386] The use of any one of the preceding embodiments, wherein administration of the BET inhibitor results in downregulation of EDN1.

[0387] The use of any one of the preceding embodiments, wherein administration of the BET inhibitor results in downregulation of one or more or all of IL6, IL1a, IL1b, and / or TNF. In some embodiments, the levels of one or more or all of SOX9, POMC IL6, IL1a, IL1b, TNF, and / or EDN1 are reduced by about >60%, >70%, >75%, >80%, >85%, >90%, >95%, >96%, >97%, >98%, or >99% following administration of the BET inhibitor.

[0388] The method of any of the preceding embodiments, wherein the disorder or disease is selected from diseases or disorders in which a therapeutic effect is achieved by reduction of cytokine biomarkers, including downregulation of one or more of the cytokines IL17A / F, TGFβ, collagen and fibronectin genes, and upregulation or downregulation of other genes associated with fibrosis and inflammatory pathways. The fibrosis TGFβ regulatory pathway is one of the main pathways known to be altered in PF and leading to TGF-β mediated myofibroblast differentiation. The method of any of the preceding embodiments, wherein downregulation of genes associated with the fibrosis TGFβ regulatory pathway includes collagen and fibronectin. The method of any of the preceding embodiments, wherein other genes in the myofibroblast differentiation pathway are also affected, with some regulation favoring and others unfavoring the myofibroblast differentiation process. The method of any of the preceding embodiments, wherein the vehicle does not have a significant effect on gene expression.

[0389] 5. The use of any of the preceding embodiments, wherein the fibrotic or respiratory disorder or disease comprises a pulmonary disorder selected from pulmonary fibrosis (PF), idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), non-specific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptopathic organizing pneumonia (COP), and lymphocytic interstitial pneumonia (LIP).

[0390] The use of any of the preceding embodiments, wherein the fibrosis or respiratory disorder or disease is PF, and the PF is selected from one or more of environmental PF, occupational PF, drug-induced PF, radiation-induced PF, autoimmune lung disease, and idiopathic PF.

[0391] The use of any of the preceding embodiments, wherein upon topical application of about 0.001% to about 0.1% of said BET inhibitor, there is a reduction in at least one symptom of said fibrotic or respiratory disorder or disease.

[0392] The use of any one of the preceding embodiments, wherein the compound and / or pharmaceutical composition is well tolerated, at therapeutically effective amounts and durations.

[0393] The pharmaceutical composition of any of the preceding embodiments, wherein there is a reduction in at least one symptom of said fibrotic or respiratory disorder or disease.

[0394] The use of any of the preceding embodiments, wherein upon topical application of about 0.001% to about 0.1% of the BE...

Claims

1. A method for the treatment, amelioration, or prevention of an inflammatory and / or autoimmune disease or disorder or a disease or disorder related thereto, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof: [Formula 1] wherein Ring A is selected from phenyl, N-methyl-2-pyridone, and thiazole; n is 0 or 1, when A is phenyl, n is 1, when A is N-methyl-2-pyridone, n is 0, when A is thiazole, n is 0; R 2 is hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5 Phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; 2 -C 6 Alkyl; and C 1 -C 6 C optionally substituted with a substituent selected from alkoxy 3 -C 6 The method according to claim 1, wherein the alkyl group is cycloalkyl.

2. The disease or disorder is a. wounds, non-healing wounds, wound swelling, burns, pyoderma gangrenosum (PG), generalized pustular psoriasis (GPP), and palmoplantar pustulosis (PPP); b. Pigmentation or pigmentation-related diseases or disorders; c. joint or joint-related diseases or disorders; d. Respiratory or respiratory-related diseases or disorders; and e. Fibrosis or fibrosis-related diseases or disorders The method of claim 1 , wherein the compound is selected from the group consisting of

3. 3. The method of claim 2, wherein the pigmentation or pigmentation-related disease or disorder is selected from vitiligo, chemical leukoplakia, tinea versicolor, albinism, and pityriasis alba, atrophy of the skin, Griscelli syndrome, lentigo areoforms, Hermansky-Pudlak syndrome, Ito's hypomelanosis, idiopathic guttate hypomelanosis, leprosy, leukoplakia, lichen sclerosus, lupus erythematosus, morphea, mycosis fungoides, anemic nevus, depigmented nevus, mottling, leukoderma, leukoderma, postinflammatory hypopigmentation, progressive patchy hypopigmentation, tuberous sclerosis (Ashleaf spots), and Waardenburg syndrome.

4. 4. The method of claim 3, wherein the pigmentation or pigmentation-related disease or disorder comprises vitiligo.

5. 3. The method of claim 2, wherein the joint-related disease or disorder is selected from arthritis, bursitis, Ehlers-Danlos syndrome, epicondylitis, Felty's syndrome, gouty arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, Still's disease, tenosynovitis, synovitis, Sjogren's syndrome, Lyme disease, Whipple's disease, bone cancer, lupus, and other autoimmune joint disorders.

6. 6. The method of claim 5, wherein the joint or joint-related disease or disorder comprises arthritis.

7. The method of claim 5 , wherein the arthritis comprises rheumatoid arthritis.

8. 3. The method of claim 2, wherein the fibrosis or fibrosis-related disorder and the respiratory or respiratory-related disorder comprises a pulmonary disorder selected from pulmonary fibrosis (PF), idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), non-specific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptopathic organizing pneumonia (COP), and lymphocytic interstitial pneumonia (LIP), or is a secondary pulmonary disorder.

9. 9. The method of claim 8, wherein the fibrosis or fibrosis-related disorder and the respiratory or respiratory-related disorder comprises pulmonary fibrosis (PF) or idiopathic pulmonary fibrosis (IPF).

10. 10. The method of claim 9, wherein the PF is selected from one or more of environmental PF, occupational PF, drug-induced PF, radiation-induced PF, autoimmune lung disease, and idiopathic PF.

11. The method of claim 2, wherein the fibrosis or fibrosis-related disorder comprises scarring and scar formation.

12. Ring A is [Case 2] The method according to any one of claims 1 to 11, wherein the compound is selected from the group consisting of

13. Ring A is [C3] is selected from R 2 is hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5The method of any one of claims 1 to 11, wherein the aryl group is phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino.

14. The compound of formula (I) may be a compound of formula (II) or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or a hydrate, or a deuterated derivative thereof: [C4] where: Ring A is selected from phenyl and N-methyl-2-pyridone; 14. The method of any one of claims 1 to 13, wherein n is 0 or 1, and n is 1 when A is phenyl, and n is 0 when A is N-methyl-2-pyridone.

15. Ring A is [C5] The method of claim 14, wherein the

16. The compound of formula (I) may be a compound of formula (III) or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof: [C6] where: R 21 is (i) hydroxy, halo, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 5 Alkyloxy, C 1 -C 5 Alkylamino, C 1 -C 6 Fluoroalkyl, C 1 -C 5 Fluoroalkyloxy and C 1 -C 5(ii) phenyl optionally substituted with 1 to 3 substituents independently selected from fluoroalkylamino; and 1 -C 6 C optionally substituted with a substituent selected from alkoxy 3 -C 6 The method according to any one of claims 1 to 13, wherein the alkyl group is selected from cycloalkyl.

17. R 21 The method of claim 16, wherein is cyclohexyl optionally substituted with a substituent selected from: (i) phenyl, (ii) cyclobutyl, or (iii) C1-C6 alkoxy.

18. R 21 The method of claim 17 , wherein is phenyl.

19. The compound is [C7] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

20. The compound is [C8] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

21. The compound is [C9] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

22. The compound is [C10] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

23. The compound is [C11] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

24. The compound is [C12] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

25. The compound is [C13] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

26. The compound is [C14] or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof.

27. 27. The method of claim 26, wherein the compound, its tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and / or deuterated derivatives have activity against one or more BET domains.

28. 28. The method of any one of claims 1 to 27, wherein upon topical application of a therapeutically effective amount of the compound, its tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and / or deuterated derivatives, there is amelioration of at least one symptom of the disorder or disease.

29. 29. The method of any one of claims 1 to 28, wherein upon administration of a therapeutically effective amount of the compound, or a tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative thereof, there is a reduction in one or more cytokines that are elevated during inflammation.

30. 30. The method of claim 29, wherein the one or more cytokines are selected from SOX9, POMC, IL6, IL1a, IL1b, TNF, and EDN1, or selected from IL-1β, IL17, IL6, IL36, and TNFα, or selected from IL-4, IL13, and IL-31, or selected from IL-1β, IL17, TNF-α, IL8, IL-6, and IL-23.

31. 31. The method of any one of claims 1 to 30, wherein upon administration of a therapeutically effective amount of the compound, its tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and / or deuterated derivatives, the therapeutic effect is related to upregulation of the WNT pathway or WNT-involving signaling and / or upregulation of RABA3A.

32. 32. The method of any one of claims 1 to 31, wherein upon administration of a therapeutically effective amount of the compound, or a tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative thereof, the therapeutic effect is related to a reduction in MMP9 and / or soluble E-cadherin.

33. 33. The method of any one of claims 1 to 32, wherein the disorder is a pigmentation disorder and, upon administration of a therapeutically effective amount of the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative, the therapeutic effect is associated with a reduction in melanocyte rheology.

34. The method of any one of claims 1 to 33, wherein the therapeutic effect is related to a reduction in hydroxyproline levels and / or Ashcroft score.

35. 35. The method of any one of claims 1 to 34, wherein upon administration of a therapeutically effective amount of the compound, its tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and / or deuterated derivatives, the therapeutic effect is associated with a reduction in the infiltration of lymphocytes, macrophages, and neutrophils at the site of the injury.

36. 36. The method of claim 35, wherein the disorder is fibrosis.

37. 37. The method of claim 36, wherein there is a reduction in the number of fibroblasts and the formation of collagen fibers.

38. The method of any one of claims 34 to 37, wherein the disorder is pulmonary fibrosis and the reduction is in the lung interstitium.

39. 33. The method of any one of claims 1-2, 5-7, and 11-32, wherein the disorder is arthritis and, upon administration of a therapeutically effective amount of the compound, its tautomers, stereoisomers, pharma- ceutically acceptable salts, hydrates, and / or deuterated derivatives, a therapeutic effect is associated with a dose-dependent reduction in inflammation that is a reduction in joint or limb thickness or circumference.

40. there is a reduction in arthritis scoring or severity, The reduction in arthritis scoring or severity may be (a) Definite redness and swelling of the ankles / wrists or apparent redness and swelling limited to individual digits regardless of the number of digits affected; (b) Severe redness and swelling of the ankles / wrists; (c) redness and swelling of the entire foot, including the toes; and / or (d) Maximally inflamed limb with multiple joint involvement 40. The method of claim 39, wherein the reduction is

41. The method of any one of claims 29 to 40, wherein the reduction is dose-dependent.

42. 42. The method of any one of claims 29, 30, and 32-41, wherein the reduction is greater than about 50%.

43. The method of claim 31 , wherein the upregulation is greater than about 50%.

44. 44. The method of any one of claims 1 to 43, wherein the compound or a tautomer, stereoisomer or mixture of stereoisomers, or a pharma- ceutically acceptable salt, or hydrate, or deuterated derivative thereof is in the form of a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.

45. 45. The method of claim 44, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative is formulated as a suspension or partial suspension in the composition.

46. 46. ​​The method of claim 45, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative is micronized.

47. 47. The method of any one of claims 45 and 46, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative is in the form of nanoparticles.

48. 45. The method of any one of claims 1 to 44, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative is solubilized or partially solubilized in the composition.

49. 49. The method of any one of claims 1 to 48, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative, or the pharmaceutical composition is administered locally, topically, or systemically.

50. 50. The method of any one of claims 1 to 49, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative, or the pharmaceutical composition is administered by single injection, sequential injections, or infusion.

51. 51. The method of claim 50, wherein the administration is into or near the epidural space, other spinal space, foraminal space, intra-articular space, lesion, peri-articular space, perineal space, soft tissue, or location of inflammation, pain, and / or injury.

52. 50. The method of any one of claims 1 to 49, wherein the compound, its tautomer, stereoisomer, pharma- ceutically acceptable salt, hydrate, and / or deuterated derivative, or the pharmaceutical composition is administered by inhalation.

53. 52. The method of any one of claims 50 and 51, wherein the composition comprises one or more components selected from PLGA microspheres, carboxymethylcellulose, hyaluronic acid, and a lubricant or lubricin.

54. 54. The method of any of claims 50, 51 and 53, wherein when injected intra-articularly in a therapeutically effective amount, the concentration of dissolved compound in synovial fluid is greater than about 3000 times the concentration in plasma on day 14 and / or ranges from about 5000 times to about 1000 times the concentration in plasma on days 7 to 21.